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ABSTRACT 
W T H i n OACMCYCLES AMI THEIR USE IN THE TKATCWT (P C A i T O . 
Six macrocyclic ligands have been synthesized f o r binding 
y t t r i u m ( I I I ) . Of the s ix , 1,4,7,10-tetraazacyclododecane-1,4,7,10-
te t raacet ic acid (DOTA) forms the most stable y t t r i u m ( I I I ) complex in 
aqueous so lu t ion , log K(ML) = 24.9 and ha l f l i f e ~ 2 weeks at pH 1.0. 
In addi t ion to an acid-dependent dissociat ive mechanism, release of Y 3 + 
from Y(DOTA) may, i t is t en ta t ive ly suggested, be promoted by metal 
ions. DOTA also demonstrates rapid uptake of Y 3 + (987. l a b e l l i n g 
e f f i c i e n c y at 310 K with [DOTA] = 10"* M and [Y 3 + ] ~ 10"9 M, pH 5.5 
[0.1 M ammonium aceta te] ) . 
Accordingly, an aminobutyl C-functionalised der iva t ive of DOTA has 
been made and coupled to a monoclonal antibody. Once label led with 
9 0 Y 3 + , a long range /?"-emitter, the conjugate can be used to se lec t ive ly 
de l iver a s t e r i l i s i n g dose of radia t ion to a tumour. Preliminary 
experiments have indicated that the r ad io l abe l ed MoAb conjugate remains 
r e l a t i v e l y iner t in vivo. Tumour regression studies are in progress. 
Jonathan Paul Lawrence Cox (September 1989) 
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ABBl&EVIATIINS 
EDTA Ethylenediamine-N,N,N',N'-tetraacetic acid 
DTPA Diethylenetriamine-N,N,N',N",N"-pentaacetic acid 
NTA N i t r i l o t r i a c e t i c acid 
PCA Polyaminocarboxylate complexing agent 
DOTA l,4,7,10-Tetraazacyclododecane-l,4,7,10-tetraacetic acid 
TRITA 1,4,7,10-Tetraaazacyclotridecane-1,4,7,10-tetraacetic acid 
TETA 1,4,8,11-Tetraazacyclotetradecane-1,4,8,11-tetraacetic acid 
DOTA-BMA 4-(N-Benzyl-N-methylcarboxamidomethyl)-1,4,7,10- tetraaza-
cyclododecane-1,4,7-triacetic acid 
ODOTRA l-0xa-4,7,10-triazacyclododecane-4,7,10-triacetic acid 
DTCTA 1,7-Dioxa-4,10,13-triazacyclopentadecane- 4,10,13- t r i a c e t ic 
acid 
NOTA 1,4,7-Triazacyclononane-1,4,7-triacetic acid 
RIT Radioimmunotherapy 
DNA Deoxyribonucleic acid 
MoAb Monoclonal antibody 
IgG Immunoglobulin G 
3 ,2 ,3- te t 4,7-Diaza-1,10-dodecanedi amine 
cyclam 1,4,8,11-Tetraazacyclotetradecane 
mal Maleimide 
Me Methyl 
Et Ethyl 
Ac Acetyl 
Ph Phenyl 
Bz Benzyl 
Ts (Tosyl) 4-Toluenesulphonyl 
Ar Aromatic 
THF Tetrahydrofuran 
Ln Lanthanide 
MPt Melting point 
dec Decomposes 
IR Inf rared 
UV U l t r a v i o l e t 
NMR Nuclear magnetic resonance 
HPLC High performance l i q u i d chromatography 
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MS Mass spectroscopy 
CI Chemical ionisat ion 
DCI Desorption chemical ion isa t ion 
FAB Fast atom bombardment 
TLC Thin layer chromatography 
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CHAPTER ONE 
INTRODUCTION 
1.1 CANCER-
Cancer i s a c e l l u l a r disorder, of variable sever i ty , a r i s i n g from 
two or more d i s t i n c t genetic events ' . Factors t r i g g e r i n g these events 
are p a r t l y inher i t ed , p a r t l y environmental and not wel l understood. 
The disorder manifests i t s e l f through an affected c e l l ' s i n a b i l i t y 
to respond to normal growth contro l mechanisms. Divis ion of that c e l l 
leads to a group of ce l l s ca l led a tumour. The tumour may remain where 
i t i s ( i n which case i t i s a benign tumour) or i t may fragment and 
spread to other tissues ( i n which case i t is a malignant tumour). The 
l a t t e r process, metastasis, is the more d i f f i c u l t to cont ro l and i s 
consequently the major cause of cancer death. 
1.2 THE INCIDENCE OF CANCER3'4 
Cancers are normally c l a s s i f i e d according to the organ in which 
they o r ig ina te . Of the hundred or so generated by th i s system, cancer 
of the colon, lung and breast are the commonest. Indeed, cancer of the 
colon is the second most common malignancy in Western Europe, k i l l i n g 
20,000 people a year in the United Kingdom alone. Figure 1.1 i l l u s t r a t e s 
the s i tua t ion in the United States, where cancer i s responsible f o r 
nearly a f i f t h of the deaths each year. 
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Figure 1.1: 77ie incidence of cancer in the United States 
[pre-AIDS]. (Source: Ref-4)-
1.3 THE TREATMENT OF CANCER 1 
There are two categories of treatment, surgery and therapy. 
Surgery involves the d i rec t removal of the tumour and is e f f e c t i v e 
against benign tumours. Therapy employs agents which attack the tumour 
in situ, eg. radia t ion in the form of X-rays and 7-rays (radiotherapy), 
5 6 
and drugs such as 5 - f l uo rou rac i l and c i s p l a t i n (chemotherapy). 
Radiotherapy, l i k e surgery, i s successful only against benign tumours. 
Chemotherapeutics, on the other hand, have had some success against 
metastatic disease: resul ts with c i s p l a t i n have been p a r t i c u l a r l y 
impressive, wi th complete remissions of t e s t i cu l a r cancer i n 857. of a l l 
patients t reated, and a high e f f i c a c y against ovarian and bladder 
cancers. There are s t i l l many cancers, however, which are in need of an 
improved therapy. In order of increasing p r i o r i t y , these are cancer of 
the breast, prostrate gland, colon, rectum, stomach, lung and pancreas. 
There i s another reason f o r improvement. Therapy works by damaging 
tumour c e l l DNA. As a large proportion of tumour ce l l s in a single 
tumour are rap id ly d i v i d i n g , t he i r DNA is p a r t i c u l a r l y sensitive to t h i s 
damage which resul ts i n c e l l , and eventually tumour, destruct ion. 
Unfortunately, i t fo l lows that the rap id ly d iv id ing ce l l s of other 
t issues such as the gas t ro - in te s t ina l t r ac t and bone marrow are equally 
prone to t h i s treatment, g iv ing r i se to unpleasant s ide-ef fec t s . 
For an e f f e c t i v e and painless treatment therefore , the anti-tumour 
agent must have some means of d iscr iminat ing tumour ce l l s from normal 
c e l l s . Discrimination may be achieved using antibodies. 
1.4 RADIOIMHUNPTHERAPY (HIT) 
1.4.1 Antibodies 5 
Antibodies are glycoproteins, more s p e c i f i c a l l y immunoglobulins 
( I g ) , which the body generates in response to the presence of a fo re ign 
mater ia l , or antigen. A t y p i c a l antibody such as IgG (Figure 1.2) 
consists of four polypeptide chains, two l i g h t (L) and two heavy (H), 
l inked by disulphide bridges between cysteine residues on adjacent 
chains. 
The polypeptide chains can be divided in to variable and constant 
regions. There are spec i f i c s i tes i n the variable regions, hyper-
var iable regions, which are responsible f o r antigen binding. The 
constant regions mediate e f f ec to r func t ions , eg. i n i t i a t i n g a sequence 
of immunological reactions terminating i n the e l iminat ion of the 
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antigen. Figure 1.2 also shows another useful d i v i s i o n of the antibody 
in to two Fab fragments (F f o r fragment, ab f o r antigen binding) and an 
Fc fragment (c pertains to the f ac t that t h i s fragment i s read i ly 
c r y s t a l l i s a b l e ) . 
variable region 
hypervariable 
regions 
constant region 
glycoprotein 
Figure 1.2: The structure of a typical antibody (IgG). 
The antigen binding si tes combine s p e c i f i c a l l y wi th a pa r t i cu l a r 
molecular determinant, known as a hapten, on the surface of the antigen. 
Only one pa r t i cu la r type of antibody can combine with a pa r t i cu l a r 
hapten (Figure 1.3). 
antibody /-binding site 
• 
ANTIGEN 
antibody 
^ N hapten 
Figure 1.3: Antibody-antigen binding specificity. 
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1.4.2 Antibodies and WIT 
A tumour c e l l i s coated wi th glycoproteins and g l y c o l i p i d s , some of 
which are fo re ign to the body and therefore cons t i tu te antigens. By 
developing antibodies spec i f i c f o r the various haptens (hereafter 
refer red to as antigens themselves) on these antigens, a tumour c e l l can 
be dist inguished from a normal c e l l . I f the antibody i s label led wi th a 
sui table radionucl ide, i t can del iver a s t e r i l i s i n g dose of rad ia t ion to 
the tumour c e l l to which i t attaches i t s e l f (Figure 1.4). This i s the 
basis of radioimmunotherapy (RIT). 
1.4.3 Monoclonal Antibodies 
o 
For t h i r t y years a f t e r i t s i n i t i a l conception , the implementation 
of RIT was scotched because i t was not possible to generate a spec i f i c 
antibody f o r a spec i f i c antigen. The development of monoclonal an t i -
Q 
bodies by Kohler and Mi l s t e i n i n 1975 r e c t i f i e d t h i s state of a f f a i r s . 
Antibodies are made by plasma c e l l s . I f one plasma c e l l i s 
immunised against one pa r t i cu l a r antigen, i t w i l l secrete antibodies 
radiolabelled 
antibody 
R 
surface antigen 
TUMOUR CELL 
R: Radionuclide 
Figure 1 .4: Radioimmunotherapy. 
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spec i f i c only f o r that antigen. Growing one such c e l l i n cul ture would 
resu l t in a colony of iden t ica l ce l l s (a clone) a l l producing the same 
antibody. However, plasma ce l l s do not survive in cu l ture . 
Kohler and Mi l s t e i n found that i f they fused a plasma c e l l 
immunised against a spec i f i c antigen wi th a myeloma c e l l ( i r o n i c a l l y , a 
myeloma is a tumour of the immune system) - which has the property that 
i t can be cultured i n d e f i n i t e l y - the hybrid c e l l , or hybridoma, 
preserved the ind iv idua l properties of i t s parent c e l l s , namely that i t 
was immortal and produced large amounts of i d e n t i c a l , or monoclonal, 
antibody (Figure 1.5). Hence an ample supply of monoclonal antibody 
could be raised f o r any given tumour antigen. 
r 
ANTIGEN 
OS—§3-
f7= ANTIGENIC 
- DETERMINANT 
SPLEEN 
LYMPHOCYTES 
ANTIBODY 
ANTIGEN 
ANTISERUM % ' 
MIXED ANTIBODIES 
LYMPHOCYTES MYELOMA CELLS 
FUSE 
HYBRID-
MYELOMA 
CELLS 
/ I w 
CLONE 1 
MONOCLONAL ANTIBODIES 
S 
Figure 1.5: Monoclonal antibody technology - A lymphocyte is the 
precursor of a plasma cell (Reproduced from Ref.7). 
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1.4.4 CMaaeric Antibodies ' 
Despite the above development, making monoclonal antibodies f o r 
human tumour antigens has proved d i f f i c u l t . 
With mice, which Kohler and Mi l s t e in used f o r t he i r seminal work, 
the plasma ce l l s f o r a spec i f i c antigen were obtained by f i r s t i n j e c t i n g 
the mice wi th the antigen, and then removing the ce l l s from the spleen 
of the animal. I n j e c t i n g humans wi th tumour antigens is obviously an 
unsat isfactory way of obtaining the required antibody. The a l t e rna t ive 
is to use murine (mouse) antibodies. But murine antibodies, since they 
are fo re ign to the body, evoke an immune response which can seriously 
i n t e r f e r e with therapy, or cause a l l e rg i c s ide -e f fec t s . 
These problems have been pa r t ly overcome by using chimaeric 
antibodies, antibodies wi th the hypervariable regions of a ra t or mouse 
spec i f i c f o r the tumour antigen, and human constant and variable 
regions. Such antibodies, although s t i l l not idea l , should evoke a 
lesser immune response than the murine antibodies. 
1.4.5 Choice of Radionuclide f o r R I T 1 2 
Radionuclides f o r RIT should have the f o l l o w i n g propert ies: 
(a) A h a l f - l i f e (T x ) between 6-200 h . , long enough f o r tumour 
2 
l oca l i s a t ion while minimising the r i s k to organs involved in 
antibody breakdown; 
(b) Be c a r r i e r - f r e e , to maximise the amount of "hot" antibody and 
therefore the dose received by the tumour; 
(c) Low yields of penetrating radia t ion (X-rays, 7-rays); 
(d) Stable daughter products; 
(e) Be cheap and readi ly avai lable . 
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According to the pa r t i c l e emitted and i t s range, radionuclides 
which s a t i s f y the above c r i t e r i a can be divided in to f i v e categories: 
211 
(1) Alpha emitters (range 50-90 #m), eg. At ; 
199 a 
(2) Short range beta emitters (mean range < 200 ^m), eg. Au; 
67 
(3) Medium range beta emitters (200 /im < mean range < 1mm), eg. Cu; 
(4) Long range beta emitters (mean range > 1 mm), eg. ^ Y ; 
(5) Radionuclides decaying by electron capture and/or in te rna l 
131 
conversion, eg. Cs. 
I t i s also important to match tumour morphology with the range of 
the radionucl ide 's par t icu la te emission. For instance, c i r c u l a t i n g 
single tumour c e l l s , as found in leukaemia, would be best el iminated by 
a source with short range (approximately one c e l l diameter) emissions -
alpha and short range beta emitters f a l l in to t h i s category - damage to 
normal ce l l s would therefore be minimal. Large, dense tumours, on the 
other hand, may have a non-uniform d i s t r i b u t i o n of antigen, and 
c ro s s - f i r e from long range (100 - 1000 c e l l diameters) beta emit ters , 
90 
such as Y, would make a pos i t ive con t r ibu t ion to the absorbed dose 
(Figure 1.6). 
1.4.6 Radionuclear Properties of Yttrium-90 
At t r ibu tes which make Y highly desirable as a therapeutic 
13 
radionuclide are: (a) T A = 64 hours; (b) pure 0 -emit ter of in ter -
2 
mediate energy (2.3 MeV); (c) stable daughter product; (d) readi ly 
obtainable from i t s long-l ived parent, ^ S r (T, = 28 years) and (e) 
exhibi ts good complexation chemistry (see Section 1.4.8). ^ Y decays as 
fo l lows : 
90 ft- 90 
39Y > 4 oZr (stable) 
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i K blood a vessel 
alpha particle emission 
- £ > long range beta particle emission 
• circulating leukaemia cell 
normal tissue 
3r ant igen-r ich area 
antigen-poor 
area 
long range beta emission 
Figure 1.6: Schematic diagram showing the importance of matching 
tumour morphology to choice of radionuclide: 
(i) circulating leukaemia cells; (ii) a densely 
packed tumour. 
As a long range (3.9 mm) /? -emi t te r , Y is ideal f o r stomach, 
14 15 16 lung, ovarian , colorectal ' and breast cancers. I t s major 
disadvantages are, however, the damage caused to normal t issue as a 
12 
resu l t of these long range emissions (see Figure 1.6) and the lack of 
J A 
7-rays i n i t s decay process wi th which to image the tumour . However, 
86 
Y, a positron emitter (Tf 14.6 hours) could be used. [A positron 
combining with an electron produces two 7-rays which can be detected 
with a gamma camera. This is the basis of positron emission tomography 
(PET), a diagnostic technique]. 
1.4.7 B i func t iona l Gomplexing Agents 
Yttrium-90 and the other radionuclides discussed so f a r (except f o r 
211 
At) are a l l metals and as such cannot be attached to an antibody via 
a stable covalent bond. Instead, r ad io labe l l ing is real ised using a 
17 18 
b i f u n c t i o n a l complexing agent ' . This consists of a chemically 
react ive func t iona l group and a complexing moiety. The chemically 
reactive group f a c i l i t a t e s conjugation to the antibody via, f o r example, 
the -NH.2 group of a lysine side chain, while the complexing moiety is 
responsible f o r binding the radioactive metal ion , eg. 1-(4-isothio-
cyanatobenzyl)-EDTA(l) (Figure 1.7). 
/ — C 0 2 H 
^ — C O , H 
/ — C O j H 
SC 
V > — C O , H 
X D antibody antibody 
N 
H H 
Radionuclide metal ion 
Figure 1.7: Radiolabelling a monoclonal antibody using a bifunctional 
complexing agent such as l-(4-isothiocyanatobenzyl)-EDTA. 
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1.4.8 Cheoical Properties of Y t t r i u o ( I I I ) 
As a resul t of the lanthanide contract ion, y t t r i u m ( I I I ) has s imi la r 
ionic r a d i i (8 and 9 coordinate) and hence displays a s imi la r 
complexation chemistry to the t r i v a l e n t lanthanides, p a r t i c u l a r l y those 
in the middle of the series such as g a d o l i n i u m ( I I I ) , t e r b i u m ( I I I ) and 
h o l m i u m ( I I I ) 1 9 . I t i s a spherical ion , radius (9 coordinate) = 1.07A 
( c f . 9 coordinate ionic radius of ho lmium(I I I ) , also 1 .07A)^ , of low 
p o l a r i s a b i l i t y , which tends to form non-direct ional and e lec t ros ta t i c 
bonds with hard donors, eg. 0 and N. I t s r e l a t i v e l y large radius allows 
f o r large coordination numbers, t y p i c a l l y 8-9, and i t s complexes show a 
preference f o r square ant ipr ismat ic and dodecahedral geometries 
(Figure 1.8). 
i 
+-
Figure 1.8: The favoured i) square antiprismatic and ii) 
dodecahedral stereochemistries of yttrium(III). 
1.4.9 Acyclic B i func t i ona l Complexing Agents f o r Y t t r i u a ( I I I ) 
DTPA (2 ) , wi th eight donor atoms (5 oxygens, 3 nitrogens) and the 
a b i l i t y to adopt a dodecahedral geometry, forms a very thermodynamically 
21 
stable complex wi th y t t r i u m ( I I I ) ( log K M T = 22.1) . 
- 11 -
The o r i g i n of t h i s s t a b i l i t y l i e s also in the chelate e f f e c t ^ , a 
phenomenon best explained by considering what happens when one molecule 
of DTPA complexes (which w i l l probably have a solvat ion number of 9) 
in aqueous so lu t ion : 
DTPA5" + Y(H 2 0)g + Y(DTPA)2" + 9H20 log = 22.1 
and by r e c a l l i n g tha t : 
AG = -RT log K M L = AH - TAS 
Thus one molecule of DTPA displaces nine water molecules r e su l t i ng in a 
net increase in entropy such that AG becomes more negative, and log 
becomes more pos i t i ve . Another way of looking at t h i s would be to th ink 
of a second binding s i t e (and t h i r d and four th etc) being brought in to 
closer proximity wi th the metal ion by the i n i t i a l complexation between 
metal ion and l igand than i f i t were a separate e n t i t y in so lu t ion . 
Because of t h i s s t r i k i n g thermodynamic s t a b i l i t y , and also the 
k i n e t i c s t a b i l i t y of the Y(DTPA) complex in serum, several workers have 
employed DTPA conjugated to an antibody via i t s dianhydride de r iva t ive 
(Figure 1.9) as a complexing agent f o r 9 0 Y 3 + f o r use in R I T 1 4 " 1 5 > 2 2 - 2 4 . 
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MoAb 
0„H 
N H 
c 
v — C O , H 
N H ^ — C O , H 
MoAb N 
NH 
Figure 1.9: The DTPA dianhydride derivative and its 
conjugation to a monoclonal antibody. 
However, r ad io l abe l ed monoclonal antibody (MoAb) conjugates of acycl ic 
polyaminocarboxylate complexing agents are unstable in vivo f o r two 
reasons. F i r s t l y , there is competition f o r the radionuclide from other 
complexing agents such as the blood proteins t r a n s f e r r i n and 
18 
haemoglobin . Secondly, there is a small amount of acid-promoted (and 
possibly metal ion promoted - see Chapter 3) d issocia t ion of the 
radionuclide from the chelate, the chelate-radionuclide complex being 
s u f f i c i e n t l y f l e x i b l e to al low, f o r example, the attack of a proton at 
25 
one of the binding nitrogens . Since the pH of serum is 7.4 and that 
of the body can be as low as 1.0, i t i s unsurprising that studies 
conducted i n the former medium have f a i l e d to i d e n t i f y an acid-dependent 
d issoc ia t ive mechanism. So, although the k ine t i c s t a b i l i t y of the 
r a d i o l a b e l e d MoAb conjugate in serum is a prerequis i te f o r i t s use i n 
RIT, i t i s not an adequate assessment of i t s k i n e t i c s t a b i l i t y in vivo. 
Sites l e f t vacant by these leakage e f f ec t s w i l l almost ce r t a in ly 
not be reoccupied by the f ree radionuclide, but w i l l instead take up 
2+ 2+ 2+ 
other metal ions such as Zn , Ca or Mg , a l l present i n s i g n i f i c a n t 
concentrations i n the blood (10" 5 , 10" 3 and 10" 3 M re spec t ive ly ) 2 ^ . A 
p o t e n t i a l l y l e tha l d i s t r i b u t i o n of radionuclide resu l t s . Free Y 3 + , f o r - 13 -
instance, local ises i n the bone marrow (Section 4.8) where i t can cause 
myelosuppression (depletion of the immune c e l l populat ion) . 
Clearly f o r RIT to be successful, there i s a need f o r a 
b i f u n c t i o n a l complexing agent which binds ^ Y ' ^ + quan t i t a t ive ly to form a 
thermodynamically and a k i n e t i c a l l y stable complex. The other l i m i t i n g 
f ac to r is that complexation should be f a s t (< 2 hours) between pH 4-6 at 
37°C. 
1.4.10 Macrocyclic Corapleximg Agents and the Hacrocyclic E f f e c t 
Macrocycles, organic heterocycles of r i n g size > 9 atoms, form 
complexes with metal ions of even greater thermodynamic s t a b i l i t y than 
27 
those formed by acycl ic complexing agents such as EDTA and DTPA . 
Examples of the various macrocyclic classes are shown in Figure 1.10. 
C H S 
/ \ / \ Ha CHs 1 c c C H S TSH N N > •9/ 3 J CH 3 ' CHa W W 
CHa 
I I II 
Figure 1.10: Examples of some macrocyclic compounds: 
i) coronand; ii) cryptand; Hi) spherand. 
Although enthalpy plays a pa r t , i t i s l i k e l y t ha t , f o r monomacrocyclics 
1Q 
at leas t , the o r i g i n of t h i s so-called macrocyclic e f f e c t is mostly 
entropic: whereas an acycl ic complexing agent must undergo considerable 
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conformational change to form a stable complex wi th the metal ion, the 
macrocyclic r i n g must undergo r e l a t i v e l y few - i t i s said to be pre-
organised. 
Another r ami f i ca t ion of the macrocyclic e f f e c t is the enhanced 
k ine t i c s t a b i l i t y of the macrocyclic complex r e l a t i ve to i t s acycl ic 
2+ 
counterpart. Consider, f o r instance, the dissociat ion of Cu(cyclam) 
2+ 
(3) and i t s acycl ic analogue, Cu(3,2,3-tet) (4) in strongly acidic 
28 
media (Scheme 1.1) . In both cases dissociat ion proceeds via the 
breakage of a Cu-N bond to give the intermediates (5) and (6 ) . But the 
2+ 
rate at which the Cu-N bond is broken in Cu(cyclam) i s much slower 
2+ 
than the rate at which the Cu-N bond i s broken in Cu(3,2,3-tet) . The 
l a t t e r breakage is e f fec ted by the displacement of a nitrogen donor by a 
solvent molecule S. The donor subsequently swings out of the primary 
2+ 
coordination sphere of the Cu ion and becomes protonated to give the 
intermediate (6 ) , which i s f u r t h e r s t ab i l i sed by solvation of the NH+ 
group. 
H* 
HN NH 
HN \ H 
H+ •NH* 
aj 
H 
y 
H 
H [ 
H V V NH N 
(1) 
4J 
Scheme 1.1: Breakage of the first G-N bond during the dissociation 
of Cu(cyclam)2* (3) and Cu(3,2,3-tet)2* (£) in strongly 
acidic media. 
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The Cu(cyclam) intermediate (5) i s produced by the protonation of 
a n i t rogen donor and the occupation of the vacant coordination s i t e by a 
solvent molecule. However, by the t w i s t i n g and f o l d i n g of the r i n g , the 
leaving group i s held i n the primary coordination sphere, hindering the 
coordination of the solvent molecule and also the solvation of the NH+ 
group. The formation of t h i s intermediate i s thus considerably slower 
2+ 
than tha t of the Cu(3,2,3-tet) intermediate (6 ) . The enhanced k i n e t i c 
2+ 
s t a b i l i t y of Cu(cyclam) i s therefore a property of the macrocyclic 
r i n g . 
1.4.11 Macrocyclic Complexing Agents f o r Y t t r i u m ( I I I ) and the Scope of 
t h i s Work 
Judicious choice of macrocycle can lead to a metal ion complex 
which i s both thermodynamically and k i n e t i c a l l y stable. With t h i s i n 
mind, the fo l lowing macrocyclic ligands were proposed as y t t r i u m ( I I I ) 
complexing agents ( f o r t h e i r s t ructures , see Figure 1.11): 1,4,7,10-
tetraazacyclododecane-l,4,7,10-tetraacetic acid (DOTA) (7 ) , 1,4,7,10-
te t raazacyelotr idecane- l ,4 ,7 ,10- te t raacet ic acid (TRITA) (8 ) , 1,4,8,11-
te t raazacyc lo te t radecane- l ,4 ,8 , l l - t e t raace t ic acid (TETA) ( 9 ) , 4-(N-
benzyl-N-methylcarboxamidomethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-
t r i a c e t i c acid (DOTA-BMA) (10), l-oxa-4,7,10-triazacyclododecane-4,7,10-
t r i a c e t i c acid (ODOTRA) (11) and l ,7-dioxa-4,10,13-tr iazacyclopenta-
decane-4,10,13-triacetic acid (DTGTA) (12). As such, they possess the 
f o l l o w i n g v i r tues : 
(a) A coordination number of eight(seven in the case of (11 ) ) . 
(b) N and 0 hard donor s i t e s . 
(c) At least three l i g a t i n g carboxylate groups with which to 
reduce the charge density on Y 3 + . In addi t ion , DOTA-BMA (10) 
- 16 -
H05Q CO,H H 0 p C Q H 
C0 2 H qp 2 H 
C0 2H 0 ) 2 H H02C C0 2H H0 2C > ^ C0 2H 
DOTA TRITA TETA 
(i) (a) (a) 
^ C 0 2 H 
Me / N j ^ X 
p h . ^ ^ > ^ 
DOTA-BMA 
(10) 
^ C 0 2 H 
HO2C^MI ^^co 2 H Jb N f l ) w 
CO2H HOgb Cfo2H 
ODOTRA DTCTA 
(11) (12) 
Figure 1.11: Uacrocyclic candidates for complexing yttrium(III). 
has a neutral l i g a t i n g amide arm. Amides are known to 
s t a b i l i s e cations of high charge density such as L i and Ca 
(and Y 3 + has a r e l a t i v e l y high charge densi ty) , eg. in the 
ortho l i t h i a t i o n of benzamide: 
L i 
f 
2 
Stab i l i s a t i on is achieved p r i n c i p a l l y through an electro-
s t a t i c in t e rac t ion , amides having appreciable ground state 
dipole moments (3.70 - 3.85 d e b y e ) 2 9 ' 3 0 . 
The aims of t h i s research were to synthesize each of the above 
macrocyclic ligands and to gauge, where possible, the thermodynamic 
s t a b i l i t y of t h e i r y t t r i u m ( I I I ) complexes, and t h e i r rate of uptake of 
Y 3 + in aqueous so lu t ion , the l a t t e r wi th the aid of *H NMR spectroscopy 
and HPLC radiometry (Chapter 2 ) . I t was then undertaken to measure the 
rate of dissociat ion of Y(DTPA) as a func t ion of pH and to attempt a 
comparison wi th the y t t r i u m ( I I I ) macrocyclic complexes of promising 
candidates from ligands (7) - (12) (Chapter 3 ) . The ligand which 
exhibi ted rapid Y 3 + uptake and which in addi t ion formed an y t t r i u m ( I I I ) 
complex which was both thermodynamically and k i n e t i c a l l y stable at low 
pH (0-3) would then be funct ional i sed f o r linkage to a monoclonal 
antibody in order that the r ad io l abe l ed MoAb conjugate might be used in 
radioimmunotherapy (Chapter 4 ) . 
- 17 -
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CHAPTER TWO 
SYNTHESIS OF THE MACROCYCLIC LIGANDS AND ASPECTS OF THE 
STABILITY, STEREOCHEMISTRY AND RATE OF FORMATION 
OF THEIR YTTRIUM(III) COMPLEXES 
2.1 IWTMDUCTI1W 
The use of gadolinium complexes as contrast-enhancing agents f o r 
nuclear magnetic resonance imaging 1 has led to a boom i n lanthanide 
1- 3 
macrocyclic chemistry . Consequently, several of the ligands chosen 
f o r t h i s work had considerable precedent. 
DOTA, TRITA and TETA were f i r s t made in 1976 by Stet ter and Frank 6 . 
Notably they found that DOTA forms the most therroodynamically stable 
calcium complex in aqueous so lu t ion known to date ( log = 1 7 . 2 ) . 
Other workers have since shown that the Ln(DQTA)" complexes possess even 
larger s t a b i l i t y constants [eg. log K = 24.6 f o r Gd(DOTA)"] 8 ' 9 . Also 
encouraging was the f a s t complexation k ine t i c s (bQ^s of the order of 
-1 10 s ) observed f o r DOTA and TETA-alkaline earth systems . 
DOTA-BMA and ODOTRA can be thought of as being derived from DOTA by 
replacing an N-acetate group wi th an amide arm and an ether linkage 
respect ively. The loss of a charged donor to a neutral one should give 
a neutral y t t r i u m ( I I I ) complex - the y t t r i u m ( I I I ) complexes of DOTA, 
TRITA and TETA on the other hand a l l bear a single negative charge. 
Being neutral should make the complex less sensi t ive to acid-promoted 
1 Nuclear magnetic resonance imaging (Ref.4) is a technique used to 
locate tumours as opposed to destroying them (therapy). I t r e l i e s on 
the d i f fe rence in the values of Ti ( s p i n - l a t t i c e re laxat ion time) and T2 
(spin-spin re laxat ion time) of the water protons i n normal and malignant 
t i ssue . I f a uniform magnetic f i e l d i s applied across a section of 
t issue eg. in the leg, a l l the water protons i n that section w i l l 
resonate at one pa r t i cu la r frequency. I f , however, a gradient f i e l d is 
applied across the section, water protons at d i f f e r e n t points along the 
gradient w i l l resonate at d i f f e r e n t frequencies and a cor re la t ion can be 
established between proton frequency and distance along the gradient . 
Thus the pos i t ion of tumour-associated water protons, and therefore the 
tumours themselves, can be picked out . Paramagnetic contrast-enhancing 
agents (Ref.5) shorten the Ti and T2 times of water protons which i n 
turn afreets signal i n t e n s i t y . I f the contrast-enhancing agents can be 
directed to the s i t e of a tumour, by l i n k i n g them to antibodies f o r 
instance, they w i l l increase the d i f fe rence between the signal 
i n t ens i t i e s of normal t issue and those of malignant t issue and the 
pos i t ion of the tumour w i l l therefore become more d i s t i n c t . 
- 21 -
dissocia t ion and therefore k i n e t i c a l l y more stable. 
Although there was no precedent f o r DTCTA, the s t a b i l i t y constants 
of the lanthanide complexes of a macrocyclic ligand s imi la r to i t , (13), 
had been reported* 1 . 
g o 
The macrocyclic ligand (13) exhibited a s e l e c t i v i t y f o r lanthanides i n 
the middle of the series (Figure 2.1) which was ascribed to the match 
between the size and charge density of the metal ion. Incorporating a 
t h i r d carboxylate group in to a s imi la r 15-membered r i n g , i t was 
reasoned, could only improve t h i s match. 
10 
S 
+ + 
_ 1 _ 1 _ i 1 1 L _ 
56 57 5 8 59 60 61 62 63 64 65 66 67 68 69 70 71 72 
Lo Eu Lu 
Atomic number 
Figure 2 . 1 : Logarithmic stability constants for the lanthanide 
complexes of (13) (Ref.ll). 
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Like ODOTRA and DOTA-BMA, DTCTA should form a neutral complex wi th Y 3 + . 
A f t e r ou t l i n ing the syntheses of the ligands, the emphasis of t h i s 
chapter i s placed on the thermodynamic s t a b i l i t y and the rate of 
formation of t he i r y t t r ium complexes. Kinet ic s t a b i l i t y i s discussed in 
Chapter 3. 
2.2 SYNTHESIS 
2.2 .1 Synthesis of the Tetraaza Tetracarboxylic Acid Hacrocycles 
The general synthesis of the tetraaza te t racarboxyl ic acid 
macrocycles as used by Stet ter and Frank i s given in Scheme 2 .1 . 
r 
(CH2)n 
Ts y—vTs 
Ts 
i . i l 
Ts 
DOTA: m=2; n=2 
TRITA: m=3; n=2 
TETA: m=3; n=3 
r 
( C H 2 ) n 
T s y — v Ts 
Ts 
(CH 2 ) m -
Ts 
111,1V 
< r 
(CH2)n 
< 
COzH 
N> 
CO2H 
CCfeH 
( C H 2 ) m 
< 
> 
CQ>H 
Scheme 2 . 1 : Reagents: i, NaOEt; ii, TsOfCfc)mOTs, DMF; Hi, H2S04 
or HBr, CH3C02H, PhOH; iv, ClCHo^H, NaOH. 
In the synthesis of DOTA, our own work employed two modif icat ions 
to t h i s route. The f i r s t was to use caesium carbonate/DMF i n the 
cyc l i s a t i on step and the second was to use a dissolving metal reduction 
to deprotect the 12N4 r ing (Scheme 2 .2 ) . 
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C0 2 H CO,H 
H H TsN NTs N N . . . ^ 
T & N N T s Hf^ N 
HTs Ts 
HTs 
< > 
CO,H C O , 
0,H (!§-) 15.) (14J 
(2D 
Scheme 2.2: Reagents: i, TsO(CH2)20Ts, Cs^COz> DMF; ii, Li, NH3, 
EtOH, THF; i n , ClCfoflkH, NaOH. 
12 13 
The caesium carbonate reaction ' has two advantages over the 
sodium ethoxide cyc l i sa t ion method: i t can be applied to the synthesis 
of large rings (up to 28-membered) wi th high yields and i t i s not messy. 
The reaction i s carr ied out in a single vessel in DMF in which caesium 
carbonate forms a suspension. One equivalent of caesium carbonate is 
required per tosylamide to be deprotonated - HCOg is not a strong enough 
base to deprotonate the second tosylamide e i ther cleanly or at a 
reasonable ra te . As a dipolar aprot ic solvent with good cat ion and poor 
anion solvat ing a b i l i t i e s , DMF promotes S 2^ reactions. Two S^2 
displacements are involved in t h i s pa r t i cu l a r cyc l i s a t ion (Figure 2 .2 ) . 
Ts Ts Ts 
T s O ^ 
N N " Cs Ts O 
c o J C 1 + s N N - Cs N~ Cs+ T s Ts Ts Ts 
( IV) III) ( ID ( I ) 
Figure 2.2: The caesium carbonate reaction. 
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The e f f e c t iveness of caesium carbonate in mediating these displacements 
is a resu l t of the caesium ion being highly solvated i n DMF. This leaves 
two reactive species in so lu t ion , the doubly deprotonated tosylamide ( I ) 
and the singly deprotonated tosylamide ( I I I ) . As a dinucleophile, ( I ) 
w i l l be approximately twice as reactive as ( I I I ) , a mononucleophile. 
Thus ( I I ) w i l l prefer to react with ( I ) , ie. k ^ k ^ , and ol igomerisat ion, 
the major side reaction in cyc l i sa t ions , w i l l be minimised. Other a l k a l i 
metal carbonate sa l t s are less e f f e c t i v e in promoting cyc l i s a t i on , 
implying that t h e i r cations are less wel l solvated by DMF. 
Reagents used f o r the d issolving metal reduction were l i t h i u m in 
ammonia wi th ethanol as the proton source and THF as the co-solvent. 
This procedure was adopted because i t gave 1,4,7,10-tetraazacyclo-
dodecane, cyclen (16) , as a white c r y s t a l l i n e s o l i d , corresponding to 
i t s tetrahydrochloride monohydrate s a l t , i n good y i e l d (727.) while 
avoiding the laborious work-up of the concentrated sulphuric acid 
method. Also the y ie lds obtained using the I^SO^ method (<207.) were 
never as high as reported (>907.)^ and inconsistent . 
A lky la t ion of cyclen was achieved with chloroacetic acid. During 
the course of t h i s reaction i t was important to maintain the pH between 
9 and 10 with periodic addit ion of sodium hydroxide in "order to 
neutral ise the HC1 generated and ensure that the nitrogen lone pairs 
were unprotonated and f r ee to act as nucleophiles. 
TRITA was synthesized according to Scheme 2 . 1 , subs t i tu t ing the 
caesium carbonate method f o r the sodium ethoxide method in step i . 
Hydrobromic ac id , g l a c i a l acetic acid and phenol were used to 
reduct ively deprotect the tosylated r i n g since the resul tant amine was 
easi ly isolated as i t s 4HBr s a l t . 
As the 14-membered tetraamine, cyclam, was commercially avai lable , 
the synthesis of TETA was ef fec ted according to l i t e r a t u r e precedent . 
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2.2.2 Syatlesis of MTA-BOA 
The strategy adopted to synthesize DQTA-BMA was to f i r s t introduce 
the pendent amide arm onto the 12N4 r i n g by a sui table monoalkylation 
reaction and then to attach the three carboxylic acid groups. 
15 
Of the several methodologies avai lable f o r monoalkylating 
polyazamacrocycles, two were attempted: a lky la t ion of t r i - p ro t ec t ed 
cyclen [Scheme 2 . 3 ( i ) ] and select ive a l k y l a t i o n of cyclen 
[Scheme 2 . 3 ( i i ) ] . 
Alkylation of Tri-protected Cyclen 
Perversely, the t r i - p r o t e c t e d cyclen was obtained by a select ive 
a l k y l a t i o n . This involved react ing cyclen with two equivalents of t o s y l 
chlor ide in the presence of t r ie thylamine and separating the di tosyla ted 
and t r i t o s y l a t e d der ivat ives by column chromatography. A f t e r react ing 
the t r i t o s y l a t e d cycle (19) wi th l-bromo-N,N-dimethylethanamide, 
deprotection was attempted wi th a hydrobromic ac id , g l a c i a l acetic acid 
and phenol mixture. A f t e r two weeks, the monotosylated der ivat ive (21) 
was isolated (as confirmed by CI mass spectroscopy and *H NMR) as i t s 
£3rf N 
NR'R" H 
C*7 ^ 
RN NH 0|0 K2CQ, 
H 
NR'R ( i f i j R=H 
N 
R=Ts 
R=H 
R'=Me 
RB=CH2Ph 
R=Ts 
R'=R"=Me 
Scheoe 2.3 
- 26 -
HBr s a l t . 
H 1 NMe sr H N Ts 
( 2 1 ) 
Prolonged treatment under the same conditions f a i l e d to remove the 
tosyla te group. Lithium, ammonia and ethanol may have been successful, 
but competitive t e r t i a r y amide reduction was deemed l i k e l y to occur. 
Selective Alkylation 
By choosing an a lky l a t i ng agent with a UV act ive chromophore, the 
a l k y l a t i o n reaction could be monitored by ana ly t i ca l cat ion exchange 
HPLC. The a l k y l a t i n g agent i n t h i s case was 2- bromo-N-benzyl-N-niethyl-
ethanamide. Two peaks developed over 24 h. (Figure 2 .3 ) . Separation of 
these peaks by semi-preparative cation exchange HPLC and analysis by 
NMR and DCI mass spectroscopy indicated that the f i r s t (R_t 7.6 min) was 
the d ia lky la ted cyclen der ivat ive and that the second (R^ 8.1 min) was 
the monoalkylated der ivat ive (20). 
I 
ft 
Time (min) 
Figure 2.3: HPLC trace showing appearance of mono- and dialkylated 
products (at 8.1 and 7.6 min respectively) in the treatment 
of cyclen with 2-bromo-N- benzyl-N-methylethanamide. 
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The carboxylic acid groups were not introduced at t h i s stage because the 
conditions of attachment (ClCH^CO^H/NaOH) would have resulted in 
a lka l ine hydrolysis of the amide group. Instead, ester f u n c t i o n a l i t i e s 
were attached using ethyl bromoacetate in DMF in the presence of 
potassium carbonate. Af te r p u r i f i c a t i o n , the ester groups were 
se lec t ive ly hydrolysed under mi ld ly basic conditions to give DOTA-BMA 
(Scheme 2 .4 ) . 
^ 0 2 H 
< 
3 Me N H H N Ph 1,11,111 N H HN L71 
OoH 
DOTA-BMA 
(Ul ) 
Scheme 2.4: Reagents: », BrCH2C0NMeBz, K2C0z, DMF; i i , BrCH2C02Et, 
K2C03, DMF; Hi, MeAN0H, MeOH, H20. 
2.2.3 Synthesis of the Polyoxa Polyaza Tr ica rboxyl ic Acid iacrocycles 
Scheme 2.5 outl ines the synthesis of ODOTRA. 
C3 H Ts £3 £ H o 2 c r ^ N NH 11 1,11 > H Ts N N NH H Ts 
OM {23.) 
(11) 
Scheme 2.5: Reagents: i, Ts(OCH2CH2)oOTs, CsoC03, DMF; ii, HBr, 
CH3CO2H, PhOH; Hi, ClCH2C02H, Me4iWH. 
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The only point of note here i s the p u r i f i c a t i o n of the HBr sa l t of (25) . 
The anion exchange resin used f o r t h i s was converted to the OH" form 
with a tetramethylammonium hydroxide solut ion as opposed to a sodium 
hydroxide or potassium hydroxide so lu t ion , thereby avoiding the 
p o s s i b i l i t y of complexation of Na+ or K + by the l iberated f ree amine. 
For the same reason, tetramethylammonium hydroxide was used as the base 
in the subsequent a lky l a t i on react ion. 
The synthesis of DTCTA (Scheme 2.6) began with the tosy la t ion of 
the known d i o l (26) followed by a Gabriel synthesis to convert the two 
-OTs groups into primary amines. 
(-<r\ 
HN 
Co 
H H 
HN I V . V . V I 1,11, I I I 
J NTs  NH HN 
OH H 
12, (2S. 
< 
0,H 
V - N N-^y 
N 
V I I , V I I I 
N  
i2C CO, oH HO 
( 1 2 ) 
Scheme 2.6: Reagents: i, TsCl, pyridine; ii, potassium phthalimide, 
DMF; Hi, N2HA, HCl; iv, TsCl, faC02, H-,0; v, TsOCH2CHoOTs, 
Cs2C03, DMF; vi, HBr, CH3C02H, PhOH; vii, BrCH2C02Bz, " 
Cs2C03, DMF; viii, HCl. 
The second tosy la t ion , step i v , was found to give better yie lds (607. vs. 
<507o) using potassium carbonate rather than pyridine as the base. Steps 
v and v i were as previously ou t l ined . Caesium carbonate was used as the 
base i n the a lky l a t i on react ion, step v i i , to avoid any metal ion 
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HBr s a l t . 
H 
Me 
H 
N 
Ts 
(21) 
Prolonged treatment under the same conditions f a i l e d to remove the 
tosy la t e group. Li thium, ammonia and ethanol may have been successful , 
but competit ive t e r t i a r y amide reduction was deemed l i k e l y to occur. 
Selective A Iky lot ion 
By choosing an a l k y l a t i n g agent wi th a UV act ive chromophore, the 
a l k y l a t i o n react ion could be monitored by ana ly t i ca l cation exchange 
HPLC. The a l k y l a t i n g agent in t h i s case was 2-bromo-N-benzyl-N-methyl-
ethanamide. Two peaks developed over 24 h. (Figure 2 .3 ) . Separation of 
these peaks by semi-preparative ca t ion exchange HPLC and analysis by *H 
NMR and DCI mass spectroscopy indicated that the f i r s t (R^ 7.6 min) was 
the d i a l k y l a t e d cyclen der iva t ive and that the second (R^ 8.1 min) was 
the monoalkylated der iva t ive (20) . 
(V 
g» u 
Time (min) 
Figure 2.3: HPLC trace showing appearance of mono- and dialkylated 
products (at 8.1 and 7.6 min respectively) in the treatment 
of cyclen with 2-bromo-N- benzyl-N- methylethanamide. 
complexation by the r i n g , the caesium ion being too large (6-coordinate 
ionic radius = 1.67A) to be incorporated into i t s in te rna l cavi ty 
(diameter approximately 1.70 - 2 . 2 0 A ) 1 7 . The reaction was monitored by 
ana ly t i ca l cation exchange HPLC, the benzyl group of 2-bromobenzyl 
acetate providing a convenient UV chromophore. 
During the course of the a l k y l a t i o n , methanol was advent i t ious ly 
introduced in to the reaction mixture. Semi-preparative cation exchange 
HPLC succeeded in i so la t ing two products: (a) the t r i benzy l ester (33) 
and (b) a dibenzyl methyl ester (34), as characterised by DCI mass 
spectroscopy and H NMR. Presumably (34) had arisen from some methanolic 
t r a n s e s t e r i f i c a t i o n of (33). 
Cqjdco2CH2Ph 2 CjCco2R 1 * M . 
i m (24-) 
I t was not possible to specify the precise subs t i tu t ion pattern of (34). 
The t r ibenzy l ester (33) appeared to be unstable even when 
preserved under a nitrogen atmosphere, changing from a colourless to an 
orange o i l . Acid hydrolysis , as adduced by ^ NMR, did not give clean 
product. Curiously, acid hydrolysis of the mixed ester (34), by the 
same c r i t e r i o n , d i d . 
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2.3 STABILITY CTOCTAOTS W TBE TBTEMZA TOTMCAfflBSHmiC ACT 
E3ACRI0CYG.L1C CPLEXES HDF YTTRUE ( I I I ) 
The s t a b i l i t y constants of the 1:1 y t t r ium ( I I I ) complexes of DOTA, 
TRITA and TETA were measured2 by slow (up to 48h. in the case of DOTA) 
potentiometric t i t r a t i o n s . 
There are two experimental de ta i l s worthy of note. F i r s t , a 
potentiometric t i t r a t i o n with the pre-formed Y(DOTA) complex allowed 
ca lcula t ion of the protonation constant f o r the l a t t e r , pK = 3.08. 
Second, tetramethylammonium n i t r a t e as opposed to potassium n i t r a t e or 
sodium chloride was used to keep the ionic strength constant during the 
t i t r a t i o n s . DOTA in pa r t i cu la r has been shown to form stable complexes 
with K + ( log K M L = 1.6) and Na+ ( log K M L = 4 . 4 ) 7 . [The Ln(DOTA)" 
8 Q 
s t a b i l i t y constants measured by several groups ' must therefore be 
treated with some suspicion] . 
The t i t r a t i o n data were analysed by the computer program 
18 
SUPERQUAD . This i s able to minimise the errors encountered during a 
t i t r a t i o n , eg. from electrode readings and ligand impur i t i e s , by a non-
l inear least squares treatment. The s t a b i l i t y constants obtained by 
t h i s method are given in Table 2.1 together with the s t a b i l i t y constants 
of Y(DTPA)2" and Y(EDTA)" f o r comparison. 
SPECIES D0TAa TRITA a TETAa DTPA19 EDTA1 9 
YL 24.9 19,6 16.3 22. l b 1 8 . l b 
Table 2 . 1 : Stability constants (log K) of the yttrium(III) complexes 
of DOTA, TRITA, TETA, DTPA and EDTA; a) T=298±0.1K, 1=0.1M 
[(Ch)iMOi]; b) T=298K, 1=0.1M [KNOi]. 
Therefore of these f i v e complexes, Y(DOTA)" i s the most stable by almost 
2 by Ri tu Kataky. 
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three orders of magnitude. 
Within the tetraaza te t racarboxyl ic acid macrocyclic series, the 
trend i n s t a b i l i t y i s Y(DOTA)" > Y(TRITA)" > Y(TETA)". Factors 
in f luenc ing th i s trend might be the s te r ic crowding and tors iona l s t r a in 
w i t h i n the metal chelate rings of the complexes: 
6b 6b 6b ^ i j u 
DOTA TRITA TETA 
I t i s known that the propylenediamine groups of 6-membered chelates 
are more s t e r i c a l l y crowded (ie. there are more unfavourable ecl ips ing 
in teract ions) than the ethylenediamine groups of 5-membered chelates^. 
Since s t e r i c crowding resul ts i n a loss of s t a b i l i t y , Y(TETA)", with two 
6-membered and two 5-membered chelates, w i l l be less stable than 
Y(TRITA) with three 5-membered and one 6-membered chelate, which in 
tu rn w i l l be less stable than Y(DOTA)" with four 5-membered chelates. 
Furthermore, the to r s iona l s t ra in imposed on the 5-membered ethylene-
diamine chelate r i n g i s less than that imposed on the 6-membered 
propylenediamine chelate r i ng f o r the chelation of a r e l a t i v e l y large 
metal ion such as y t t r i u m ( I I I ) , ie. the "b i te" of the ethylenediamine 
un i t i s bet ter suited to the ionic radius of y t t r ium (here 8-9 co-
ordinate) than i s the "b i t e " of the propylenediamine un i t (the s i tua t ion 
+ 2+ 20 
is reversed with r e l a t i v e l y small ions such as L i and Be ) - . 
Another f ac to r in f luenc ing the trend in s t a b i l i t i e s i s molecular 
geometry, i n which the conformation of the macrocyclic r i n g plays a 
v i t a l par t . Macrocyclic conformation i s usually described in terms of 
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the number of bonds between corners in a r i n g . To define a corner i t 
is necessary to introduce the concepts of the gauche bond, the an t i bond 
and the to rs iona l angle. The to r s iona l angle, d), i s the angle between 
the neighbouring bonds which propagate the hydrocarbon chain in the 
niacrocyclic r i n g (Figure 2 .4 ) . 
2 1 
3 
Figure 2.4: Newman projection depicting the torsional angle (j) 
for a macrocyclic ring. 
Gauche bonds are defined as those bonds with < 90° . Thus a n t i bonds 
are those wi th |(b| > 90° . Corners occur (a) at the junct ion of two 
gauche bonds, (b) at the junct ion of an isolated gauche bond and the 
adjacent bond with the smaller |<b| and (c) where an isolated gauche bond 
has a two- fo ld axis . Thus the 9-membered NgS macrocyclic r i n g adopts a 
2+ 21 
[234] conformation i n i t s Cu complex , there being two, three and 
four bonds between i t s three corners: 
98 116 
-50 
38 
Cu 75 
67 N N 
85 
150 
45 
I 2 3 4 I 
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From a c rys ta l s tructure of the Eu(DCTA)H20~ complex 2 2 and from NMR 
studies, our own (see Section 2.4) and those of Desreux2"*, i t i s l i k e l y 
that the geometry of the donors in the Y(DOTA)" complex is square an t i -
pr ismatic , with the four oxygen atoms of the carboxylate groups in one 
plane of the square ant ipr ism, and the four nitrogen atoms of the r i n g 
in the other (Figure 2 .5 ) . 
N — — — — — N 
Figure 2.5: Proposed square antiprismatic geometry of the 
Y(DOTA)- complex. 
The repulsion energy of the square antiprism is the smallest f o r any 
8-membered polyhedron. 
I t is also l i k e l y that the 12N4 r i n g , both i n solut ion and in the 
s o l i d s tate , adopts a square quadrangular [3333] conformation. Of the 
two conformations a 12-membered r ing may adopt (the other being a 
rectangular [2424] arrangement), t h i s is the more stable. In t h i s 
conformation the nitrogen atoms are directed towards the same side of 
the r i n g and the protons of the methylenic groups are f u l l y staggered, 
it. i n t h e i r gauche forms (Figure 2 .6 ) . 
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1 79 N 79 60 166 
15 
Figure 2.6: Proposed [3333] conformation of the DOTA macrocyclic 
ring in Y(l)OTA). 
I n the absence of Ln(TRITA)" c rys t a l s t ructures 3 and in terpre table 
H NMR data (see Section 2 .4 ) , i t is not possible to say whether the 
arrangement of donors in the Y(TRITA)" complex i s square ant ipr ismat ic 
or dodecahedral. However, from the l i t t l e that is known about the 13N4 
system i t is probable that the macrocyclic r i n g exists in a [3334] 
conformation. I f i t does, the protons in the ethylene uni t d i r e c t l y 
opposite the propylene un i t w i l l be eclipsed, leading to a less stable 
s t ructure than that of the 12N4 system (Figure 2 .7) . 
N 
N 
N N 
Figure 2.7: [3334] conformation of the Ni(12,12-dimeihyl-l,4,7,10-
ietraazacycloIridecane)'2* complex (Rej[.21). 
The c rys ta l s t r u c t u r e 2 5 of Tb(TETA)" and H and 1 3 C NMR studies of 
the lanthanide TETA complexes suggest that the Y(TETA)" complex w i l l 
3A1though a sui table c rys t a l of Y(TRITA)" was obtained, the R f a c t o r of 
the complex was 29%, making d i s t i n c t i o n between ethylene and propylene 
uni ts impossible (Ref.24). 
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be dodecahedral and the r i n g w i l l assume a stable [3434] geometry. As 
implied above, the dodecahedral arrangement of donor atoms is less 
stable than the square ant ipr i smat ic . Figure 2.8 depicts t h i s 
dodecahedral arrangement in the c rys t a l s t ructure of Tb(TETA)". Note 
that the four carboxylate oxygens are no longer co-planar, and nor are 
the four nitrogen atoms. 
O f 
\ o r 
\ 
\ 
X / 
/ 
N 
Figure 2.8: Dodecahedral arrangement of donor atoms in the Tb(TETji)' 
complex (Kef.26). 
Fina l ly i t i s important to stress that the high thermodynamic 
s t a b i l i t i e s of Y(DOTA)", Y(TRITA)" and Y(TETA)" are not a resul t of the 
niacrocyclic e f f e c t . The cavi t ies of these ligands are too small ( r a d i i 
< 0.75A) ' to accommodate Y , which w i l l therefore l i e above the 
plane of the nitrogens. The importance of the macrocyclic r i ng l i e s 
more in i t s a b i l i t y to act as a frame to constrain the nitrogens and 
carboxylate groups i n a near spherical arrangement and to preorganise 
the nitrogen lone pairs f o r binding Y^ + such that they are a l l directed 
towards the centre of t h i s arrangement. The preorganisation leads to a 
favourable entropy term in the f r ee energy of complexation. 
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2.4 1M WK CMPLEMTM MPERIMTS 
The purpose of the H NMR complexation experiments was t w o - f o l d : 
f i r s t l y to obtain a q u a l i t a t i v e measure of the rate of uptake of by 
the ind iv idua l macrocyclic ligands i n aqueous so lu t ion and secondly to 
i n f e r the stereochemistries of the complexes from the *H NMR spectra. 
Spectra (250 MHz) of the ligands and t h e i r y t t r i u m ( I I I ) complexes 
(0.028 M) in buffered at pD 5.0 wi th deuterated sodium acetate 
(0.14 M) and acetic acid (0.06 M) at 293 K are shown in Figure 2.9. 
DOTA, TRITA, QDOTRA and DTCTA4 a l l formed 1:1 y t t r ium complexes 
(subsequently confirmed by FAB mass spectroscopy) i n less than 10 
minutes. Adding another equivalent of and heating the so lu t ion to 
50°C f o r 1 hour produced no f u r t h e r change. 
The Y(TETA)" spectrum did not appear to d i f f e r from the spectrum of 
TETA alone. This observation seems to contradict the s t a b i l i t y constant 
measurement of log K [Y(TETA)"] = 16.3 (Section 2 .3 ) , ie. that the 
formation of the Y(TETA)" complex is thermodynamically favourable. But 
t h i s value does not take in to account e i ther the protonation of TETA [at 
p P 5.0 the s i gn i f i c an t species w i l l be (TETA)H^~]^ or the competition 
f o r Y'*+ from other ligands, in t h i s case a 10- fo ld excess of AcO wi th 
respect to both metal ion and ligarid (Aft. log K [Y(AcO) 2 + ] = 1 . 6 8 and 
log K [Y(AcO)2] = 3 . 1 7 ) 1 9 . Both f ac to r s w i l l lead to a reduction in the 
thermodynamic s t a b i l i t y of Y(TETA)". Also, at pH 5.0, the Y(TETA)" 
complex could become protonated to form Y(TETA)H, the s t a b i l i t y 
constant, log K ^ h * of which w i l l be considerably lower than log K 
4As the charge on a po1yaminocarboxylate l igand and on i t s y t t r i u m ( I I I ) 
complex depends on t he i r degree of protonation, i n turn depending on the 
pH, the convention i n t h i s and subsequent chapters has been to omit the 
charge, other than where i t has been possible to be more precise. 
5pH rather than pD is considered here, simply f o r c l a r i t y . 
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Figure 2.9: MT spectra (250 Mz) of the ligands ( l ) - ( l t ) 
and their 1:1 complexes with P + (020, pD 5.0, 293K 
i) DOTA and Y(DOTA); ii) TRITA and Y(TRITA). 
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Figure 2.9: Hi) TETA and TETA in the presence ofY* + , 
(cent 1 d) iv) DOTA-BMA antY(DQTA-BttA). 
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Figure 2.9: v) ODOTRA and Y(ODOTRA); vi) DTCTA and ¥(DTCTA) 
(cont 'd) 
[Y(TETA)"], probably less than 10, 
DOTA-BMA complexed Y 3 + more slowly. Af t e r 1 week and heating to 
50°C f o r 1 hour, complexation was s t i l l not complete. Addition of 
another equivalent of Y gave the 1:1 complex. 
The complexity of the Y(TRITA), Y(DOTA-BMA) and Y(DTCTA) spectra 
precludes any detai led analysis. However, the sharpness of the l a t t e r 
two spectra indicates that at room temperature the DOTA-BMA and DTCTA 
rings are r i g i d . On the other hand, the broad Y(TRITA) spectrum 
suggests that the 13N4 r ing i s conformationally mobile at the same 
temperature. The v a l i d i t y of these comments w i l l become apparent in the 
f o l l o w i n g discussion of the Y(DOTA) and Y(ODOTRA) spectra. 
2 .4.1 Y(DUTA) 
The spectrum of Y(DOTA) [Figure 2 . 9 ( i ) and Figure 2.11] shows a 
d i s t i n c t AB s p l i t t i n g pattern to high frequency [(a) and ( c ) , J^g = 16 
Hz], ha l f of another AB system to low frequency [ ( e ) , J^g = 14 Hz] and 
what are essent ia l ly two mul t ip le ts [(b) and ( d ) ] . By analogy with 
Desreux's work on the diamagnetic lanthanide (La and Lu + ) complexes 
23 
of DOTA , the AB system to high frequency can be assigned to the 
acetate CH2 protons. They appear as an AB system according to the 
f o l l o w i n g ra t iona le . 
The acetate protons of aminocarboxylate complexes can appear as 
a s ingle t or as an AB quartet. Which depends on the r e l a t i v e l i f e t i m e s 
of the metal-nitrogen and metal-oxygen bonds. I f both are short a 
s ingle t i s obtained. But i f the l i f e t i m e of the metal-nitrogen bond is 
long r e l a t i v e to that of the metal-oxygen bond, an AB pattern is 
observed. Newman projections along the acetate ( ^ - N bond with the 
carboxylate group ro ta t ing help to demonstrate t h i s : 
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When R 4- R 1 , i n EDTA where R = an ethylene group and R1 = H, then 
and are non-equivalent (diastereotopic) i n a l l three or ientat ions and 
an AB pattern arises. When R = R 1 , as in NTA (R = Ch^CO^), and 
are equivalent in a l l three or ienta t ions and a s inglet resul ts 
(Figure 2.10). 
Y(EDTA) 
JU 
Y(NTA) 
4 3 
8(ppm) 8{ppm) 
Figure 2.10: iH MR spectra (250 MHz) of ihe 1:1 P+: EDTA 
and NTA complexes. 
In DOTA, R = R1 = an ethylene group, and therefore the acetate CH9 
protons should appear as a s ing le t . However, the square [3333] 
conformation of the r ing means that although the four ethylene groups 
are i n iden t i ca l conformations, t h e i r d i spos i t ion r e l a t i v e to each other 
on e i ther side of a coordinating nitrogen atom w i l l be d i f f e r e n t . Thus 
28 
R f R ' , the nitrogen atom is a stereogenic centre and the acetate Ch^ 
protons w i l l be diastereotopic, appearing as the AB quartet (a) and ( c ) . 
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The protons at ( b ) , (d) and (e) integrate i n the r a t i o 4:8:4 
respect ively. Figure 2.11 shows the 12N4 r ing in i t s [3333] conformation 
and the probable locations of these protons. 
Y(OOTA) 
d 
e 
b e 
N e 
N 
N 
A N 
d 
4 
5(ppm) 
Figure 2 .11: Assignment of peaks in the 1H MR spectrum of Y(DOTA). 
The four protons (b) are assigned to those at the corners of the 
s t ructure and directed in to the plane of the paper because in these 
posi t ions they w i l l be near the carbonyls of the acetate groups and 
therefore subject to the carbonyl anisotropic deshielding e f f e c t . 
The AB doublet at (e) is assigned to the four protons geminal to 
the (b) protons. These are directed out of the plane of the paper and 
as such are remote from the influence of the carbonyl groups. A 
spin-spin decoupling experiment i n d i r e c t l y confirmed t h i s assignment. 
The decoupling power was applied to the mul t ip le t at ( d ) . Following 
i r r a d i a t i o n , the protons at (b) collapsed to an AB doublet with the same 
coupling constant ( f o r that pa r t i cu la r spectrum), 13 Hz, as the AB 
doublet at (e) : 
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The protons at ( b ) , (d) and (e) integrate in the r a t i o 4:8:4 
respect ively. Figure 2.11 shows the 12N4 r i n g in i t s [3333] conformation 
and the probable locations of these protons. 
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Figure 2 .11 : Assignment of peaks in the 1 H AW spectrum of Y(DOTA). 
The four protons (b) are assigned to those at the corners of the 
s t ruc ture and directed in to the plane of the paper because in these 
posi t ions they w i l l be near the carbonyls of the acetate groups and 
therefore subject to the carbonyl anisotropic deshielding e f f e c t . 
The AB doublet at (e) is assigned to the four protons geminal to 
the (b) protons. These are directed out of the plane of the paper and 
as such are remote from the influence of the carbonyl groups. A 
spin-spin decoupling experiment i n d i r e c t l y confirmed t h i s assignment. 
The decoupling power was applied to the mu l t i p l e t at (d ) . Following 
i r r a d i a t i o n , the protons at (b) collapsed to an AB doublet wi th the same 
coupling constant ( f o r that p a r t i c u l a r spectrum), 13 Hz, as the AB 
doublet at (e ) : 
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At room temperature, the energy barr ier f o r interconversion of the 
ethylene groups in Y(DOTA) is obviously too high. 
Thus invoking the p re fe ren t i a l adoption of the [3333] 12N4 r ing 
conformation permits an in te rpre ta t ion of the Y(DOTA) spectrum. 
2.4.2 Y(ODOTRA) 
Unlike Y(DOTA), the Y(ODOTRA) complex is conformat iona l^ mobile at 
room temperature [Figure 2 . 1 3 ( i v ) ] . Cooling down to 278K resulted in 
f u r t h e r broadening [Figure 2 . 1 3 ( i ) - ( i i i ) ] . Because of the p o s s i b i l i t y 
of DgO f reez ing , the behaviour of the complex below 278K was not 
invest igated. Raising the temperature above 293K, to 333K, resulted in 
considerable sharpening and the appearance of several AA'BB1 systems. 
The o r i g i n of these AA'BB1 systems can be explained with reference to 
Figure 2.12. At high temperatures the ethylene groups rapid ly inter-
convert between the two forms shown, with the resul t that the two 
posi t ions which each proton can occupy become indis t inguishable - an 
AA'BB' pattern ar ises . 
Peaks ( a ) - ( f ) [Figure 2 .13(v i ) ] integrate in the r a t i o of 
2:2:6:6:2:4 respect ively . Spin-spin decoupling experiments indicate 
that the peak at (c) corresponds to the three acetate Ch^ protons (ie. 
they are unaffected by any decoupling). Peaks (a) and (b) are coupled 
to (e) and two protons hidden under (d ) . The four protons corresponding 
to ( f ) , probably NCH^ protons, are coupled to the other four protons at 
(d ) . These re la t ionships are summarised in Figure 2.14. 
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Figure 2,13: lH NMR spectra (250 MHz) of Y( ODOTRA) at various 
temperatures in DiO (pD 5.0). 
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Figure 2.14: 1 H NMR spectrum (250 MHz) showing coupling 
within Y(ODOTRA) at 333K. 
At high temperatures, the ethylene groups of the lanthanum(III) and 
l u t e t i u m ( I I I ) complexes of DOTA also exh ib i t AA'BB' s p l i t t i n g patterns 
while the acetate CR^  protons appear as a s ing le t . This suggests tha t 
i f i t were possible to lower the temperature to below 278K, the broad 
peaks of the Y(ODOTRA) spectrum would resolve in to AB (acetate CH2 
protons) and ABCD (ethylenic protons) systems, as observed f o r the two 
lanthanide complexes. A r b i t r a r i l y tak ing 278 ± 5K as the coalescence 
temperature, T , of the Y(ODOTRA) ethylenic protons, and est imating A^ 
to be 33 ± 2 Hz gives a f r ee energy of ac t i va t i on of 58 ± 2 kJ mol"*, 
according to the f o l l o w i n g equation: 
AG+ = RTC(22.96 + In [T / A f ] ) 
This f i g u r e is very close to the f r ee energy of ac t iva t ion of the 
e thylenic protons of La(DOTA), AG+ = 61 ± 1 kJ m o l " 1 . Thus Y(ODOTRA) 
shows a s i m i l a r low temperature r i g i d i t y to the lanthanide DOTA 
complexes. 
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2.5 RATE TOF FMRUAR1D) BIMMNfi AS ASSESSED BY IPLC M l I M f f i T I Y 6 
3+ 1 
The concentrations of macrocyclic l igand and Y used in the H NMR 
experiments above, 0.028 M, are much greater than those of monoclonal 
antibody conjugate (ie. the MoAb l inked to a macrocycle) and ^V* + which 
would be used in radioimmunotherapy: i f administrat ion of 20 mCi of 
i s required to destroy a tumour o f , f o r example, 5g, and i f the i n i t i a l 
r ad io l abe l l i ng of the MoAb conjugate were ef fected in 1 ml of solut ion 
with a MoAb c o n j u g a t e : ^ Y 3 + r a t i o of 10:1, the concentrations of the 
l a t t e r would be 4 x 10" 6 M and 4 x 10" 7 M respectively (1 mCi of 9 0 Y = 
-11 90 3+ 2 x 10 mol). The concentrations of macrocyclic ligand and Y used 
in these semi-quantitative HPLC radiometric experiments, 1 x 10 - 5 x 
10"^ M and ( i n i t i a l l y ) a 10"** - 10" ^ M respect ively, were therefore 
more representative of c l i n i c a l condit ions. A 10:1 r a t i o of ligand : 
90y3+ c o u y n o t j j 6 r e a i i s e ( j under normal laboratory circumstances 
because of the safety hazard incurred in using a c t i v i t i e s of greater 
than 2 raCi. 
In a t y p i c a l experiment, the extent of complexation ( l a b e l l i n g 
e f f i c i e n c y ) was estimated by removing an a l iquot of the reaction 
mixture, adding a so lu t ion of DTPA (the so lu t ion so formed being 5 x 
10 M with respect to DTPA and 1 x 10" M with respect to macrocyclic 
l igand) to complex any f r e e ^0y3+^ and analysing the r e l a t ive amounts of 
^ Y (macrocyclic ligand) complex and ^Y(DTPA) by anion exchange HPLC 
(Hichrom AX 300 column coupled to a Beckman 170 Radioisotope Detector, 
e l u t i n g wi th 0.2 M ammonium acetate : 107. a c e t o n i t r i l e ) - see, f o r 
example, Figure 2.15. 
6work done by Al ice Harrison and Karl Jankowski, Medical Research 
Council Radiobiology Uni t , Harwell. 
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Figure 2.15: HPIC analysis of a typical 9OY-D0TA 
complexation reaction. 
Addition of DTPA, with the p o s s i b i l i t y of metal exchange between i t 
and the ^Y(macrocyclic ligand) complex, also provided a measure of the 
k i n e t i c s t a b i l i t y of the l a t t e r in the presence of a complexing agent 
(DTPA) also forming a thermodynamically stable complex with Y 3 + . 
I n i t i a l l y , with the ^Y-DOTA system as the model, several fac tors 
were varied in order to optimise l a b e l l i n g e f f i c i e n c y : bu f fe r anion and 
ca t ion , pH, ionic strength, temperature and incubation period. Buffers 
were chosen with an operating range of between 4 and 6. This would be 
the range used when rad io labe l l ing the MoAb conjugate, chosen so as to 
minimise non-specific binding (Section 4 .6 ) . 
A d i rec t cor re la t ion seemed to exist between l a b e l l i n g e f f i c i e n c y 
and the s t a b i l i t y constants f o r the 1:1 Y(buffer anion) and buf fe r 
cat ion (DOTA) complexes. Thus f o r a given counterion and at pH 5.5, the 
l a b e l l i n g e f f i c i e n c y decreased according to the fo l l owing sequence 
( s t a b i l i t y constants, [ log K ^ ] , are in parentheses)^: 
AclT (1.7) > Succinate 2" (1.8)7 > C i t r a t e 3 " (7.9) and 
7 Figure f o r the protonated gadol in ium(I I I ) complex, which may be s imi l a r 
to that f o r the protonated y t t r i u m ( I I I ) complex. 
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NHt (neg l ig ib le ) > K + (1.6) > Na+ (4.4) 
Ensuing experiments therefore favoured an ammonium acetate b u f f e r . 
Increasing the pH from 4.0 to 5.5 ( p i 5.6 i s the upper l i m i t f o r 
the b u f f e r i n g action of NH^OAc) produced an increased l a b e l l i n g 
e f f i c i e n c y . The pK values f o r DOTA are 11 .1 , 9.2, 4 .2 , 4 .2 , 1.9 and 
a 
27 
1.7 . Thus at pH 4.0 the d i s t r i b u t i o n of protonated species w i l l 
favour (D0TA)H4. At pH 5.5, ( D O T A ) w i l l predominate. However, 
between pH 4.0 and 5.5, the k i n e t i c a l l y reactive species w i l l probably 
be (DOTA)H , despite there being, f o r instance, only 0.02% of t h i s 
species r e l a t i v e to (DOTA)!^ at pH 5.5. The increase i n l a b e l l i n g 
e f f i c i e n c y with increasing pH can then be ascribed to the increasing 
[(DOTA)H3"] concentration. That (DQTA)H3" rather than (DOTAJHg" i s the 
k i n e t i c a l l y reactive species in t h i s pH regime has been ra t iona l i sed i n 
terms of e l ec t ros ta t i c repulsion between macrocyclic l igand and metal 
i o n ^ . In the diprotonated DOTA species, the two protons are si tuated 
27 
on diagonally opposed nitrogen atoms : 
Only one of these nitrogen atoms w i l l be protonated in (DQTA)H . As 
the ni t rogen atoms are d i r e c t l y involved in binding, e l ec t ros t a t i c 
repulsion between metal ion and macrocyclic l igand w i l l be less between 
metal ion and (DOTA)H3" than between metal ion and (DOTA^" . 
Increasing the ionic strength (0.02 to 0.5 M), temperature (291 to 
310 K) and incubation period (5 to 45 min) also increased the l a b e l l i n g 
CH 
0=C 
x CH N N 
C D 
N — C H 2 
H 
CH 2 
x-o' 
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e f f i c i e n c y . Optimum conditions f o r the l abe l l i ng reaction were therefore 
considered to be NH40Ac (0.1 M), pH 5.5, 310 K and an incubation time of 
30 min. 0.1 M NH40Ac as opposed to 0.5 M NH40Ac was used f o r reasons 
which w i l l become apparent at the end of t h i s section. 
Label l ing e f f i c i e n c i e s under these conditions f o r DOTA, TRITA, 
TETA, DOTA-BMA, 0D0TRA and DTCTA at various concentrations with [ 9 0 Y 3 + ] 
= 10" 8 - 1 0 " 1 0 M are given in Table 2.2. 
LIGAND 
MOLARITY 
(x 10-6 M) DOTA TRITA TETA DOTA-BMA ODOTRA DTCTA 
5 84 a 
10 98 a 48 a 
100 98 a 94 a 
500 99 a 72 a 
1000 99 a 52 b 0 C 98 a 82 a 
Table 2.2: Percentage labelling efficiency for various 9 0 j ^ + . 
macrocyclic ligand systems incubated for 30 mins. at 
310 K in 0.1 M NH40Ac (pH 5.5), + y = J0-8_/0-io M, 
[macrocyclic ligand] - (5- 1000) x 10'6 M. Reactions 
quenched with DTPA (5 x 10'^ M final concentration); 
a) 10-15 min after DTPA addition; b) AO min after DTPA 
addition; c) Ih after DTPA addition. 
From Table 2.2, i t can be seen that f o r ligand concentrations > 5 x 
10 ^ M the approximate order f o r the extent of uptake of 9 ^ Y 3 + decreases 
according to : 
DOTA > DOTA-BMA » DTCTA > ODOTRA a TRITA » TETA 
with DOTA showing 987. incorporation even at 10" 5 M. The f a i l u r e of TETA 
to complex under these condit ions, supports the *H NMR resul t of 
the previous section (and also the resu l t obtained in Section 3 .3 ) . 
The f a l l in l a b e l l i n g e f f i c i e n c y when [DOTA] becomes less than 
10 5 M is probably due to metal ion impuri t ies in 9 0 Y 3 + (supplied by the 
At omic Energy Author i ty , Harwell) . Induct ively coupled plasma source 
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mass spectroscopy 8 has shown that ^ Y 3 + contains approximately 200 times 
as much Z n 2 + and Ca 2 + and 10 times as much Cu 2 + - a l l three of these 
ML metal ions form thermodynamically stable complexes with DOTA, log K 
7 
21.0, 17.2 and 22.2 respectively . Therefore, in a so lu t ion which i s a 
10 M with respect to Y , the concentration of Zn , f o r instance, 
w i l l be 2 x 10"7 M. I f [D0TA]' = 10"5 M, then the r a t i o of D0TA:Zn 2 + :Y 3 + 
w i l l be 104:200:1 and competition between Y 3 + and Z n 2 + f o r DOTA w i l l be 
neg l i g ib l e . But i f [DOTA] = 10" M, the corresponding r a t i o w i l l be 
1000:200:1, and competition between Y 3 + and Z n 2 + f o r DOTA w i l l become 
s i g n i f i c a n t . Likewise, increasing the a c t i v i t y (and therefore the 
concentration) of ^ Y 3 + w i i ] _ ? j f t n e metal ion contaminants are in 
excess of ^0y3+^ r esu l t in a reduced l abe l l i ng e f f i c i e n c y . A s t r i k i n g 
example of t h i s was seen in one pa r t i cu la r experiment when, with [DOTA] 
= 10 ^ M, increasing the i n i t i a l concentration of ^ Y 3 + f r o m K JQ 9 t 0 
x 10" M (equivalent to decreasing the r a t i o of D0TA:Zn + : Y + from 
104:200:1 to 100:200:1) reduced the l abe l l i ng e f f i c i e n c y from 98 to 517.. 
Another possible source of metal ion contaminants may be the acetic 
acid (Aldr ich) and ammonium acetate (Aldr ich , Gold Label) used to make 
the ammonium acetate bu f f e r . Analysis by atomic absorption spectroscopy 
has shown that the s i g n i f i c a n t metal ion contaminant in both is calcium 
(0.0087« in acetic acid and 0.00037o in ammonium acetate). To minimise 
interference with the ^Y-macrocyclic ligand complexation react ion, the 
molar i ty ( i n th i s case essent ia l ly the ionic strength of the solut ion) 
of the ammonium acetate was maintained as low as possible without 
reducing the l a b e l l i n g e f f i c i e n c y , it. 0.1 M. 
In addi t ion to displaying the highest l a b e l l i n g e f f i c i e n c y , 
^Y(DOTA) remained k i n e t i c a l l y iner t i n the presence of DTPA over 72 
90 
hours. Y(DOTA-BMA) remained reasonably k i n e t i c a l l y stable in the 
8Performed at the Mountjoy Research Centre, Durham. 
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presence of DTPA over 24 hours, showing 27. dissociat ion with [DOTA-BMA] 
= 10" 5 M and 107. dissociat ion with [DOTA-BMA] = 10" 4 M; at a l igand 
concentration of 5 x 10" 4 1 over 48h 90Y(DTCTA) was k i n e t i c a l l y 
unstable, undergoing complete d issocia t ion. 
2.6 CONCLUSIONS 
i i 
H NMR experiments and HPLC radiometry demonstrate that of the s ix 
candidates put forward as y t t r ium binders, the rate of uptake of Y + is 
fas tes t f o r DOTA. The mechanism f o r uptake i s probably a two-stage 
23 
process : the f i r s t involves the formation of an intermediate complex 
in which the carboxylate groups co-ordinate to the metal ion , which 
nevertheless remains outside the DOTA "cage" of nitrogen atoms and 
carboxylate groups; slow rearrangement then leads to complete 
encapsulation of the metal ion. 
Of the tetraaza tetracarboxylic acid macrocyclic y t t r i u m ( I I I ) 
complexes, Y(DOTA) is the most thermodynamically stable in aqueous 
solut ion ( log = 24.9) and is almost three orders of magnitude more 
stable than Y(DTPA) . I t i s also l i k e l y that i t i s more stable than 
the y t t r ium complexes of DOTA-BMA, ODOTRA and DTCTA, according to the 
f o l l o w i n g arguments. 
O Q 
During the course of t h i s work, Delgado et al. prepared ODOTRA 
and measured the s t a b i l i t y constants of i t s a lka l ine earth complexes. 
In each case the corresponding DOTA complexes were two to four orders of 
magnitude more stable (Table 2 .3 ) . Replacement of a hard donor (the 
nitrogen atom) by a harder donor (the oxygen atom) would therefore seem 
not to compensate f o r the loss of a charged donor (the carboxylate 
group) when comparing the r e l a t ive thermodynamic s t a b i l i t i e s of the 
ODOTRA and DOTA complexes. 
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ION ODOTRA DOTA 
Mg 2 + 10.3 11.9 
Ca 2 + 13.0 17.2 
S r 2 + 11.4 15.2 
Ba 2 + 9.9 12.9 
Table 2.3: Stability constants, log K, of 1:1 ODOTRA and DOTA 
alkaline earth metal complexes; T=298K, 1-0.10 
[(CH3)4MN03] (Ref.29). 
o 
Sherry et al. have made a compound s imi la r to DOTA-BMA, a 
secondary amide der ivat ive of DOTA, DOTA-PA (36) . 
C-N 
r .v_v v_Co t 
(36) 
They found that the log of i t s gadolinium complex [which may be 
s imi la r to Y(DOTA-BMA)] was 20 .1 , approximately f i v e orders of magnitude 
less stable than Y(DOTA)". Again, the loss of a charged donor to a 
neutral one appears to be the cause of th i s decreased s t a b i l i t y , f o r i t 
is un l ike ly that the postulated square ant ipr ismat ic arrangement of 
donor atoms in Y(DOTA)" w i l l be al tered in Gd(DOTA-PA). 
DTCTA has not been synthesized before, so comparisons of s t a b i l i t y 
constants are not possible. However, on charge considerations alone i t s 
y t t r i u m ( I I I ) complex would be expected to be less stable than Y(DOTA)". 
Chapter 3 compares the favourable binding and thermodynamic 
properties of the Y-DOTA system with i t s k i n e t i c s t a b i l i t y and also 
discusses the k i n e t i c s t a b i l i t y of the DTPA, TRITA and TETA y t t r i u m ( I I I ) 
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complexes in aqueous so lu t ion . 
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Figure 3.5: Partial NM spectrum (62.9 BHz) showing the 
carbonyl peaks corresponding to the Y(DOTA) complex 
(a) and DOTA alone [(b) and (c)] at pff 0, 293K. 
3.5 SlffiARY AWP CONCLUSIONS 
Between pH 4.0 and 5.0, in the presence of a 5 - f o l d 
2+ 
excess of Ni , the k ine t i c s t a b i l i t y of the y t t r ium(I I I ) -po lyamino-
carboxylate complexes discussed in t h i s chapter decreases according t o : 
Y(DOTA) » Y(DTPA) » Y(TRITA) » Y(TETA) 
The Y(DOTA) complex is iner t over a period of months, Y(DTPA) and 
Y(TRITA) have ha l f l ives of the order of 4 hours and Y(TETA) does not 
apparently form at a l l . 
I n the case of Y(DTPA), the d issocia t ion is promoted by both 
hydrogen ions and n i c k e l ( I I ) ions. The existence of such a metal ion-
dependent pathway suggests that the k i n e t i c i n s t a b i l i t y of the ^Y-DTPA-
MoAb conjugate in vivo may ar ise not only from hydrogen ion at tack, as 
2+ 
was proposed in Section 3 . 1 , but also from metal ion attack, eg. Ca , 
2+ 2+ 
Mg and Zn. . These ions are a l l present in considerable excess of the 
r a d i o l a b e l e d conjugate i n blood ( [ M g 2 + ] = [Ca 2 + ] = 10" 3 M, [ Z n 2 + ] = 
10" 5 M , 7 [90Y-DTPA-MoAb] ~ 1 0 " 1 1 H) and a l l form thermodynamically 
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CHAPTER THREE 
THE KINETICS OF DISSOCIATION OF THE YTTRIUM(III) COMPLEXES 
OF DTPA, TRITA, TETA AND DQTA IN AQUEOUS SOLUTION 
3.1 ITOMPTOTMH 
Despite improvements i n the conjugation of DTPA to a monoclonal 
antibody (Section 4 . 2 . 2 ) , the subsequently r a d i o l a b e l e d MoAb remains 
r e l a t i v e l y k i n e t i c a l l y unstable in vivo (Section 4.10) probably due to 
acid-catalysed release of the radionucl ide. I t therefore seemed germane 
to q u a n t i f y the rate of d issocia t ion of the unattached yt tr ium(III)-DTPA 
complex as a func t ion of pH at a f i x e d ionic strength and to compare i t 
wi th the rate of dissociat ion of Y(DOTA) under s imi l a r conditions. I n 
a d d i t i o n , i t was hoped to assess the k i n e t i c s t a b i l i t i e s of Y(TRITA) and 
Y(TETA). This chapter describes the methodology and resul ts of these 
inves t iga t ions . 
3.2 DISSOCIATION KINETICS OF THE YTTRIUM(III)-DTPA COMPLEX 
The yt t r ium(II I ) -DTPA complex, l i k e other y t t r ium(I I I ) -po lyamino-
carboxylate complexes, does not have a chromophore in the UV/visible 
region (190 - 800 nm) with which to monitor i t s rate of dissociat ion 
spectrophotometrically. To circumvent t h i s problem, another metal ion 
( M n + ) which did form a DTPA complex wi th a convenient chromophore^'2 was 
used t o scavenge any f ree l igand a r i s i n g from the dissociat ion of 
Y(DTPA): 
Y(DTPA) > Y 3 + + DTPA 
no UV-active 
chromophore 
DTPA + M n + » M(DTPA) 
UV-active 
chromophore 
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The success of th i s method r e l i e s on the f r ee ligand binding the 
scavenger metal ion M a + in preference to f ree Y 3 + t o form a stable 
complex. To t h i s end, an excess of scavenger metal ion was employed. 
Also, the rate of dissociat ion should be independent of the 
concentration of M n + , ie. the l a t t e r should not assist the d issocia t ion 
of Y(DTPA). The rate equation f o r dissociat ion would then be: 
9 n m 4. n 
d[Y(DTPA)] = k d[Y(DTPA) 2"] + S k n[Y(DTPA)H n] + E k„ [Y(DTPA)HJ [ H + ] p 
dt 
The rate constant f o r the dissociat ion of the unprotonated complex 
in the absence of an acid-dependent mechanism, k^, w i l l be small , of the 
-12 -13 - 1 
order of 10 - 10 s ( t h i s f i g u r e originates from a consideration 
of : 
k f 
Y 3 + + DTPA5" £ Y(DTPA)2" 
k d 
K 2 [Y(DTPA)2"] 
[Y(DTPA) ] = 
[Y 3 + ] [DTPA 5 " ] 
where the rate of association is probably d i f f u s i o n - c o n t r o l l e d , k^ = 10^ 
1 0 - 1 - 1 9 9 - 1 
- 1 0 i U M s , and K[y(DTPA) 2~] = k f / k d ~ 1 0 - ) " t h e f i r s t t e r m 
f o r d[Y(DTPA)]/dt w i l l therefore be neg l ig ib l e . The protonated and 
unprotonated forms of Y(DTPA) are l i k e l y to be in equi l ibr ium with each 
other i n acidic solut ion and therefore n is l i k e l y to be 1 in the second 
term. In the t h i r d term, m w i l l probably be 0 and 1, the unprotonated 
and protonated complexes being subject to acid-promoted d issoc ia t ion 
(with a f i r s t or second order dependence on [ H + ] , p = 1 or 2 ) . 
We used n i c k e l ( I I ) to scavenge the f ree DTPA, the rate of 
d issocia t ion of Y(DTPA) being monitored by the increase i n absorbance at 
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385 - 390 nm due to the bui ld up of Ni(DTPA) (Figure 3 .1) . 
350 370 390 410 430 450 
WAVELENGHTH (nm) 
Figure 3 . 1 : Scans at 3 hourly intervals showing the build up 
of .M(DTPA) at 390 nm due to the dissociation 
of Y(DTP4), pH 4-6, 298K. 
Inspection of the s t a b i l i t y constants of Y(DTPA) and Ni(DTPA), 
log = 22.1 and 20.2 respectively' , might suggest that the formation 
of any Ni(DTPA) i s thermodynamically improbable, the f r ee DTPA resu l t ing 
from d i s soc ia t ion p re fe r r ing to reassociate wi th Y + . However, as 
explained in Section 2.4, these s t a b i l i t y constants r e fe r to the 
formation of the species Y(DTPA)2" and Ni(DTPA)^" in non-competing media 
- the existence of other species such as Y(DTPA)H", Ni(DTPA)H2" and 
N i ( D T P A ) i s not considered (neutral complexes are un l ike ly to form) , 
protonation of the ligands is neglected and the e f f e c t of other ligands 
competing f o r N i 2 + and Y ^ + , eg. acetate, i s ignored. But a conditional 
stability constant^, log K ^ , can be calculated f o r both Y(DTPA) and 
Ni(DTPA) which takes the l a t t e r two fac tors in to account: 
log K ' L = log K M L - log aM - log o H 
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where represents the extent of competition fo r the metal ion from a 
l igand other than L, A, say, while represents the extent of 
protonation of L at a given pH. 
can be wr i t t en in terms of the overa l l s t a b i l i t y constants (0 ) 
f o r the formation of MA, MA2 . . . MAQ and [ A ] : 
y = i + ^ [ A ] + / ? 2 [ A ] 2 + / ? 3 [ A ] 3 + . . . + / ? n [ A ] n 
and OJJ can be wr i t t en in terms of the protonation constants, K j , K 2 . . . 
K , f o r the ligand L: 
K-i K D K o K n . . K 1 1 2 1 2 n 
For a system buffered with sodium acetate/acetic acid at pH 4 . 6 , 
A = AcO" , [AcO"] = 9 . 8 x 1 0 " 2 M and [H + ] = 2 . 5 x 1 0 " 5 M; f o r Y(AcO) 2 + 
and Y(AcO) 2 , ^ = 4 7 . 9 and fi2 = 1 4 7 9 ; f o r Ni(AcO) + , ^ = 5 . 5 ; f o r DTPA 
3 - 11 - Q the protonation constants are = 3 . 2 x 10 M, K 2 = 2 . 5 x 10 M, 
K 3 = 5 . 5 x 1 0 " 5 M, K 4 = 3 . 9 x 1 0 " 3 M, and K 5 = 8 x 1 0 " 3 M. Using the 
above expressions, log K'[Y(DTPA)] = 1 0 . 7 and log K'[Ni(DTPA)] = 1 0 . 0 , 
ie. Y(DTPA) and Ni(DTPA) have comparable thermodynamic s t a b i l i t i e s under 
these conditions. 
Dissociation was monitored at pH 3 . 2 , 3 . 7 , 4 . 6 and 5 . 4 . Solutions 
were buffered using sodium acetate and acetic acid, ionic strength ( I ) 
being maintained at 0 . 4 2 M wi th sodium perchlorate. At each pH [ Y 3 + ] = 
[DTPA] = 4 x 10 M, and the rate of dissociat ion was measured f o r 
[ N i 2 + ] = 1 x 1 0 " 2 , 2 x 1 0 " 2 and 4 x 1 0 " 2 M, two and a h a l f , f i v e and ten 
times the concentration of Y(DTPA) respect ively. 
^obs v a ^ u e s f ° r the dissocia t ion of Y(DTPA) were calculated by 
taking absorbance measurements at equal time in tervals over one ha l f 
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l i f e and are given in Table 3 . 1 . These values show good agreement with 
f i r s t order k ine t i c s . 
pH [ N i 2 * ] 
( x 10-2 M) 
k(obs) 
( x 10-5 S ' 1 ) 
3.2 1 12.2 
2 17.9 
4 40.8 
3.7 1 8.79 
2 9.82 
4 19.5 
4.6 1 4.70 
2 6.22 
4 7.06 
5.4 1 2.81 
2 3.11 
4 4.84 
Table 3 . 1 : k(obs) for the dissociation of Y(DTPA) in the presence 
of 1M\ X = 385 nm, I = 0.A2 M (NaCl04), [DTPA] = [P +J 
= 4 x 10-3 M, [Ac0-J = 3 x 10-3 M ( p f f 3/2), 2 x lOr* M 
(pH 3.7), 0.098 B (pH 4 . 6 ) and 0.172 M (pH 5.4), 298 K. 
From these resul ts i t can be seen that the rate of dissociat ion of 
Y(DTPA) is c lear ly not independent of [ N i 2 + ] over the range of N i 2 + 
concentrations invest igated. The n i c k e l ( I I ) ion must therefore assist 
the dissociat ion of Y + from Y(DTPA). The i n v a l i d i t y of using Ni as a 
non-intrusive scavenger f o r measuring the rate of d issocia t ion of 
Y(DTPA) notwithstanding, an analysis of the resul ts was attempted. 
2+ 
A plot of against [Ni ] (Figure 3.2) would seem to suggest 
that k Q k g is a composite of several terms: 
(a) The points f o r the two lower pH values, 3.2 and 3.7, seem 
better f i t t e d by curves rather than s t ra ight l i ne s , these 
curves having a strong dependence on both [H + ] and [ N i 2 + ] . 
2+ 
That k k doubles f o r a two- fo ld increase i n [Ni ] suggests 
that the rate of d issocia t ion i s f i r s t rather than second order with respect to [Ni ] . I t would be reasonable to 
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0-1 , , r 
0 1 2 3 4 
[N i 2 + ] (x10" 2 M . ) 
Figure 3.2: Plot of kfobs) versus [Ni**] for the dissociation 
of Y(DTPA) in the presence of Ni?+ at pH 3.2 (a), 
3.7 (A-;, 4 . 6 (o) and 5.4 (a), 298 K, I = O.42 B. 
propose, therefore , k^2+ [Ni ] [H ] as a cont r ibut ing term 
(with possible contributions from higher terms such as 
k j j . 2 + [ N i 2 + ] [ B + ] 2 ) . 
(b) At the two higher pH values, 4.6 and 5.4, the curves tend 
towards s t ra ight l ines with shallow gradients, which implies 
that as [H + ] becomes smaller, the rate of dissociat ion 
2+ 
becomes proport ional to [Ni ] alone. Another term might 
then be k N I 2 + [ N i 2 + ] . 
2+ 
(c) By t e n t a t i v e l y extrapolat ing the curves and l ines to [Ni ] 
= ° ' k o b s v a l u e s o f ( 2 - 2 * ° - 5 ) X 1 0 5 S _ 1 ( P H 5 - 4 ) ; ( 4 - ° ± 
1.0) x 10"5 s"1 (pH 4.6); (6.1 ± 1 . 0 ) x 10"5 s"1 (pB 3.7) and 
(6.6 ± 2.0) x 10"5 s"1 (pH 3.2) are obtained. The increase 
in these values wi th increasing [H + ] indicates that there is 
a n i c k e l ( I I ) independent term involved in the overa l l rate 
constant which is dependent on [H + ] (and probably also on 
[ H + ] 2 ) . The large errors of the k Q b s values at [ N i 2 + ] = 0 
make the precise dependence on [H + ] d i f f i c u l t to determine. 
The terms in ( a ) , (b) and (c) can be col lected to give the complete 
(and q u a l i t a t i v e ) expression f o r k ^ : 
kobs = k d + k ' t H + ] + k N i 2 + t N i 2 + ] + k N i H N i 2 + H H + ] + k J J i 2 + [ N i 2 + ] [ H + ] 2 
Two rate-determining pathways would therefore seem to be operative 
in the d issocia t ion of Y(DTPA) in the presence of a 2.5 - 10- fold excess 
2+ 
of Ni . The f i r s t , represented by the f i r s t two terms in the rate 
expression f o r k ^ , involves the d i rec t d issocia t ion of the protonated 
and unprotonated forms of Y(DTPA), which w i l l probably be i n rapid 
equi l ibr ium wi th each other: 
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Y(DTPA)' 
Y(DTPA)B~ 
(DTPA)H. 
(DTPA)H 
+ Y' 
2+ 
3+ 
Subsequently, the f r ee DTPA w i l l rapidly complex Ni . 
The second pathway, represented by the last three terms of k Q j ) g , 
3+ 2+ involves the d i r ec t displacement of Y from Y(DTPA) by Ni . Again 
t h i s i s l i k e l y to proceed via the unprotonated and protonated species: 
Y(DTPA)Z" 
I 
Y(DTPA)H" 
+ Ni • 2+ 
Ni(DTPA)' 
Ni(DTPA)H 2-
+ Y 3+ 
3.3 KINETIC STABILITY OF THE TRITA, TETA AMD DMTA COMPLEXES OF 
YTTRIUM ( H I ) 
Using Ni to scavenge f r ee ligand was also the method of choice 
f o r monitoring the dissocia t ion of Y(TRITA), Y(TETA) and, i n i t i a l l y , 
Y(DOTA). The relevant absorption band f o r Ni(TRITA) and Ni(TETA) occurs 
at 580 nm, that of Ni(DOTA) at 540 nm, conveniently removed from the 
absorption bands of aqueous nickel (395 and 725 nm). 
No attempt was made to examine the dependence or independence of 
the rates of d issocia t ion on [ N i 2 + ] . He were interested only in 
determining the k ine t i c s t a b i l i t y of the y t t r i u m ( I I I ) complexes i n the 
presence of excess N i 2 + at a given pH. 
3 2+ 
Under iden t i ca l conditions ([complex] = 4 x 10 M, [Ni ] = 2 x 
10" 2 M, pH 4 . 6 ) , the k ine t i c ha l f l i f e ( t { ) of Y(TRITA) was comparable 
to the t f f o r Y(DTPA), both being of the order of 4 hours. On addi t ion 
of N i 2 + to Y 3 + and TETA to give a solut ion 2 x 10" 2 M in N i 2 + and 4 x 
10" 3 M in Y 3 + and TETA at pH 4.0 ([AcO~] = 3.6 x 10" 2 M), the appearance 
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of the Ni(TETA) absorption band was rap id , reaching a maximum in < 5 
min. This suggests that ei ther Y(TETA) had not formed and that the rate 
2+ 
of appearance of the band merely re f lec ted the rate of uptake of Ni by 
the completely uncomplexed TETA, or that the rate of dissociat ion of 
Y(TETA) was f a s t , i n which case the complex would have a tf- < 5 min 
under these condit ions. The h NMR resu l t of Section 2.4 and radiometry 
r e su l t of Section 2.5 support the former explanation, the existence of 
the protonated complex and competition from a n i n e - f o l d excess of AcO 
f o r y t t r i u m ( I I I ) cont r ibu t ing to make Y(TETA) unstable wi th respect to 
d issocia t ion at t h i s pH. 
In the presence of a f i v e - f o l d excess of n i c k e l ( I I ) (2 x 10 M), 
the Y(DOTA) complex ( i n t h i s pa r t i cu la r experiment the preformed 
Y(D0TA)Na.5H20 complex as a so l id was added to the N i ( I I ) so lut ion at pH 
- 3 
3.0 to give a solut ion 4 x 10 M in complex) remains stable over at 
_ o 
least s ix months at pH 3.0 (maintained using glycine (5 x 10 M) -
_ 2 
hydrochloric acid (1.1 x 10 M) as a b u f f e r ) . I t was not possible to 
invest igate the s t a b i l i t y of Y(DOTA) at a lower pH because Ni(DOTA) does 
not form below pH 3.0. 
3.4 DISSOCIATION OF THE YTTRIUM(III)-DOTA COMPLEX AT LOW pE 
Since the physiological pH can be as low as 1.0, f o r instance in 
the stomach, i t was important to examine the k i n e t i c s t a b i l i t y of 
Y(DOTA) below pH 3.0. This was done in two separate ways, by HPLC 
13 
radiometry and by C NMR. 
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3.4.1 Rate of Dissociation of Y(M)TA) as Monitored by 1PIC tadioaet ry 1 
In t h i s technique the extent of decomplexation of 90Y(DOTA) ([DOTA] 
= 2.5 x 10" 4 M, [ 9 0 Y 3 + ] ~ 10" 9 M) at a given pH was estimated 
radioraetr ical ly by separating any unbound 9 * V * + from complexed ®®\^+ ^ 
ana ly t i ca l anion exchange HPLC, the r e l a t i v e amounts of each species 
being given by t h e i r corresponding peak areas ( c f . Figure 2.15). 
The 9^Y(D0TA) complex was formed at pH 5.5 (0.1 M ammonium 
acetate) , incubating at 310K f o r 30 mins. An a l iquot of t h i s so lu t ion 
was removed and rebuffered to the required pH wi th in the region 1.7 -
2.8 wi th glycine-hydrochloric acid. Aliquots of the resul tant solutions 
were taken at given time in te rva l s , treated wi th DTPA (to give a 5 x 
10 M solut ion of the l a t t e r ) - previous cont ro l experiments had 
established that 90Y(DOTA) was stable at pH 5.5 wi th respect to 9 0 Y 
exchange with DTPA (5 x 10 M), see Section 2.5 - to bind any f r ee 
9 ^ Y 3 + , quenched with 0.1 M ammonium acetate (pH 5.5) and analysed by 
anion exchange HPLC. The percentage 9^Y(D0TA) remaining at a given time 
was corrected f o r the decay of 9 ^ Y . 
No dissociat ion was observed over 10 days above pH 2.6. 
Dissociation between pH 1.7 and 2.3 was f i r s t order wi th respect to 
complex; kQ^s values are given in Table 3.2. 
k(obs) 
pH (x 10-8 s - i ) 
2.3 5.43 
2.0 30.8 
1.8 84.4 
1.7 130 
Table 3.2: k(obs) for the dissociation of 90Y(D0TA) between 
pH 1.7 and 2.3, 298K. 
iWork carr ied out by Mandy Randall, MRC Radiobiology Uni t , Harwell. 
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From a graph of k ^ g against [ H + ] ^ (Figure 3.3) i t appears that : 
A possible mechanism f o r the dissociat ion of Y(DOTA) might then be as 
f o l l o w s : 
[Y(DOTA)"]* [Y(D0TA)II]* [Y^OTA)!^] * > 
{ [ Y ^ G T A ) ! ^ ] * } * Y 3 + + H (D0TA)m + 
(m = 0, 1 or 2, n = 4, 5 or 6 f o r pH < 2.3) 
I t i s proposed that the f i r s t proton attacks the anionic complex, 
[Y(DDTA)"]* [the pK of Y(D0TA)~ i s 3.08 (Section 2 .3 ) , therefore at pH 
2.0 f o r every molecule of Y(DOTA)" there w i l l be 12 molecules of 
Y(D0TA)H], starred to acknowledge the possible involvement of other 
species in the d issocia t ive mechanism, eg. metal ions. As the ^ y 3 + 
used i n these experiments contains approximately 200 times as much Zn^ + 
2+ 3+ 
and Ca as V (Section 2 .5 ) , such involvement is not unreasonable. I t 
would perhaps be bet ter then to rewrite k ^ as 
<obs 
k nh* = k C H + ] X + k ' [ M n + ] x + k " [ M n + ] x [ H + ] x 
x = 1 or 2 
Attack of the second proton in the proposed mechanism produces 
[Y(D0TA)H2] , impl ica t ing t h i s as the k i n e t i c a l l y unstable species. 
I t is of passing interest with respect to t h i s mechanism that the 
s t a b i l i t y constants of the protonated and diprotonated Y(DOTA) complexes 
have been estimated as 16.9 and 7.7 respectively. (The estimations were 
made using the equation:' 
l o s %LH l = l 0 S KMLH n 1 - pKn(D0TA) + P K n [(D0TA)H n ] 
- 63 -
w 
CO 
o 
X 
in 
O 
100H 
[ H + ] 2 ( X 10 ' 4 M. 2 ) 
Figure 3.3: k(obs) versus [H+ P for the dissociation 
of ^Y(DOTA), 298 K. 
Here log K M L = 24.9 and pK1[(D0TA)H] = 3 . 0 8 (Section 2 .3 ) , pK^DOTA) = 
11.1 and pK2 (DOTA) = 9 . 2 6 and pK 2[(D0TA)H 2] was assumed to be zero) . 
3.4.2 Eate of Dissociation of Y(MTA) as Monitored by 13<C MM. 
Accurate determination of the rate of d issocia t ion of the 
yttr ium(III)-DOTA complex by in tegra t ion of the NMR spectrum of the 
reaction mixture was impeded by the large l i n e widths of both complex 
and f r e e ligand (Section 2.4) and also the overlap of t h e i r peaks. The 
13 
l i n e widths f o r the carbonyl signals of complex and l igand in the C 
NMR spectrum, however, are considerably smaller; furthermore, these 
peaks are separated by a &8 of approximately 9 ppm (Figure 3 .4) . 
Therefore, providing the r e l a t i v e amounts of these two species could be 
measured, a non- invasive means of monitoring the rate of d issocia t ion of 
the Y(DOTA) complex was avai lable . 
b 
180 
— i — 
140 200 160 
5(ppm) 
Figure 3.4: Partial l*C NMR spectrum (62.9 MHz) showing the 
carbonyl peaks corresponding to a) DOTA and 
b) Y(D0TA), pH 1.0, 293 K. 
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The r e l a t i ve amounts of complex and ligand were estimated by 
in tegra t ion . This was considered v a l i d because t h e i r s t r u c t u r a l l y 
iden t i ca l and environmentally s imi la r carbonyl atoms ought to have 
s imi la r s p i n - l a t t i c e re laxat ion times, T j , and thus the integrals ought 
to be a f a i t h f u l representation of the r e l a t i v e amounts of complex and 
f ree l igand in so lu t ion . In acquiring the spectrum a two second in t e rva l 
between pulses ensured that the carbonyl carbon atoms of complex and 
ligand were f u l l y relaxed. (Decreasing the i n t e rva l to 1 second did 
a l t e r the integrals whereas increasing the i n t e r v a l to 4 seconds did 
not. The optimum in t e rva l was therefore considered to be 2 seconds). 
13 
The C NMR method posed two surmountable problems. The f i r s t was 
the po ten t i a l error introduced by the time taken to accumulate a 
spectrum (say 30 minutes f o r a concentrated sample). I f the 
dissocia t ion occurred in a matter of a few hours, t h i s error would 
become s i g n i f i c a n t . To reduce the accumulation time and therefore the 
13 
er ror , a C carbonyl-labelled der ivat ive (37) was used in the 
decomplexation experiments. 
This was made by subs t i tu t ing BrCBy 0C0 2H f o r C1CH2C02H in the f i n a l 
13 
step of the synthesis of unlabelled DOTA (Scheme 2 .2 ) . Using the Ci-
der i va t i ve of DQTA, i t took 4-8 minutes to accumulate a spectrum (62.9 
MHz, 293K, acquis i t ion time 0.27s, re laxat ion delay 2s, 200-400 scans, 
1 3 C0 2 H 1 3 C0 2 H 
1 3 C0 2 H 1 3 C0 2 H 
(31.) 
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8K data storage). Time points were taken at the middle of t h i s period. 
The second problem was as f o l l o w s . Routine i r r ad i a t i on of protons 
13 
wi th a separate radiofrequency during a C broad band decoupling 
experiment can lead to warming of the sample, caused by the power of the 
decoupling i r r a d i a t i o n . In a k ine t i c experiment, the temperature of the 
sample should remain constant. To avoid the heating e f f e c t , therefore , 
inverse gated decoupling was employed. In t h i s pulse sequence, the 
decoupling power i s applied f o r a short time in t e rva l (~ 1 ms) rather 
than continuously. Warming i s then minimised and the temperature of the 
sample w i l l remain that of the probe (293K in these experiments) and of 
the thermostatted room. 
The Y(DOTA) complex (1.2 x 10" 2 M) did not dissociate over 2 days 
at pH 1.0. At pH 0, the complex had a ha l f l i f e between 10 and 20 
hours. At pH -0.3 and -0.8 the rate of dissociat ion was f i r s t order 
with respect to complex, the rate constants f o r dissociat ion (k ^ ) 
being (4.9 ± 1.0) x 10" 5 and (7.2 ± 1.0) x 10" 5 s"1 respectively. The 
large error associated with these values arose because the peak due to 
13 
the f r ee ligand in the C spectrum became resolved in to two separate 
peaks below pH 1.0 (Figure 3.5) - possibly due to a conformational 
change in the r i ng - reducing the signal to noise r a t i o and producing an 
error in the in tegra l of these two f r e e ligand peaks. 
Unfortunately, two values f o r k ^ g are i n s u f f i c i e n t to deduce 
unequivocally the re la t ionship between k ^ and [ H + ] , although they 
correspond qui te closely to a f i r s t order dependence on [ H + ] . 
A 10- fo ld excess of Ca 2 + (as CaCl 2) was added to the Y(DOTA) 
complex at pH 1.0 to determine whether or not a metal-assisted decomp-
lexa t ion mechanism existed f o r Y(DOTA). Calcium(II) i s the predominant 
f r ee divalent metal ion in blood, along wi th Mg (both 10 M) . Under 
these conditions the complex has a ha l f l i f e of approximately 2 weeks. 
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Figure 3.5: Palatial 1 3 f MR spectrum (62.9 MHz) showing the 
carbonyl peaks corresponding to the Y(DOTA) complex 
(a) and DOTA alone [(b) and (c)] at pH 0, 293K. 
3.5 SUMARY AND CONCLUSIONS 
Between pH 4.0 and 5.0, in the presence of a 5 - fo ld 
2+ 
excess of Ni , the k ine t i c s t a b i l i t y of the y t t r ium(I I I ) -po lyamino-
carboxylate complexes discussed in t h i s chapter decreases according to : 
Y(DOTA) » Y(DTPA) a Y(TRITA) » Y(TETA) 
The Y(DOTA) complex is iner t over a period of months, Y(DTPA) and 
Y(TRITA) have ha l f l ives of the order of 4 hours and Y(TETA) does not 
apparently form at a l l . 
In the case of Y(DTPA), the dissociat ion is promoted by both 
hydrogen ions and n i c k e l ( I I ) ions. The existence of such a metal ion-
dependent pathway suggests that the k ine t i c i n s t a b i l i t y of the ^V-DTPA-
MoAb conjugate in vivo may arise not only from hydrogen ion attack, as 
2+ 
was proposed in Section 3 . 1 , but also from metal ion at tack, eg. Ca , 
2+ 2+ 
Mg and Zn. . These ions are a l l present in considerable excess of the 
r ad io l abe l ed conjugate in blood ( [ M g 2 + ] = [Ca 2 + ] = 10" 3 M, [ Z n 2 + ] = 
10" 5 M , 7 [90Y-DTPA-MoAb] ~ 1 0 " 1 1 M) and a l l form thermodynamically 
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stable complexes wi th DTPA in aqueous solut ion ( log K [Mg(DTPA) ] = 
9.3, log K [Ca(DTPA)3"] = 10.7, log K [Zn(DTPA)3"] = 1 8 . 8 ) 3 . 
2+ 
At pH 3.0, again in the presence of a 5 - fo ld excess of Ni , 
Y(DOTA) is stable over at least s ix months. At pH 1.0, i n the presence 
2+ 13 
of a 10-fold excess of Ca , C NMR. experiments show that the complex 
has a t j of approximately 2 weeks. But radiometric experiments show 
2+ 2+ 
that at pH 1.7, in the presence of a 200-fold excess of Ca and Zn , 
Y(D0TA) has a t { of 6 days, ie. the rate of dissociat ion has increased, 
contrary to what might be expected f o r an increase in [ H + ] . I t would 
therefore appear that a metal-assisted decomplexation pathway does exis t 
2+ 2+ 
in the dissociat ion of Y(DOTA). With Ca and Zn i n , respect ively, a 
10 8 and 1 0 6 - f o l d excess of the injected 90Y-DOTA-MoAb conjugate in the 
blood and the r e l a t i v e l y large s t a b i l i t y constants of the unprotonated, 
2+ 2+ 
protonated and diprotonated Ca and Zn DOTA complexes (Table 3 .3 ) , 
displacement of the radionuclide from the r ad io l abe l ed conjugate by one 
of these metal ions in vivo, where the pH may be as low as 1.0, might 
become important. 
METAL ION SPECIES 
STABILITY 
CONSTANT 
Ca 2 + MH2L 3.1 
MHL 8.7 
Z n 2 + 
ML 17.2 
MH2L 7.0 
MHL 13.1 
Y3+ 
ML 21.0 
MH2L 7.7 
MHL 16.9 
ML 24.9 
Table 3.3: Stability constants [log K] for the calcium(II) 
and zinc(II) complexes of DOTA, 298K, I - 0.1 i 
[(CH3)ANN03] (Ref.8) with the measured (Section 2.3) 
and estimated (Section 3.4-1) stability constants of 
the yttrium(III) complexes of DOTA for comparison. 
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However, the rate of release of radionuclide at pH 1.0 would be 
s u f f i c i e n t l y slow ( t£ ~ lOOh) as to allow the r a d i o l a b e l e d conjugate to 
loca l i se in the tumour (~ 6h) and de l iver a s t e r i l i s i n g dose of 
rad ia t ion (~ 120 h r ) . 
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CHAPTER FOUR 
SYNTHESIS OF A FUNCTIONALISED DOTA DERIVATIVE, ITS CONJUGATION TO 
AN ANTIBODY AND THE PERFORMANCE OF THE RADIOLABELLED ANTIBODY IN VIVO 
4.1 I T O O I U C T I I M 
Having i d e n t i f i e d DOTA as the macro-cyclic l igand which forms the 
most k i n e t i c a l l y and thermodynamically stable y t t r i u m ( I I I ) complex of 
the s ix candidates o r i g i n a l l y proposed, we endeavoured to make i t s 
func t iona l i sed der iva t ive f o r attachment to a monoclonal antibody. 
This chapter is divided in to three par ts . Part 1 concerns the three 
attempts to synthesize the func t iona l i sed DOTA der iva t ive . Part 2 
out l ines the attachment of the der iva t ive to the monoclonal antibody and 
the r ad io l abe l l i ng of the resultant conjugate. Part 3 discusses the 
resul t s obtained thus f a r with the r a d i o l a b e l e d conjugate. 
PART 1: FUNCTIONALISATIfflN fflF DOTA 
4.2 SYNTHETIC STRATEGIES FAIR FUNCTIfflNALISING ACYCLIC AND MACROCYTIC 
COMPLEXING AGENTS 
There are two approaches to f u n c t i o n a l i s i n g polyaza acyclic and 
macrocyclic complexing agents: one is through a nitrogen atom, the other 
i s through the hydrocarbon skeleton, N- func t iona l i sa t ion and C-
f u n c t i o n a l i s a t i o n respect ively. 
4 .2 .1 N-Functionalisat ion 
A polyaminocarboxylate complexing agent (PCA) such as DTPA can be 
conjugated to a monoclonal antibody (MoAb) through the activated 
carbonyl of a carboxylate group. Act iva t ion can be achieved by 
converting the PCA to an acid anhydride de r iva t ive . Thus DTPA has been 
l inked to a MoAb via an asymmetrical isobutylcarboxyl ic anhydride 
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der iva t ive (38) (Figure 4.1) and via a symmetrical dianhydride (see 
Figure 1.9). 
/ — C 0 2 H 
MoAb 
c 0,H N 0,H c yr-C02H H N N 
VY° H,CH(CH3)2 H c v — C O , H 
N H ^ — C O , H 1 MoAb N NH 
Figure 4 . 1 : DTPA conjugation to a monoclonal antibody v i a its 
isobutylcarboxylic anhydride derivative. 
The disadvantage of the anhydride linkage method is that a carboxylate 
binding s i t e i s los t on forming the amide bond. This leads to a dras t ic 
drop in the s t a b i l i t y of the Y(DTPA) complex, even in serum, as 
88 
Figure 4.2 demonstrates f o r the model complex Y(DTPA-monobutylamide) 
( 8 8 Y is a positron emitter , T{ = 107 days) 2 . 
100 
03 
75 CO 
to a Nitrobenzyl-DTPA 50 
a> 
o DTPA-NHBu 25 COO 
i I 
0 5 10 15 20 
Time, days 
Figure 4 .2: Loss of + f r o m N-functionalised and C-functionalised 
derivatives of DTPA in serum, pH 7.4, 57°C (Ref.3). 
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[Conjagation wi th the dianhydride UTPA de r iva t ive (Figure 1.9) can also 
lead t o in ter - and intramolecular c ro s s - l i nk ing of the E2oAb and a loss 
of iramunoreactivity] . So although i t i s possible to make the 
5 
asymmetrical anhydride of DOTA (39) , i t would be unwise to use such a 
de r iva t i ve f o r conjugation to a HoAb. 
4 .2 .2 C-Functional!sat ion 
The metal complexes of C-funct ional ised PCA der iva t ives , wi th a l l 
the carboxylates f r e e to b ind , are considerably more stable in vivo than 
t h e i r N-funct iona l i sed analogues as Gansow has demonstrated f o r the 
i n d i u m ( I I I ) complexes of C-funct ional ised DTPA and EDTA [see also 
Figure 4 .2 , but i t should be recal led (sect ion 1.4.9) that serum studies 
are an inadequate assessment of a complex's s t a b i l i t y in vivo]. C-
f u n c t i o n a l i s a t i o n at a carbon adjacent to a binding nitrogen atom is 
also thought to confer k i n e t i c s t a b i l i t y on the complex by s t e r i c a l l y 
6 
hinder ing the attack of a proton or metal ion at that nitrogen . 
OoH 
H(CH3) N 
OoH OoH 
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Polyazamacrocycles containing propylene uni ts are r e l a t i v e l y easy 
2+ 
to C-funct ional ise . For example, cyclam [ c f . Cu(cyclam) (3) , 
Section 1.4.10] can be C-functionalised by condensation of the acyclic 
tetraamine (40) with a 2-funct ional ised d i e thy l malonate ester followed 
by borane-THF reduction of the secondary amide groups (Scheme 4.1) . 
N 
N 
H H 
y — N 
^ — N H N 
H H (EtO,C),HC 
H EtOH, reflux 
H H 
(4&) 
i) BH3-1HF 
ii) 6M HCI 
H W H 
H 
H H 
H H 
Scheme 4 . 1 : Synthesis of C-functionalised cyclatn. 
The synthesis of a C-functionalised der iva t ive of DOTA (which 
contains no propylene groups) was less f a c i l e . A l l three of our 
attempts were based on a general route to C- funct ional i sed polyamino-
carboxylate complexing agents, the precursor of which i s a (2S)-a- amino 
acid (Scheme 4.2) . 
The amino acid is f i r s t e s t e r i f i e d and then amidated. Choice of 
amine f o r the amidation can give r i se to d i f f e r e n t complexing agents. 
I f ammonia i s used, C-functionalised EDTA resu l t s . I f ethylenediamine 
is used, C-funct ional ised DTPA resu l t s . Af t e r borane-THF reduction, the 
carboxylate groups can be introduced using chloro- or bromoacetic acid. 
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* MsOH B H2NR' 7 BH 3 -THF 
"CONHR' c " 
¥ R° 
H'^'* ' ^ — ^ C 0 2 H 
o 
,C CO,H 
,NHR' 
CICHzCQ-H 
or 
BrCHgCC^H 
R= amino acid side chain 
R'= H, R"=CH 2C0 2H (EDTA) 
R'=CH 2CH 2NH 2 i R"=CH 2CH 2N(CH 2C0 2H) 2(DTPA) 
Scheme 4.2: General route to C-functionalised polyaminocarboxylate 
complexing agents based on an a-amino acid precursor. 
The amino acid side chain (R) provides the means of attachment to 
the MoAb. The side chain commonly used is the 4-nitrobenzyl moiety 
(Scheme 4 .3 ) , the n i t r o group of which acts as a masked primary amine. 
0 , N 
Pd-C, H 2 , pH 10 
SCN 
C I ^ ^ C I 
Scheme 4.3: Modification of the ^-nitrobenzyl group of an 
acyclic complexing agent. 
A f t e r attaching the acetic acid groups to the modified amino acid i n the 
f i n a l step of Scheme 4 .2 , the primary amine can be unmasked by c a t a l y t i c 
hydrogenation. Reaction wi th thiophosgene gives the isothiocyanate 
75 
group which can be coupled e f f i c i e n t l y to a lysine e-amino group on the 
MoAb4 (see Figure 1.7). We also, but f o r s l i g h t l y d i f f e r e n t reasons 
(section 4 .4 ) , required a primary amine on the side chain of the amino 
acid precursor f o r the synthesis of C-functionalised DOTA. 
4.3 SYNTHESIS OF C-FUNCTItSNAIISED PiTA 
Our f i r s t attempt at synthesizing C-functionalised DOTA employed 
(+)-(2S)-(4-ni t rophenyl)alanine, a commercially available unnatural 
amino acid, as the precursor. The second and t h i r d attempted syntheses 
used (+)- (2S)- lys ine , also commercially avai lable . 
4 .3 .1 Attempted Synthesis of (2S)-(4-Nitrophenyl)D0TA 
The proposed synthesis of (2S)-2-(4-nitrophenyl)DOTA (46) i s given 
in Scheme 4.4. Successful steps are indicated by so l id arrows, 
unsuccessful steps by broken arrows. Steps i - i i i had previously been 
carr ied out by Gansow et al. in t h e i r synthesis of a C-functionalised 
DTPA d e r i v a t i v e 4 . 
The synthesis f a i l e d at the cyc l i s a t ion stage (step v i ) . During 
the course of t h i s step, the colour of the reaction mixture changed from 
deep red to dark red-brown. Work-up gave an inseparable multi-component 
mixture as assessed by *H NMR and mass spectroscopy and from IR and TLC 
data. The y i e l d of the te t ra tosyla ted cycle (46) was less than 57.. 
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ONH 0,H CUWe 
NH H H O 
12J 
NH NHTs 
IV 
H I HTs 
(45. 44) 
H H A 
(17) 4gJ 
V I I I C0 2 H C0 2 H 
( ) 
CO,H C 0 2 
C0 2 H C0 2 H 
(4J. ) 
Scheme 4.4: Reagents: i, MeOH, HCl; ii, NH3, Me OH; Hi, BH3-THF; 
iv, TsCl, pyridine, (PC; v, NaOEt; vi, TsO(CH2CH2NTs)2-
(CH2)2OTs, DMF; vii, H2S0A; viii, ClCH2C02H, Ma OH. 
One possible explanation of t h i s resu l t might be that the a c i d i t y 
of the benzylic protons i s enhanced by the presence of the n i t r o group, 
the negative charge generated by a deprotonation being s tab i l i sed w i t h i n 
the benzene nucleus to give r i se to the f l e e t i n g red colouration 
observed in the reaction mixture. The base in t h i s scheme might be 
another tosylamide anion of (45) [denoted X" below]: 
*0 H 
r 
x 
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The f a t e of t h i s anion presumably involves more than jus t reprotonation. 
I f t h i s explanation i s correct then the n i t r o group does not remain 
passive during the course of the synthesis. A d i f f e r e n t amino acid side 
chain i s needed. 
4.3.2 Atteapted Syntheses of (2S)- (4- Aainobutyl)D(DTA (tomtes 1 and 2) 
(+)-(2S)-Lysine was chosen as the a-amino acid precursor i n these 
routes because the aminobutyl side chain should not , once protected, 
i n t e r f e r e with the cyc l i sa t ion react ion. 
In Route 1 (Scheme 4 .5 ) , the protect ion « a s e f fec ted i n the f i r s t 
2+ 
step by masking the a- amino group wi th Cu and se lec t ive ly acyla t ing 
the c-amino group with benzoyl chloride between pH 9 and 10 at 0°C. 
8 
Copper(II) masks the a-NB^ group by forming a square planar complex 
with the a-Nh^ and carboxylate groups of two lysine molecules which 
probably adopt the fo l lowing stereochemistry: 
Once the acylat ion was complete, the copper(II) complex was 
destroyed by bubbling hydrogen sulphide through the aqueous reaction 
mixture. E s t e r i f i c a t i o n followed by amidation wi th ethylenediamine 
1 Carr ied out in conjunction wi th I . M . Helps and K. Jankowski. 
Route I 1 
H 
N 
Cu 
N R 
H 
R= (CH 2 ) 4 NH 
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OoMe 0 ,H 0 ,H 
H N H H„N H 
H H 
(5jL (55.) 15. 
f T 
HN NH NH HN 
I l V 
H H 
H H 
(53) 
NTs TsN TsN NHTs 
' ^ ^ ^ T l N N T s 
v I 
HTs 
Ts Ts 
(5_5_) 5_4 
NH HN 
V 
PhT "N NH 
H 
(5_aj 
Schetae 4.5: Reagents: i, CuC03 • Cu(0H)2; PhCOCl, KOH, H2S; ii, Me OH, 
SGI; Hi, H2N(CH2)2NH2; iv, BHZ-THF; v, TsCl, K2C03, H20; 
vi, TsN(CH2GH20Ts)2, Cs2C03, DtiF; vii, Li, NH3, EiOH, THF. 
fol lowed by borane-THF reduction gave the tetraamine (53). Note that 
the benzamide protect ing group was reduced to a benzamine in th i s las t 
step. Tosylation and cyc l i sa t ion by the caesium carbonate method (see 
Section 2.2.1) gave the tosylated cycle (55). Reductive cleavage of the 
f i v e t o sy l groups with l i t h i u m in ammonia in the presence of ethanol 
af forded the corresponding pentaamine (56). 
At t h i s po in t , i t was intended to remove the benzyl group by 
c a t a l y t i c hydrogenolysis and then reprotect the exocyclic primary amine 
so generated as a benzamide. However, attempts to remove the benzyl 
group wi th two d i f f e r e n t cata lysts , Pearlman's [ P d ^ H ^ ] and palladium 
black, in a var ie ty of d i f f e r e n t solvent systems [9:1 formic acid:water; 
1:1 formic acid: 4- dioxane; 4:1:4 formic ac id .-methanol: 4- dioxane] were 
unsuccessful. S imi l a r l y , attempts to oxidise the the benzylic methylene 
group of the pentatosylated cycle (55) to a carbonyl, thereby e f f e c t i n g 
the d i r ec t conversion to the benzamide, also f a i l e d . Oxidising agents 
used in these attempts were a cerium(IV) sa l t [ ( N H ^ C e ^ O g j g ] in 
aqueous acetic acid and a permanganate sa l t [(Bu)^NMnO^] in dichloro-
methane. 
Thus t h i s synthesis f a i l e d as a resul t of the benzamide protect ing 
group being converted in to a benzylamine in step iv (Scheme 4.5) which, 
a f t e r c y c l i s a t i o n , subsequently resisted a l l attempts to remove i t . 
Route 22 
To avoid producing the quiescent benzyl group, a second route was 
proposed (Scheme 4.6) i n which the protect ion of the e-amino group was 
delayed u n t i l after the borane-THF reduction of the amide (see general 
2The las t two steps of t h i s synthesis were performed by B. Boyce and 
A.T. M i l l i c a n at Cell tech L t d . , Slough. 
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NHCOPh 
" 1 —NH 
C02Me 
(5Z) 
ii) BHj-THF 
1^. H 2NC 
i) CuJ* 
ii) PhCOCI/OH' 
Hi) H2S 
•t> H,Nc 
i ) TSCI/K 2co 3 
i i) TsN /CsjCOs/DMF 
C 0 T S 
i) L i / N H j / E J O H NHCOPh N N 
ii) BrCH2C02Et N N 
K jC0 3 /DMF 
H02C _^.N N 
N N 
T*IPN? 
(62J 
'NHCOPh 
Scheme 4.6: Synthesis of (+)-(2S)-(4-aminobutyl)DOTA. 
route to C-functionalised PCA's - Scheme 4 .2 ) . 
A f t e r e s t e r i f i c a t i o n of (+)-(2S)- lysine (49) and t rea t ing the ester 
(57) wi th neat ethylenediamine, the r e su l t i ng amide (58) was reduced 
with borane-THF to give the tetraamine hydrochloride (59). The e-amino 
group was then se lec t ive ly acylated wi th benzoyl chloride i n a fashion 
s imi l a r to that f o r the acylat ion of (+)- (2S)- lys ine i n Route 1. Here, 
2+ 
however, the Cu protected a diethylenetriamine subunit as opposed to a 
single o-amino group. I t was noted before the synthesis that diethylene-
2+ 
tr iamine forms a stable 1 : 1 complex wi th Cu in aqueous solut ion 
Subsequent steps were effected according to Route 1 . The l i t h i u m / -
ammonia/ethanol reduction of the te t ra tosy la ted cycle ( 6 2 ) gave the 
desired amine ( 6 3 ) i n 577o y i e l d with 117. of the benzylamine compound 
( 5 6 ) (see Scheme 4 . 5 ) and <107o of the deprotected amine ( 6 6 ) as deduced 
by Hi NMR (Figure 4 . 3 ) and mass spectroscopy. 
( log K M L = 16.1). 
PhCtfjNH 
PI CH 
H 
5(ppm) 3 
Figure 4 .3: Partial NMR spectrum (250 MHz) of the N-benzyl 
and N-benzoyl products of the lithium/ammonia 
reduction of the tetratosylated macrocycle (62). 
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The low y i e l d of the benzylamine (56) was probably due to 
protect ion of the secondary amide as i t s l i t h i u m salt^ during the course 
of the reduction: 
Before t h i s step was attempted, we were aware that aromatic primary and 
secondary amides, ArCONHR, underwent Birch reduction without attendant 
amide r e d u c t i o n ^ . 
Ethoxycarbonylmethylation of the tetraamine (63) gave the te t ra-
ester (64) which was hydrolysed to a f f o r d aminobutyl C-functionalised 
DOTA (65). 
The te t ra tosyla ted cycle (62), the tetraamine (63) and (4-amino-
99 
butyl)DOTA (65) were a l l dextrarotatory, [ o ] ^ = + 14 (c 1.00 in 
CH2C1.2), H p 5 - + 2.5 (c 0.80 in CH2C12) and [a]f = + 2.7 (c 0.75 in 
H 20) respect ively, suggesting that the steps i n t h i s route are not 
accompanied by racemisation. The ove ra l l y i e l d of t h i s route from the 
methyl ester (57) is 77.. 
By replacing TsN(CH2CH20Ts)2 wi th TsOCH2CH2OTs at the cyc l i sa t ion 
stage, Route 2 has also been successfully applied by our group to the 
synthesis of (2S)-(4-aminobutyl)-1,4,7-tr iazacyclononane-1,4,7-tr iacetic 
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acid [(4-aminobutyl)-N0TA] (67): 
T > N / r ~ \ l H T s T^XhfeCHgOTs 0 
CszCQj, DMF P t T ^ N 
H T s 
C 0 2 H 
Simultaneous wi th t h i s work, Meares et al. published the synthesis 
of another C-funct ional ised DOTA compound, (2S)-(4-nitrophenyl)D0TA 
(Scheme 4 . 7 ) , based on a te t rapept ide precursor, Nt^-Phe-Gly-Gly-Gly, 
and which employed a clever ireiramolecular r i ng closure. 
S> .o J> 
° V ' N H NH NH OH t (^-" 
^ N T j N f j NTs OTi T * / ^ T " 
COOH 
COOH 
Scheme 4.7 : Synthesis of (2S)-(4-nitrophenyl)D0TA (reproduced from 
Ref.3); Reagents: a) BH3-THF; b) TsCl, NEt3, MeCN; 
c) Cs2C03, DMF; d) H2S04> PhOff; e) BrCH2C02H, NaOH. 
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The overa l l y i e l d of th i s route is 13%. This does not take in to account 
the l i b e r a t i o n of the amine from the n i t r o group (but t h i s i s usually 
quant i ta t ive)^ and the i n i t i a l tetrapeptide synthesis. At f i r s t glance, 
then, t h i s is a comparable synthesis of C-functionalised DOTA to our 
own. However, i t is longer and less ve rsa t i l e - f o r instance, i t 
appears less amenable to the synthesis of the NOTA analogue (67). Also, 
the s t a r t i n g mater ia l , (+)-(2S)-(4-ni t rophenyl)alanine, i s 250 times 
more expensive than (+)- (2S)- lys ine . Our route has been scaled up to 
"Good Laboratory Practice" to produce 2g of aminobutyl C-functionalised 
DOTA. 
PART 2: RAPIELABELLINQ THE MONOCLONAL ANTIBODY 
4.4 SPACER GROUPS 
Attaching a macrocyclic (as opposed to an acycl ic) complexing agent 
d i r e c t l y to a monoclonal antibody leads to a poor l abe l l i ng y i e l d on 
11 
subsequent addi t ion of the radionuclide . To achieve a good radio-
l a b e l l i n g y i e l d , i t is necessary to interpose a spacer group between 
antibody and macrocycle, much as a spacer group is required f o r good 
12 
yields in so l id phase oligonucleotide synthesis . In the absence of 
1113 
the spacer, i t has been suggested ' that the macrocycle becomes 
buried wi th in the antibody structure and that the path the radionuclide 
must take to become bound by the macrocycle i s therefore s t e r i c a l l y 
hindered ( t h i s does not explain, however, why the same problem i s not 
encountered wi th acycl ic complexing agents). 
Spacer groups are b i f u n c t i o n a l , one f u n c t i o n a l i t y spec i f i c f o r 
t h i o l residues on the MoAb (Section 4 .5 ) , the other f o r the exocyclic 
amine of the macrocycle. Figure 4.4 shows two t y p i c a l spacers groups, 
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the ac t ive esters of 2-vinyl-6-(4-carboxy-2-oxabutyl)pyridine (68) and 
3-carboxy-4-oxa-4- (2,5-dicarboximidocyclopentane)maleimide (69). 
amine specific 
OoN 
r 
thiol specific 
Figure 4 .4: Vinylpyridine (68) and maleimide (69) spacer groups used in 
the conjugation of a macrocyclic complexing agent to a MoAb. 
The 2-v iny lpyr id ine un i t of (68), wi th an operating range pH 5 to 9, i s 
extremely t h i o l - s p e c i f i c (being 300 times more react ive towards t h i o l s 
13 
than towards amino groups) . The maleimide un i t of (69) i s less 
s p e c i f i c , but i s more react ive towards t h i o l s . In add i t ion , above pH 7, 
the maleimide r i n g i s prone to hydrolys is : 
OH H 2 0 
R 
pH>7 NHR 
The r e su l t i ng acycl ic maleamic acid has less a f f i n i t y f o r t h i o l s . 
However, the maleimide (69) i s commercially avai lable - production of 
the v i n y l p y r i d i n e (68) requires a 6 step synthesis. (2S)-(4-Amino-
butyl)D0TA has been coupled to both the v iny lpy r id ine and the maleimide 
spacer groups to give compounds (70) and (71) respect ively: 
- 84 -
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C 0 2 H C 0 2 
N 
H 
OoH 
OoH OoH 
0 c > 
C 0 2 H C O , 
H 
oH 
(ZD 
Treating the MoAb with the maleimide der iva t ive (71) resulted in a 
bet ter coupling e f f i c i e n c y (1-3 molecules per antibody) than with the 
v iny lpyr id ine der iva t ive (70), which gave less than one macrocycle per 
antibody. Our work has thus favoured the use of the maleimide-coupled 
macrocyclic antibody conjugate. 
4.5 GENERATION OF THIOLS ON A OONOCLONAL ANTIBODY 
The class of monoclonal antibody used in t h i s work (IgG) does not 
possess any f ree t h i o l residues. Introducing a small number of t h i o l 
residues (between 3-5) allows the attachment of an equally small number 
(1-3) of t h i o l - s p e c i f i c macrocycles, ie. macrocycles which have been 
previously coupled to spacer groups as out l ined i n the preceding 
section. The t h i o l residues are generated by t r e a t i n g the MoAb wi th 
2 - imino th io lane^ (Traut 's reagent), which reacts wi th lys ine e-amino 
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groups on the MoAb. The t h i o l - s p e c i f i c macrocycle can then be coupled 
to the MoAb according to Figure 4.5. 
NH„+ 
MoAb MoAb H H N 
H 
Figure 4 .5 : Generation of a thiol on a monoclonal antibody 
using Trout's reagent. 
The disadvantage of t h i s method i s that t h i o l residues may be 
created on the two binding s i tes of the MoAb, impairing i t s immuno-
r e a c t i v i t y . I t is therefore important to tes t the l a t t e r a f t e r 
r ad io l abe l l i ng a MoAb (Section 4 .6 ) . 
Another in te res t ing and more recent way of generating f ree t h i o l s 
on a MoAb (col labora t ive work with Celltech) which avoids a l t e r a t i on of 
the binding s i tes is as fo l lows . The MoAb is se lec t ive ly cleaved 
(pepsin digest ion) to give a F(ab')2 section and several smaller 
fragments (Figure 4 .6 ) . The disulphide bridge between the heavy chains 
of the F(ab')2 section i s reduced wi th 2-aminoethanethiol to give the 
f r ee t h i o l s . A macrocycle bearing two t h i o l spec i f i c spacer groups can 
then be inserted between these t h i o l s . 
An even more recent method of generating a t h i o l at a spec i f i c s i t e 
on the MoAb has been to replace, by recombinant DNA technology, an amino 
acid in the constant region of the MoAb wi th a cysteine residue 
1 5 
(cysteine has a f r ee t h i o l group) 
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V Partial (ab')a reduction Pepsin SH 
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1 1 > F „ 
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Figure 4.6: Production of a Di-F(ab<)-maleitnide SoAb(DFM). 
4.6 M M (SMELLING PtfflCHDIME 
The monoclonal antibody used f o r t h i s work was B72.3 which has a 
high a f f i n i t y f o r tumour-associated glycoprotein (TAG-72) found i n human 
colon and breast cancer. TAG-72 has been found i n 807. of colon 
carcinoma3 s tudied. B72.3 i s unreactive towards normal adult t issue^. 
A general r ad io labe l l ing procedure, beginning wi th the generation 
of the f r ee t h i o l s , is described schematically i n Figure 4.7. The MoAb 
is treated with 2-iminothiolane, p u r i f i e d by g e l - f i l t r a t i o n 4 to remove 
any unreacted 2-iminothiolane and f u r t h e r reacted wi th a two- to three-
f o l d excess of the maleimide-coupled macrocycle (71) . G e l - f i l t r a t i o n , 
capping any unreacted t h i o l groups with iodoacetaraide and fu r the r gel-
f i l t r a t i o n gives the macrocyclic antibody conjugate ( I V ) . These steps 
are performed in ammonium phosphate b u f f e r , pH 8.0, to minimise metal 
ion contamination. Metal phosphates tend to be insoluble and are 
therefore easi ly removable. 
At t h i s stage, i t is important to quant i fy the number of 
macrocycles bound to the antibody, not only f o r characterisat ion 
purposes, but also to enable an accurate determination of the radia t ion 
dose delivered to a pa t ient . The number of macrocycles per antibody is 
57 2+ 
estimated by adding a solut ion of Co (posi t ron emit ter , T | = 270 
2 
days) of known a c t i v i t y and therefore concentration in ammonium c i t r a t e 
bu f f e r (pH 4.0) and incubating f o r 20 minutes at 4°C. The antibody-
57 2+ 
bound macrocycles w i l l complex Co . Adding DTPA w i l l complex any 
3 A carcinoma is a malignant tumour of the epithelium (the outermost 
layer coating an organ or t i s sue ) . 
4 G e l - f i l t r a t i o n separates small molecules, eg. 2-iminothiolane, from 
larger ones eg. prote ins . Separation is achieved by passing the mixture 
down a column of carbohydrate beads (normally Sephadex G50 or PD-10). 
The smaller molecules are able to enter the beads, whereas the larger 
ones cannot. As a consequence of the diminished volume available to 
them, the larger molecules elute f i r s t (Ref.16). 
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f r ee ^ C o ^ + . The ^Co-raacrocyclic antibody conjugate is separated from 
57 
Co(DTPA) by g e l - f i l t r a t i o n , and the a c t i v i t y of the two f r ac t i ons 
measured. Knowing the concentration of prote in in the antibody f r a c t i o n 
(from the absorbance at 280 nm), the number of macrocycles per antibody 
can be calculated. 
On addi t ion of yt tr ium-90 i n the f i n a l step of the pro tocol , there 
i s , as wel l as the desired macrocyclic binding of ^ Y ^ + , the p o s s i b i l i t y 
of ^0y3+ becoming loosely or non-specifically bound to the antibody. 
Non-specific binding s i tes include peptide bonds along the protein 
backbone and the amide and carboxylate groups of amino acid side chains, 
eg. of asparagine and glutamic ac id . 
In the body the loosely bound radionuclide may be complexed by 
t r a n s f e r r i n and transported to the l i v e r . Ul t imate ly , the ^ Y -
t r a n s f e r r i n complex would be catabolised (broken down) and the f r ee 
90y3+ w o u i ( j loca l i se in the bone marrow. Direct release of the non-
s p e c i f i c a l l y bound ^ Y ^ + in to the blood would also resu l t in bone marrow 
loca l i s a t i on (Section 4 .8 ) . 
To avoid such a hazardous d i s t r i b u t i o n of radionuclide, three 
precautions are taken when r a d i o l a b e l l i n g . F i r s t , a b u f f e r is used 
which competes wi th the non-specif ic s i tes on the prote in f o r the metal 
ion, eg. ammonium acetate. Second, r ad io l abe l l i ng is e f fec ted at a pH 
at which the major i ty of the amino acid side chains w i l l be protonated, 
eg. pH 4-6. Th i rd , a f t e r r a d i o l a b e l l i n g , the ^Y-MoAb conjugate i s 
challenged with another complexing agent such as EDTA or DTPA. 
G e l - f i l t r a t i o n and size exclusion HPLC then remove any small complexes 
formed. 
Before i n j e c t i n g in to the body, the r a d i o l a b e l e d MoAb (VI) must be 
tested against unmodified MoAb ( I ) f o r any loss in immunoreactivity. 
1 & 17 
The tes t i s a technique known as a f f i n i t y chromatography ' : 
88 
y u Y-B72.3 i s incubated with ce l l s bearing the TAG-72 antigen. The 
mixture is then passed down a column covalently attached to which are 
groups (X, f o r example) with a high a f f i n i t y f o r cell-bound B72.3 (and 
not f r e e 9 0 Y-B72.3 , which w i l l elute r a p i d l y ) . The cell-bound 9 0 Y-B72.3 
i s eluted with a high concentration of soluble X. The concentrations of 
90 
cell-bound and non-cell bound Y-B72.3 can then be compared with a 
s imi l a r experiment in which the ce l l s bearing TAG-72 are incubated with 
unmodified B72.3. Typica l ly , immunoreactivity is los t when B72.3 i s 
l inked to more than two macrocycles. 
PART 3: BIODISTRIBOTION STUDIES* 
4.7 INTRODUCTION 
As a prerequisite to t r ea t ing human pat ients , the r ad io l abe l ed 
MoAb must f i r s t undergo t r i a l s in animals. Mice were used in our case. 
I t must be emphasised that due to the d i f f e r e n t const i tu t ions of mice 
and men, what happens to the r ad io l abe l ed MoAb in a mouse i s not 
necessarily related d i r e c t l y to what happens to i t in a human being. 
Animal experiments merely provide a guidel ine . The t r i a l s involve two 
stages: 
(a) I n j e c t i o n of the r ad io labe led MoAb into athymic (immuno-
suppressed) mice to assess whether i t remains stable in vivo. 
Athymic mice w i l l be the type used i n the tumour regression 
studies of stage (b ) . 
(b) I f the r ad io l abe l ed MoAb maintains i t s s t a b i l i t y , i t can be 
injected in to tumour-bearing athymic mice. This i s the 
Performed by Alice Harrison and Carol Walker at the Medical Research 
Council Radiobiology Uni t , Harwell. 
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c ruc ia l test to determine the effectiveness of the 
radiolabel led MoAb as a therapeutic agent. Tumour regression 
can be monitored by h i s to log i ca l techniques and by measuring 
the size of the tumour d i r e c t l y . 
At the time of w r i t i n g , the t r i a l s have reached the f i r s t stage. 
Before embarking on any of these experiments, two important 
controls were required, namely to determine the f a t e of the f ree ^ Y ^ + 
and of 90Y(DOTA) i n the mouse. 
Figures given in the fo l l owing sections, unless otherwise stated, 
r e f e r to the percentage of the injected dose of r ad ioac t i v i t y per gramme 
of t issue - each i s the average of data recorded f o r three or more mice. 
4.8 THE FATE OF FREE YTTRIlff l(III) 
90y3+ w a s in jected in to athymic mice as i t s c i t r a t e , acetate and 
chlor ide sal ts [ Y ( c i t r a t e ) , Y(acetate)g and YCl^ respectively] in-sodium 
phosphate buffered saline so lu t ion . Af t e r 24 hours, the mice were 
k i l l e d and the retent ion of r a d i o a c t i v i t y in the various tissues 
measured (Table 4 .1 ) . 
YC13 Y(acetate)3 Y(c i t r a t e ) 
TISSUE 7.Dose/g 7,Dose/g 7,Dose/g 
BLOOD 0.06 ± 0.03 0.08 ± 0.05 0.05 ± 0.02 
KIDNEYS 0.71 ± 0.06 0.39 ± 0.05 2.11 ± 0.11 
LIVER 21.9 ± 2.69 20.8 ± 4.09 1.79 ± 0.04 
LUNGS 0.41 ± 0.16 0.37 ± 0.11 0.80 ± 0.17 
SPLEEN 3.13 ± 0.08 3.92 ± 0.70 0.25 ± 0.07 
BONE 3.44 ± 1.10 3.04 ± 0.95 13.3 ± 4.42 
7.RET 41 42 7 
Table 4 . 1 : Murine distribution after 2 4 hours of 9 0 Y ( I I I ) injected 
as three different salts; 7,RET - percentage retention of 
original dose (whole body retention). 
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For the chloride and acetate sa l t s , the highest amount of y t t r i um was 
found in the l i v e r , probably as a resul t of t r a n s f e r r i n uptake, wi th 
s i g n i f i c a n t amounts i n the bone and spleen. In the case of the c i t r a t e 
s a l t , the highest amount of y t t r ium was found in the bone, suggesting 
that a mechanism other than jus t t r a n s f e r r i n uptake determines the f a t e 
of the y t t r i u m ( I I I ) c i t r a t e . No skin measurements were made. 
These resul ts are s imi la r to another s t u d y ^ in which ^Y(ace ta te ) 
was in jec ted in to normal and leukaemic mice. In both instances, ^0y3+ 
was found to local ise i n , in decreasing amounts, the bone, sk in , l i v e r 
and kidney. 
4.9 THE FATE TOF THE YTTRIUKl(III)-DMTA COHPLEX 
Twenty four hours a f t e r i n j e c t i o n of ^Y(DOTA) in to athymic mice, 
the amount of r ad ioac t i v i t y i n the bone and bone marrow was too low to 
measure, while the amounts in the l i v e r , lungs and spleen were 
measurable but s t i l l very low: 0.02, 0.03 and 0.047o respectively 
(Table 4 .2) . 
TISSUE 7«Dose/g 7oDose 
BLOOD 0.003 0.01 
KIDNEYS 0.22 0.13 
LIVER 0.02 0.04 
LUNGS 0.03 0.004 
SPLEEN 0.04 0.003 
STOMACH -- 0.04 
SMALL INTESTINE -- 0.12 
LARGE INTESTINE -- 0.19 
URINE 0.17 0.08 
Table 4 .2: Murine distribution of 9 0 Y ( I I I ) 2 4 hours after 
injection of 90Y(D0TA). 
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Approximately 0.5% of the o r i g i n a l dose was retained a f t e r 24 hours, i n 
stark contrast to the much greater retentions of ^ Y ^ + when administered 
as i t s ch lor ide , acetate and c i t r a t e sal ts (Table 4 . 1 ) , implying that 
Y(DOTA) i s rap id ly cleared from the body and, more importantly, that i t 
remains k i n e t i c a l l y stable in vivo. 
4.10 BliDISTRIBUTION OP THE ^ - L A B E L L E D IOTA-MOCIJNAL ANTIBOPY 
CONJUGATE AND COMPARISON UITM TEE BIODISTRIBOTION IF THE ^-LABELLED 
DTP A- MNOCUNAL ANTIBODY CONJUGATE 
Table 4.3 compares, over a 120 hour per iod, the b i o d i s t r i b u t i o n of 
9 0 Y 3 + i n athymic mice injected with the 9 0Y-DQTA-[mal]-B72.3 conjugate 
(mal = the maleimide spacer group) with the b i o d i s t r i b u t i o n of 9 ^ Y 3 + i n 
mice injected wi th the 9 0Y-DTPA-[mal]-B72.3 conjugate [DTPA l inked to 
the MoAb through i t s maleimide der iva t ive ( 7 2 ) ] . Table 4.4 expresses 
these f igures i n terms of the t issue to blood r a t i o . 
As B72.3 i s unreactive towards normal t i ssue , the 9 0 Y - l a b e l l e d 
MoAb, whether as the DOTA or DTPA conjugate, should remain i n the blood 
and ex t race l lu la r f l u i d (with an expected 50% blood leve l a f t e r 24 
hours). Any build-up of a c t i v i t y in other tissues w i l l be a resul t of 
the dissocia t ion of 9 0 Y 3 + from the MoAb conjugate or the catabolism of 
90 
the Y-label led MoAb. The t issue to blood r a t i o i s thus an indicator 
of the in vivo s t a b i l i t y of the 9 ^Y- label led MoAb. For a safe therapy, 
t h i s r a t i o should not show a substantial increase over a given t ime, 
p a r t i c u l a r l y that f o r a dose- l imi t ing organ such as bone (here 
represented by the femur). 
This c r i t e r i o n i s met f o r both r a d i o l a b e l e d MoAb conjugates, 
implying that they remain in tac t in vivo. There are small d i f fe rences , 
however, which suggest that i t would be preferable to use 90Y-DOTA-
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C0 2H 
COzH 
C0 2H 
C0 2H 
COzH 
9 0 Y - DTP A- [mal]-B72.3 soy-DOTA- [mal]-B72.3 
TISSUE 
24h 90h 120h 24h 77h 120h 
BLOOD 13 1 8 78 4 72 11.9 8 60 5 68 
LIVER 4 19 3 53 7 89 4.76 4 27 4 72 
KIDNEYS 3 37 2 49 2 39 3.05 2 20 1 78 
LUNGS 5 23 2 72 2 51 3.48 2 63 2 23 
SPLEEN 2 54 2 52 3 77 3.19 2 76 3 24 
FEMUR 1 82 1 71 2 10 1.70 1 43 1 67 
Table 4.3: Murine distribution (\injtcted dose/g of tissue) 
O f 9 o p + a i various time intervals after injection 
of *°Y-DTPA-[mal]-B72.3 and 9 °Y-D0TA-[mal ] -B72 .3 . 
90Y-DTPA- [mal]-B72.3 9<>Y-D0TA- [raal]-B72.3 
TISSUE 
24h 90h 120h 24h 77h 120h 
LIVER 0.32 0 42 1.53 0 39 0 58 0 97 
KIDNEYS 0.26 0 28 0.40 0 27 0 31 0 33 
LUNGS 0.43 0 31 0.51 0 30 0 37 0 40 
SPLEEN 0.19 0 29 0.65 0 28 0 34 0 57 
FEMUR 0.14 0 20 0.44 0 14 0 19 0 29 
Table 4 .4 : Murine tissue to blood ratio of 90f3+ a i various time 
intervals after injection of 90Y-DTPA-[mal]-B72.3 and 
^Y-D0TA-[mal]-B72.3. 
N 
N 
4 N N H 
(zjy 
[mal]-B72.3 f o r RIT. In par t i cu la r , the marginal increase i n the tissue 
to blood r a t i o seen f o r a l l tissues f o r both r ad io l abe l ed MoAb 
conjugates is more marked in the case of the r ad io l abe l ed DTPA 
conjugate, especially with regard to the l i v e r and femur. Furthermore, 
considering Table 4.3, there is a small increase in r a d i o a c t i v i t y in the 
femur f o r ^Y-DTPA- [mal]-B72.3 whereas there is a small decrease in 
r a d i o a c t i v i t y i n the femur f o r 9 0Y-D0TA- [mal]-B72.3. 
4.11 SUTOIRY 
The aminobutyl C-functionalised der iva t ive of DOTA was successfully 
synthesized from the methyl ester of lysine in eight steps wi th an 
overa l l y i e l d of 77,. Linkage of t h i s der iva t ive via a maleimide spacer 
group to the monoclonal antibody B72.3 gave an average of two 
macrocycles per antibody. The modified MoAb complexed e f f i c i e n t l y 
[707., pH 5.5, 0.1 M NHjOAc, 310K, 1.5h incubation period, DTPA quench 
(over 25 min, f i n a l [DTPA] = 5 x 10 Mj] and with no loss of immuno-
r e a c t i v i t y . Preliminary animal experiments have indicated that 9 ^Y-
D0TA-[mal]-B72.3 is s l i g h t l y more stable than 9 0Y-DTPA-[mal]-B72.3 in 
vivo. Results of tumour regression studies wi th 9^Y-D0TA-[mal]-B72.3 
are awaited. 
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CHAPTER FIVE 
EXPERIMENTAL 
5.1 SYNTHETIC EXPERIMENTAL 
5.1.1 teagents and Techniques 
A l l reactions, except those involv ing water as the solvent and 
detosylat ions, were carried out under n i t rogen. Water throughout refers 
to deionised water. Other solvents were d i s t i l l e d p r i o r to use from the 
appropriate drying agent: d ie thy l ether ( l i t h i u m aluminium hydride); 
tetrahydrofuran (sodium benzophenone); ethanol and methanol (from t h e i r 
respective magnesium alkoxides); toluene (sodium); e thyl acetate 
(calcium hydride); dichloromethane and chloroform (phosphorus pent-
oxide) ; t r ie thylamine (3A molecular sieves). A c e t o n i t r i l e was Aldr ich 
HPLC grade. DMF and borane-THF (1.0 M) were obtained from Aldr ich as 
Sure-Seal reagents, pyridine from the same company as a Gold Label 
reagent. Organic extracts were dried over anhydrous potassium carbonate. 
Melt ing points were obtained on a Kof le r block and are uncorrected. 
The o p t i c a l rota t ions quoted f o r compounds (62), (63) and (65) were 
measured wi th a Thorn-Automation NPL polarimeter. HPLC, ana ly t ica l and 
semi-preparative, was performed on a Varian Vista 5500/Polychrom 9060 
system. Columns and gradient e lu t ion conditions were as fo l lows : 
CATION EXCHANGE: Column: SynChropak CM300 
TIME(min) 7.A 7.B 7.C 
0 
5 
10 
80 
60 
0 
0 
20 
80 
20 
20 
20 
A 
B 
C 
H 20; 
Ammonium acetate (1.0 M, pH 5.6); 
CH3CN 
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AWIH3 EXCHANGE: Column: SynChropak AX 100 
TIME(min) 7. A 7.B 7,C 
0 70 10 20 
20 0 80 20 
A = B = C - Same as f o r cation exchange (above) 
EEVE1SE PHASE: Column: Spherisorb S0DS2 
TIME(min) 7.A 7.B 7.C 
0 95 0 5 
20 5 0 95 
A = 0.17. t r i f l u o r o a c e t i c ac id /H20; 
C = 0.17. t r i f luoroacetic acid/CH3CN 
Flow rates were 1.4 ml/min (ana ly t ica l ) and 4.0 ml/min (semi-
preparat ive) . Water refers to water p u r i f i e d by the M i l l i - Q system. 
Other solvents were Aldr ich HPLC grade. The wavelength monitored was 
254 nm. 
In f ra red spectra were recorded as t h i n f i l m s , KBr discs or Nujol 
mulls on a Perkin-Elmer 577 spectrophotometer. 
Proton and carbon NMR spectra were recorded on a Bruker AC 250 
spectrometer (250.13 and 62.90 MHz respec t ive ly) . The only 60 MHz *H NMR 
spectrum was recorded on a Perkin-Elmer R-24B spectrometer. Chemical 
s h i f t s are quoted i n ppm. TMS was the in te rna l standard f o r CDCl^ 
solut ions . D2O solutions were externally referenced to TMS or i n t e r n a l l y 
referenced to t -bu tanol . CD^ CN solutions were also i n t e rna l l y referenced 
to TMS. (CDg^SO solutions were external ly referenced to TMS. 
Mass spectra were obtained on a VG7070E spectrometer and were 
recorded in the DCI mode unless otherwise stated. I n the DCI and CI 
modes ammonia was employed as the irapingent gas. DCI samples were 
presented as dichloromethane solutions unless otherwise stated. The 
matrix used f o r FAB samples was glycerol unless otherwise stated. 
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Accurate masses were measured in the DCI mode. 
Column chromatography refers to f l a sh chromatography using Merck 
60 9385 s i l i c a . 
5.1.2 Synthesis of DOTA (7) 
1,4,7,10-Tetrakis(4-tolaenes^lphoayl)-l,4, 7,10-teiraazacyclododecme 
(15)- 1,2-Bis(4-toluenesulphonato)ethane (7.28g, 19.7 mmol) i n DMF (100 
ml) was added dropwise over 3h to 1,8-bis(4-toluenesulphonamido)-3,6-
bis(4-toluenesulphonyl)-1,3,6,8-tetraazaoctane (15.Og, 19.7 mmol) and 
caesium carbonate (13.5g, 41.3 mmol) in DMF (200 m l ) . The reaction 
mixture was s t i r r e d (20°C, 18h), heated at 60°C (3h) and solvent 
evaporated. The residue was taken up into hot chloroform (200 ml) ; t h i s 
solut ion was washed with water (2 x 20 ml ) , dried and evaporated. The 
residue was taken in to hot toluene (100 ml) . A f t e r s t i r r i n g (100°C, 
l h ) , the suspension was f i l t e r e d to a f f o r d the title compound as a white 
powder (10.Og, 647.; l i t . 1 807.). MPt. 278-280°C; Analysis Found: C, 55 .1 ; 
H, 5.6; N, 6.8. Required f o r C 3 6 H 4 4 N 4 S 4 0g: C, 54.8; H, 5.6; N, 7.17.; IR 
%ax ( f i l m ) : 3 0 6 0 > 1 6 0 0 > 1 3 4 0 ( S 0 2 ) a n d 1 1 6 0 ( S 0 2 ) c m 1 ; l f l N M R 
(CDC13): 2.44 (12H,s,ArCH 3), 3.43 (16H,s,NCH 2), 7.33 and 7.69 (16H,AB 
system, J A f l 8.1 Hz,ArH); 1 3 C NMR 6Q (CDClg): 21.5 (CHg); 52.3 (NCH.2); 
127.7, 129.9; 134.0, 143.9; MS m/z ( lntensi ty7.) : 789 (30,M ++1), 633 
(6,M + -155), 479 (17,M +-309). 
I, 4 , 7 , 1 0 - T e t r a a z e c y c l o d o d e c a B e tetrahydrochloride mozohydrate (16). 
Ammonia (300 ml) was condensed in to a mixture of the te t ra tosyla ted 
macrocycle (15) (4.33g, 5.49 mmol) i n THF (20 ml) and ethanol (10 ml) at 
-78UC. Lithium (1.93g, 278 mmol) was added in small port ions to t h i s 
mixture and an intense blue colour developed which discharged over 1-10 
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min. The reaction mixture was allowed to warm to room temperature, 
water (40 ml) was added and solvents evaporated. The residue was 
dissolved in hydrochloric acid (20 ml, 6M), washed with d i e t h y l ether (2 
x 30 ml) and evaporated. Recrys ta l l i sa t ion from hydrochloric acid (6M) 
gave the title compound as a white so l id (1.27g, 727.; l i t . 1 >907.). 
Analysis Found: C, 28.5; B, 7.9; N, 16.5. Required f o r CgH 2 0 N 4 .4BCl.H 2 0: 
C, 28.6; H, 7.7; N, 16.77.; *B NMR 8^ (DgO): 3.25 (s,NCH 2); 1 3 C NMR SQ 
(D 2 0) : 41.3; MS m/z (Intensity7,) CI : 173 (100,M ++1). 
I, 4 , 7 , 1 0 - T e t r & a z a c y c l o d o d e c a m - l , 4 , 7 , 1 0 - t e t r a a c e t i c acid hydrochloride 
dihydraie (DOTA) (7). Chloroacetic acid (1.47g, 15.5 mmol) i n water 
(5 ml) was neutralised wi th sodium hydroxide (0.62g, 15.5 mmol) i n water 
(5 ml ) , keeping the temperature between 0-5°C. 1,4,7,10-Tetraazacyclo-
dodecane (0.61g, 3.53 mmol) was added to t h i s so lu t ion which was then 
heated at 80°C (24h), keeping the pB between 9 and 10 with periodic 
addi t ion of a sodium hydroxide solu t ion (5 ml, 3.1M). The reaction 
mixture was concentrated under reduced pressure and the pH lowered to 
2.5 with hydrochloric acid (6M). A f t e r 12h a white microcrys ta l l ine 
so l i d precipi ta ted and was col lected to give the title compound (0.84g, 
507.; l i t . 2 827.). MPt. 265-267°C; Analysis Found: C, 40 .1 ; B, 6.9; N, 
I I . 8. Required f o r C 1 6 H 2 g N 4 0 g .HC1.2B 2 0: C, 40.3; B, 6.9; N, 11.757,; IR 
"max ( K B r ) : 2 5 0 0 b r ( N H + ) ' 1 6 9 0 ( C ° ) a n d 1 6 2 0 ( C 0 2 ) c n f l ; l f l N M R ^B ( D 2 0 ' 
pD 5.0, t-BuOD): 3.25 (16H,s,N(CH 2) 2N), 3.61 (8B,s,CB 2C0); 1 3 G NMR 8Q 
(D 2 0) : 49.0 (NCB 2), 56.9 (CJ 2C0), 178.6 (CO); MS m/z ( In tens i ty^ ) (FAB, 
m-nitrobenzyl a lcohol ) : 405 (3,M + +1). 
Yttriun(III) Complex of DOTA (35). DOTA (7) (5.0mg, 0.01 mmol) i n water 
(1 ml) was added to y t t r ium n i t r a t e hexahydrate (4.7mg, 0.01 mmol) i n 
water (1 ml) and the pB adjusted to 4.0 with sodium hydroxide (1M). The 
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volume of the solut ion was reduced to approximately 0.1 ml. Vapour 
d i f f u s i o n of propan-2-ol gave colourless tetragonal c rys ta l s (3mg, 477.). 
Analysis Found: C, 31.6; H, 4 . 1 ; N, 9.0. Required f o r C ^ H ^ Q g Y N a 
.5H 20: C, 31.9; H, 4.0; N, 9.37.; h NMR 6% (DgO, pD 5.0, t-BuOD): 2.40 
(4H,AB system,J A B 14 Hz,NCH2), 2.73 (8H,AB system,J_AB 7.3 Hz,NCH2), 3.19 
and 3.57 (8H,AB system, J_AB 16 Hz,CH2C0), 3.38 (4H,AB system,NCH2); MS 
m/z (Intensity7.) FAB: 491 (0.2, M ++2). 
5.1.3 Synthesis of TRITA (8) 
1,4,7,10-Tetrabis(4-toluenesalphoayl)-l,4,7,10-tetraazacyclotridecaQe 
(17). The title compound was synthesized according to the method f o r 
(15) to give a white so l i d (707.) • MPt. 117-118°C (from toluene); 
Analysis Found: C, 55.6; H, 6.0; N, 6.8. Required f o r C^^gN^S^Og: C, 
55.4; H, 5.7; N, 7.07.; IR i/ ( N u j o l ) : 3020, 1600, 1350 and 1160 cm" 1; 
HI clX 
[\\ NMR 6R (CDClg): 2.05 (2H,br,quin,NCH 2CH 2CH 2N), 2.43 (12H,s,ArCH 3), 
3.16 (4H,br,t,NCH2CH.2CH2N), 3.29 (4H,s,NCH 2), 3.32-3.38 (8H,m,NCH2), 
7.30-7.35 (8H,m,ArH), 7.65-7.68 (8H,AB system,J_AB 8.0 Hz,ArH); 1 3 C NMR 
8C (CDC13): 21.6 (CHg); 47.6, 4 9 .1 , 51.7 (NCB 2); 127.6, 127.9, 129.9; 
133.7, 134.4, 143.8, 144.1; MS m/z (Intensity7,) CI : 803 (46,M ++1), 647 
(21,M +-155). 
1,4,7,10-TetraazecyclotridecaBe hexahydrate (18). The te t ra tosyla ted 
cycle (17) (6.55g, 8.16 mmol) and phenol (4.55g, 48.4 mmol) were 
dissolved in 457. w/v hydrobromic acid in g l a c i a l acet ic acid (80 ml) and 
the mixture heated at 80°C (1 week) and f i l t e r e d . Anion exchange 
chromatography (Amberlite IRA-400) wi th water e lu t i on and evaporation of 
eluent afforded the title compound as a waxy white s o l i d (0.48g, 207.). 
MPt. 40-42°C ( l i t . 3 40-41°C); Analysis Found: C, 55.0; H, 12.4; N, 28 .1 . 
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Required f o r C g H 2 2 N 4 .6H 2 0: C, 54.8; H, 11.9; N, 28.47.; h NMR ^ 
(CDC13): 1.69 (2H,quin,J 5.2 Hz,NCH2CH2CH.2N), 2.31 (4H,br,s,NH), 2.64-
2.77 (16H,m,NCH2); 1 3 C NMR SQ (CDClg): 28.8 (NCH2CH2CH2N); 47.2, 47.5, 
48.7, 49.8 (NCH2); MS m/z (Intensity7.): 188 (34,M ++2), 187 (100,M++1)-
1.4.7.10- Tetraazacyclotridecaae-l,4,7,10-tetraaceiic acid trihydro-
chloride (TEITA) (8). The title compound was synthesized according to 
the method f o r (7) to give a glassy so l id (0.30g, 607.; l i t . 4 187.). MPt. 
184-185°C (dec) [ l i t . 4 185°C (dec)] ; Analysis Found: C, 38.6; H, 6.4; N, 
10.8. Required f o r C 1 7 H 3 0 N 4 O g .3HCl : C, 38.7; H, 6.3; N, 10.67.; H NMR 
<SH ( D 2 0 ) : 2.03 (2H,br,quin,CH 2CH 2CH 2), 3.24 (4H,br,t ,CH 2CH 2CH 2), 3.29 
(12H,s,N(CH 2) 2N), 3.78 (4H,s,CH 2C0 2), 3.84 (4H,s,CH 2C0 2); 1 3 C NMR <$c 
(D 2 0) : 19.3 (CH2CH2CH2); 50.4, 51.2, 52.0, 52.5, 53.7, 54.7; 169.1, 
171.7 (CO); MS m/z (Intensity7.) FAB: 419 (4,M + +1). 
5.1.4 Synthesis of TETA (9) 
1.4.8.11- Tetraazacycloteiradecaae-l,4,8,11-tetraacetic acid dihydrate 
(TETA) (9). The title compound was synthesized according to the method 
f o r (7) to give a white c r y s t a l l i n e s o l i d (587.; l i t . 4 517,). MPt. 255-
257°C (dec); Analysis Found: C, 45.7; H, 8 . 1 ; N, 12.0. Required f o r 
C 1 8 H 3 2 N 4 ° 8 - 2 H 2 0 : C ' 4 6 , 2 ; H ' 7 - 7 ; N ' 1 2 , 0 7 c ; I R "max ( K B r ) : 2 9 0 0 b r ^ 0 H ) ' 
2500br (NH + ) , 1720 (CO) and 1630 (C0 2) cm" 1; ! H NMR 6^ (D 2 0) : 1.85 (4H, 
quin,J 6.6 Hz,NCH2CH2CH2N), 3.07 (8H,t ,J 6.6 Hz,NCH2CH2CH2N), 3.14 (8H, 
s,N(CH 2 ) 2 N), 3.51 (8H,s,CH2C0); 1 3 C NMR 6G (D 2 0) : 22.5 (NCH2CH2CH2N), 
51.5 (NCH2CH2CH2N,N(CH2)2N), 56.1 (CH2C0), 175.5 (CO); MS m/z 
(Intensity7.) FAB: 429 (0 .3 ,M + -3 ) . 
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5.1.5 Synthesis of JMDTA-BM (10) 
1,4,7-¥ris(4-tolaeaesalphoDffl)-l,4,7,10-tetmazaeyclododecaae (19). 
1,4,7,10-tetraazacyclododecane (0.15g, 0.89 mmol) i n dichloromethane 
(5 ml) was added dropwise over 10 min to 4-toluenesulphonyl chloride 
(0.36g, 1.87 mmol) and tr ie thylamine (0.26 ml, 1.87 mmol) i n dichloro-
methane at 0°C. S t i r r i n g was continued (0°C, 2h) and solvent evaporated. 
Column chromatography (1% methanol i n dichloromethane) gave the title 
compound as a glassy o i l (0.06g, 117.). IR v ( f i l m ) : 3310 (NH), 1600, 
1340 and 1160 cm" 1; h NMR <$H (CDClg): 1.50 ( lH,br , s ,NH) , 2.43 (6H,s, 
ArCH 3), 2.46 (3H,s,ArCH 3), 2.91-2.96 (4fl,m,NCH 2), 3.09-3.11 (4H,m,NCH2), 
3.32 (4H, t , J 5.7 Hz,NTsCH_2CH2NTs), 3.54 (4H,t ,J 5.7 Hz,NTsCH2Cfl2NTs), 
7.26-7.36 (6H,m,ArH), 7.63-7.67 (4H,AB s y s t e m , 8 . 1 Hz,ArH), 7.75-7.78 
(2H,AB system,J A B 8.1 Hz,ArH); 1 3 C NMR 8^ (CDClg): 22.9 (CHg); 49.7, 
50.6, 50.8 (NCH2); 127.4, 127.8, 129.8; 135.1, 135.6, 141.4, 143.5; MS 
m/z ( I n t e n s i t y ^ ) : 635 (100,M ++1), 479 (15,M +-155), 325 (13,M +-309). 
A second compound, 1,7-bis(4~ toluenesulphonyl)-1,4,7,10-tetraazacyclo-
dodecane, was also isolated as a glassy o i l (0.06g, 107.). ^ NMR 6^ 
(CDClg): 2.44 (6H,s,ArCHg), 3.16-3.19 (8H,m,NHCH2CH2N), 3.40-3.41 (8H,m, 
NHCH2CH2N), 7.36 and 7.68 (8H,AB system,J_AB 8.0 Hz,ArH); 1 3 C NMR 6Q 
(CDClg): 21.5 (CHg); 49.2, 49.5 (NCH2); 127.3, 130.2; 134.1, 144.5; MS 
m/z ( Intensi ty7.) : 481 (44,M ++1). 
10-(N,fJ-DimeihylcaTboxamidometkyl)-l,4,7-tris(4-toluenestilphonyl)-
1,4,7,10- tetraazacyclododecane (20)- 2-Bromo-N,N-dimethylethanamide 
(0.08g, 0.48 mmol) was added to the t r i t o s y l a t e d macrocycle (19) (0.20g, 
0.32 mmol) and potassium carbonate (0.07g, 0.48 mmol) i n a c e t o n i t r i l e 
(10 ml) at 80°C. The reaction mixture was ref luxed (5h) and more 2-
102 -
bromo-N,N-dimethylethanamide added (0.04g, 0.24 mraol). Further r e f l u x 
(15h) and evaporation gave a residue which was column chromatographed 
(17. methanol in dichloromethane) to give the title compound as a 
colourless o i l (0.21g, 907.). IR ( f i l m ) : 3020, 1650 (CO), 1600, 
1340 and 1160 cm" 1; H NMR ^ (CDClg): 2.43 (6H,s,ArCH 3), 2.46 (3f l ,s , 
ArCH 3), 2.89 and 2.98 (6H,2xs,NCH3), 3.09-3.12 (8H,m,NCH2), 3.32-3.34 
(4H,m,NCH2), 3.52-3.55 (6H,m,NCB2,NCB2C0), 7.27-7.36 (6H,m,ArH), 7.60-
7.63 (4H,AB system,J A f i 8.1 Hz,ArH), 7.71-7.74 (211,AB system,J A g 8.1 Bz, 
ArB); 1 3 C NMR 6Q (CDClg): 21.5 (CB g ) ; 35.2, 36.7 (NCB 3); 48.8, 50.2, 
50.9, 52.6, 54.3 (NCH2); 127.5, 127.6, 129.7; 134.5, 135.8; 170.2 (CO); 
MS m/z (Intensity7.) : 720 (100,M ++1), 564 (18,M +-155). 
4 - ( N , N - D i m t h y l c a r h o x a n ) i d o f a e t h y l ) - l - ( 4 - t o l u e n e s v l p h o n y l ) - 1 , 4 , 7 , 1 0 - tetra-
azacyclododecane trihydrohromide (21). The t r i t o s y l a t e d macrocycle (20) 
(0.21g, 0.29 mmol) was dissolved in 457. w/v hydrobromic acid in g l a c i a l 
acetic acid (10 ml) and to t h i s solut ion was added phenol (0.25g, 2.60 
mmol). The mixture was heated at 80°C (2 weeks) and f i l t e r e d to give 
the title compound as a cream so l id (0.09g, 487.). 1 H NMR <$H (DgO): 2.34 
(3B,s,ArCB 3 ) , 2.92 (6B,s,NCB 3), 3.08-3.25 (14H,m,NCH2), 3.61 (2B,s, 
NCH2C0), 3.93-4.02 (2H,m,NTsCH2CH2NCH2C0), 7.40 and 7.70 (4H,AB system, 
J A B 8.1 Hz,ArB); MS m/z ( In tens i ty^) CI : 412 (100,M ++1). 
1-(N-Benzyl-N-methylcarboxamidotteihyl)-l,4,7,10-tetraazacyclododecane 
(22). 2-Bromo-N-benzyl-N-methylethanamide (113mg, 0.47 mmol) in DMF 
(3 ml) was added dropwise over 45 min to 1,4,7,10-tetraazacyclododecane 
(lOOmg, 0.58 mmol) and potassium carbonate (80mg, 0.58 mmol) in DMF 
(5 ml) at room temperature. The temperature was raised to 50°C and 
s t i r r i n g continued (24h). Solvent was evaporated and the residue taken 
in to dichloromethane (2 ml) and f i l t e r e d . Evaporation of the f i l t r a t e 
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and preparative HPLC (cation exchange) gave the title compound as a 
colourless o i l (58mg, 30%). R_t 8.1 rain; *H NMR 8^ (CDClg): 2.84 and 
2.93 (3H,2xs,CH 3), 2.96 (12H,br,s,NHCH 2), 3.05 (4H,br ,s ,NCfl 2 ) , 3.57 and 
3.64 (2H,2xs,CH2Ph), 4.47 and 4.57 (2H,2xs,CH2C0), 7.20-7.40 (5H,m,ArH); 
MS m/z (Intensity?.): 335 (7,M + +2), 334 (30,M ++1). 
The fo l l owing compound was also i so la ted: 1,4-bis(N-benzyl-N-methyl-
carboxamidomethylj-l,4, 7,10-tetraazacyclododecane or 1,7-bis(N-benzyl-N-
methylcarboxamidomethyl)-l,4,7,10-tetraazacyclododecane as a colourless 
o i l (31mg, 297.). R t 7.6 min; h NMR 8% (CDClg): 2.77-3.07 (22H,m,NHCH_2, 
NCH2), 3.44 and 3.47 (2H,2xs,CB 2Ph), 3.56 and 3.61 (2H,2xs,CH2Ph), 4.46 
and 4.51 (2H,2xs,CH2C0), 4.55 (2H,s,CH 2C0), 7.11-7.36 (10H,m,ArH); MS 
m/z (Intensity?.): 495 (36,M ++1). 
1-(N-Be®zyl-N-mthylcarboxataidomeihyl)-4,7,10-tris(ethyoxycarbonyl-
methyl)-1,4,7,10-tetraazacyclododecane (23). Ethyl bromoacetate (68/ i l , 
0.61 ntmol) was added dropwise over 10 min to the macrocyclic amide (22) 
(58mg, 0.17 mmol) and potassium carbonate (84rag, 0.61 mmol) in DMF 
(2 ml) and the mixture heated at 60°C ( lOh) . Solvent was removed under 
reduced pressure and the residue taken in to dichloromethane (2 ml) and 
f i l t e r e d . Evaporation of the f i l t r a t e and preparative HPLC (cation 
exchange) gave the title compound as a colourless o i l (16mg, 167.). 
R t 8.8 min; Found M + + l : 592.3855. Required f o r C 3 ( ) H 5 0 N 5 0 7 : 592.3710; 
h NMR 8ft (CDClg): 1.24-1.31 (9H,m,CH2CHg), 2.36 (16H,br,s ,N(CH 2 ) 2 N), 
2.90 and 2.91 (3H,2xs,NCHg), 3.33 (8H,br,s,NCH 2C0), 4.19 (6H,q,J 7.1Hz, 
CH2CHg), 4.52 (2H,s,CH 2Ph), 7.21-7.33 (5H,m,ArH); MS m/z (Intensi ty?.) : 
593 (21,M ++2), 592 (59,M ++1), 333 (8,M ++3-3CH 9C(LEt). 
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4-(N-Beazyl-N-iaethylcarhoxaiaidoiaethyl)-I,4,7,10-tetraazacyclododecaoe-
1,4,7-triacetic acid (DBTA-BUA) (10). The t r i e s t e r (23) (16mg, 0.03 
mmol) and tetramethylammonium hydroxide (30mg, 0.17 mmol) were added to 
a solution of water (0.5 ml) and methanol (0.5 ml). The reaction mixture 
was heated at 100°C (6h), solvents removed under reduced pressure and 
the residue p u r i f i e d by preparative HPLC (anion exchange) to give the 
title compound as a glassy solid (2mg, 15%). R^  7.9 min; H NMR 6^ (D 20, 
pD 5.0, t-BuOD): 2.93 and 2.99 (3H,2xs,CH3), 3.11 (8H,br,s,NCH2CH2N), 
3.31-3.44 (10H,br,m,NCH2CH2N,NCH2CO), 3.63 and 3.65 (2H,2xs,CH2Ph), 
3.70, 3.76 and 3.81 (4H,3xs,NCH2C0), 4.54 and 4.55 (2H,2xs,NCH2C0N), 
7.21-7.41 (5H,m,ArH); MS m/z (Intensity?.) FAB: 508 (0.4,M++1). 
5.1.6 Synthesis of 0D0TRA ( U ) 
4,7,10-Tris(4-toluenes%lphoByl)-l-oxa-4,7, tO-triazacyclododeame (2£). 
l,5-Bis(4-toluenesulphonato)-3-oxapentane (3.66g, 8.85 mmol) in DMF 
(50 ml) was added dropwise over 3h to a vigorously s t i r r e d solution of 
1,5-bis(4-toluenesulphonamido)-3- (4- toluenesulphonyl)-3- azapentane (5g, 
8.85 mmol) and caesium carbonate (6.06g, 18.6 mmol) in DMF (150 ml) at 
RT. The reaction was allowed to s t i r f o r a further 18h and then heated 
at 60°C f o r 3h. Solvent was removed under reduced pressure and the pale 
yellow residue taken up into dichloromethane (100 ml); t h i s solution was 
washed with water (2 x 20 ml), dried and solvent evaporated. The 
residue was rec r y s t a l l i s e d from dichloromethane-hexane to give the title 
compound as a white solid (4.26g, 767,; l i t . 5 527.). MPt. 190-192°C; 
Analysis Found: C, 55.5; H, 6.0; N, 6.3. Required f o r (^gH^NgO^Sg: 
C, 55.8; H, 5.8; N, 6.67.; IR i> v ( f i l m ) : 3040, 1600, 1350 (S0 9) and 
1165 (S0 2) cm"1; H NMR ^ (CDClg): 2.48 (6H,s,ArCH3), 2.51 (3H,s, 
ArCH 3), 3.20-3.27 (8H,m,NCH2), 3.57 (4H,t,J 6.3 Uz,NCH.2), 3.70 (4H,t,J 
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3.9 Hz,NCB2CH20), 7.36 and 7.68 (8H,AB system,J A R 6.7 Hz,ArH), 7.40 and 
7.86 (4H,AB system,J A B 8.1 Hz,ArH); 13C NMR SQ (CDClg): 21.5 (CHg); 
47.9, 50.6 (NCH2); 72.0 (0CH2); 127.3, 127.6, 129.8; 135.0, 136.7, 
143.4, 143.7; MS m/z (Intensity7o): 636 (8,M++1), 480 (2,M+-155), 327 
(3,M+- 308). 
l-0xa-4,7,10-triazacyclododecaoe (25). The t r i t o s y l a t e d macro-cycle (24) 
(2.00g, 3.15 mmol) was dissolved in 45% w/v hydrobromic acid in g l a c i a l 
acetic acid (30 ml) and to t h i s solution was added phenol (2.67g, 28.4 
mmol). The mixture was heated at 80°C fo r 3h and f i l t e r e d . Anion 
exchange chromatography (Amberlite IRA-400 converted to the hydroxide 
form with tetramethylammonium hydroxide) with water elution on the s o l i d 
collected and evaporation of the eluent afforded the title compound as a 
waxy white so l i d (311mg, 577,). MPt. 87-89°C; Analysis Found: C, 55.1; 
H, 11.25; N, 24.0. Required f o r CgH^O: C, 55.5; H, 11.0; N, 24.37.; 
IR v m & x (Nujol): 3295 (NH) cm"1; h NMR <$H (CDC13): 2.33 (3H,br,s,NH), 
2.59-2.64 (4H,m,NCH.2), 2.76-2.83 (8H,m,NCH2), 3.57-3.62 (4H,m,0CH2); 1 3C 
NMR 6 C (CDC13): 46.3, 46.4 (NCH2); 66.5 (0CH2); MS m/z (In t e n s i t y ! ) FAB: 
174 (100,M++1). 
l-0xa-4,7,10-triazacyclododecane-4,7,10-triacelic acid hydrochloride 
monohydrate (0D0TRA) (JJ). Chloroacetic acid (206mg, 2.18 mmol) in 
water (1 ml) was neutralised with sodium hydroxide (87mg, 2.18 mmol) in 
water (1 ml), keeping the temperature between 0-5°C. The triamine (25) 
( l l l m g , 0.64 mmol) was added and the temperature raised to 80°C fo r 24h 
keeping the pH above 9 with periodic addition of a sodium hydroxide 
solution (0.5 ml, 4.35 M). The reaction mixture was concentrated under 
reduced pressure and the pH lowered to 2.5 with hydrochloric acid (6 M). 
Liquid d i f f u s i o n of methanol gave the title compound as colourless 
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crystals (145mg, 657,; l i t . 5 707.). MPt. 134-136°C ( l i t . 5 132-134°C); 
Analysis Found: C, 38.2; H, 7.0; N, 9.4. Required f o r C^H^NgOy.HCl 
• O : C, 38.4; H, 6.6; N, 9.67.; IR v m a v (KBr): 3000br (OH) and 1690vs 
(CO) cm"1; h NMR 6^ (DgO, pD 5.0, t-BuOD): 3.05 (411,t,J 5.2 Hz,NCH2), 
3.34 (2H,s,CH2C02), 3.49 (4H,br,s,NCH2), 3.59 (4H,t,J 4.6 Hz,NCH2CH20), 
3.83 (4H,s,CH2C02), 3.91 (4H,t,J 4.7 Hz,NCB2CH20); MS m/z (I n t e n s i t y ^ ) 
FAB: 348 (9,M++1). 
5.1.7 Synthesis of DTCTA (12) 
1 , H - B i s ( 4 - t o l n e u e s i i l p h o z a i o ) - 6 - ( 4 - t o l ® e B e s B l p h o n y l ) - 3 , 9 - d i o x a - 6 - a z a -
undecane (27). 4-Toluenesulphonyl chloride (38.lg, 200 mmol) was added 
in small batches over Ih to a solution of 3,9-dioxa-6-azaundecan-1,11-
d i o l (26) (9.65g, 50.0 mmol) in pyridine (150 ml) at 0°C. After s t i r r i n g 
for 30 min the reaction mixture was l e f t at -10°C for 18h. The solution 
was poured onto crushed ice, s t i r r i n g continuously u n t i l the ice melted. 
The water layer was decanted leaving an o i l y residue which was dissolved 
in dichloromethane (50 ml) and combined with the subsequent dichloro-
methane extracts (3 x 50 ml) of the water layer. Washing with hydro-
chloric acid (1 M, 3 x 50 ml) and water (2 x 50 ml) followed by drying 
and solvent evaporation gave an o i l which was column chromatographed 
(0.57. methanol i n dichloromethane) to give the title compound as a 
colourless o i l (15.lg, 467.). Found M ++l: 656.0848. Required f o r 
C29 H38 N 010 S3 : 6 5 6 - 1 6 5 Q ; 1 h N M R (CDC13): 2.39 (3H,s,ArCH3), 2.41 (6H, 
s,ArCH3), 3.28 (4H,t,J 5.7 Hz,NCH2), 3.50-3.57 (8H,m,0CH2), 4.08 (4H,t, 
J 4.5 Hz,TsOCH2), 7.29 and 7.67 (4H,AB system,J^g 8.3 Hz,ArH), 7.34 and 
7.77 (8H,AB system,Ji R 8.2 Hz,ArH); MS m/z (IntensityX): 656 (2,M++1). 
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l,ll-Bis(l,2-beazeBediearboximdo)-6-(4-tolBeBesalphoayl)-3,9-diox&-§-
azmadecaae (28). The t r i t o s y l a t e d compound (27) (1.36g, 2.08 mmol) i n 
DMF (20 ml) was added dropwise over 30 min to a solution of potassium 
phthalimide (0.77g, 4.14 mmol) in DMF (10 ml) and the mixture heated 
(90°C, 20h). The solution was poured onto crushed ice with s t i r r i n g . A 
white o i l separated which, after decanting the aqueous phase, was 
dissolved i n dichloromethane (10 ml). The aqueous phase was extracted 
with dichloromethane (4 x 25 ml) and the combined dichloromethane 
solutions dried and evaporated. Recrystallisation from ethyl acetate 
gave the title compound as a white s o l i d (0.77g, 617.). MPt. 78-80°C; 
Analysis Found: C, 61.7; H, 5.0;,N, 6.8. Required f o r C^H^NgQgS: C, 
61.5; H, 5.1; N, 6.97.; IR i/ ( f i l m ) : 3060, 1770 (imide), 1710 (imide), 
1610 and 1595 cm"1; h NMR 6^ (CDClg): 2.39 (3H,s,ArCH3), 3.29 (4H,t,J 
5.8 Hz,TsNCH2), 3.52-3.64 (8H,m,0CH2CH2phthal), 3.82 (4H,t,J 5.7 fiz, 
0CH2), 7.22 and 7.62 (4H,AB system,J A f i 10 Hz,Ar(Ts)H), 7.70 and 7.76 
(4H,AB system,J^g 5.7 Hz,ArH), 7.72 and 7.84 (4H,AB system,J^g 5.5 Hz, 
ArH); 1 3C NMR 6 Q (CDClg): 21.4 (Cflg); 37.3, 48.4 (NCH2); 67.8, 69.7 
(0CH2); 123.2, 127.1, 129.5, 133.9; 132.1, 138.4, 144.9; 168.1 (CO); 
MS m/z (Int e n s i t y ^ ) EI: 147 (31,phthalimide). 
6-(4-Toluenesulphonyl)-3,9-dioxa-6-aza-l,9-undecanediamine (29). 
Hydrazine monohydrate (0.12g, 2.44 mmol) was added to a solution of the 
diphthalimide compound (28) (0.74g, 1.22 mmol) i n ethanol (50 ml) at 
60°C. After r e f l u x i n g f o r 18h, concentrated hydrochloric acid (7.5 ml) 
was added dropwise to the cooled reaction mixture which was then 
refluxed f o r a fu r t h e r 30 min. A white so l i d precipitated and was 
removed by f i l t r a t i o n . The f i l t r a t e was concentrated to a white s o l i d 
which was suspended in water (5 ml) and f i l t e r e d . The f i l t r a t e was 
basified with potassium hydroxide p e l l e t s , extracted with chloroform 
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( 4 x 5 ml), dried and evaporated to give the title compound as a 
colourless o i l (0.37g, 877.). Found 346.1242. Required f o r 
C15 H28 N3°4 S : 3 4 6- 1 8 0 1; I R Vx ( f i l m ) : 3200br (NH), 1595, 1330 (SQ2) 
and 1160 (S0 2) cm"1; XH NMR 6^ (60 MHz,GDCl3): 1.3 (4H,s,NH"2), 2.3 
(3H,s,ArCH3), 2.7 (4H,t,J 5 Hz,NCH2), 3.2-3.6 (12H,m,0CH2,NCe2), 7.3 and 
7.5 (4H,AB system,J A Q 8 Hz,ArB); 1 3C NMR <$c (CDC13): 20.7 (CH 3); 41.0, 
47.9 (NCH2); 68.9, 72.5 (0CH2); 126.3, 128.9; 136.1, 142.5; MS m/z 
(Intensity7.): 347 (9,M++2), 346 (34,M++1). 
1, ll-Bis(4-toluenesMlpkonan)ido)-6-(4-tol®eBestilphonyl)-3,9-dioxa-& 
azaundecane (30). 4-Toluenesulphonyl chloride (0.52g, 2.75 mmol) was 
added i n small batches over 30 min to a s t i r r e d solution of the diamine 
compound (29) (0.37g, 1.06 mmol) and potassium carbonate (0.38g, 2.75 
mmol) in water (30 ml) at 60°C. The temperature was raised to 80°C and 
s t i r r i n g was continued f o r 18h. The cooled solution was decanted 
leaving a white o i l y residue which was taken into dichloromethane (10 
ml) and combined with the subsequent dichloromethane extracts (4 x 10 
ml) of the aqueous phase. Drying and evaporation of the organic phase 
gave a residue which was column chromatographed (0.57. methanol in 
dichloromethane) to give the title compound as a colourless o i l (0.41g, 
607.). IR v m a x ( f i l m ) : 3290 (NH), 1600, 1330 (S0 2) and 1160 (S0 2) cm"1; 
h NMR <5H (CDC13): 2.35 (9H,s,ArCH3), 3.03 (4H,dt,J 2x5.0 Hz,CiyiHTs), 
3.21 (4H,t,J 5.0 Hz,TsNCH2), 3.39 (4H,t,J 4.7 Hz,OCfl2CH2NH), 3.46 (4fl,t. 
J 5.0 Hz,TsNCH2CH20), 5.82 (2H,t,J 5.9 Hz,NH), 7.25 and 7.71 (8H,AB 
system,J A B 8.1 Hz,ArH), 7.24 and 7.64 (4H,AB system,J A g 8.1 Hz,ArH); 
1 3C NMR 6 Q (CDC13): 21.3 (CHg); 42.7, 48.8 (NCH2); 69.0, 69.4 (0CH2); 
126.8, 127.0, 129.6; 135.8, 136.9, 143.0, 143.4; MS m/z ( I n t e n s i t y ^ ) : 
656 (21,M++3), 655 (21,M++2), 654 (100,M++1), 498 (8,M+-155). 
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decaae (31)- 1,2-Bis(4-toluenesulphonato)ethane (l.75g, 4.73 mmol) in 
DMF (50 ml) was added dropwise over 3h to a vigorously s t i r r e d solution 
of the t r i t o s y l a t e d compound (30) (3.09g, 4.73 mmol) and caesium 
carbonate (3.24g, 9.93 mmol) in DMF (150 ml) at room temperature. 
S t i r r i n g was continued f o r a further 18h, whereupon the reaction mixture 
was heated at 60°C f o r 3h. Solvent was removed under reduced pressure 
and the residue taken into dichloromethane; the organic layer was washed 
(2 x 20 ml), dried and evaporated. Column chromatography (gradient 
eluent 0.5-1.57, methanol in dichloromethane) afforded the title compound 
as a colourless o i l (0.14g, 247,). IR v ( f i l m ) : 1600, 1330 and 1165 
cm"1; h NMR ^ (CDClg): 2.42 (9H,s,ArH), 3.27 (4H,t,J 4.3 Hz,NCH_2CH20), 
3.40 (4H,s,N(CH2)2N), 3.48-3.53(1211,m,NCH2,0CH2), 7.28 and 7.64 (4H,AB 
system,J A B 8.1 Hz,ArH), 7.32 and 7.74 (8H,AB system,J^g 8.0 Hz,ArH); 1 3C 
NMR 8 C (CDCI3): 21.4 (CH 3); 42.7, 48.9 (NCH2); 69.1, 69.5 (0CH2); 126.9, 
127.1, 129.6; 135.8, 137.0, 143.1, 143.4; MS m/z (Intensity7.): 682 (3, 
M ++3), 681 (5,M++2), 680 (13,M++1), 526 (17,M+-153), 370 (23,M+-309). 
1,7-Dioxa~4,10,13-triazacyclopeutadecaBe (32). The t r i t o s y l a t e d 
macrocycle (31) (0.38g, 0.56 mmol) and phenol (0.48g, 5.08 mmol) were 
dissolved in 457, w/v hydrobromic acid in g l a c i a l acetic acid (10 ml). 
The mixture was heated (80°C,12h) and f i l t e r e d to give the trihydro-
bromide s a l t of the title compound as a yellow c r y s t a l l i n e s o l i d (0.20g, 
797.). Found M ++l: 218.1775. Required f o r ^ x^2A^r 218-1869; ^ N M R 
(D 20): 3.40 (4H,t,J 4.8 Hz,NCH2), 3.46 (4H,t,J 4.7 Hz,NCH2), 3.58 (4H,s, 
N(CH 2) 2N), 3.84-3.92 (8H,m,0CH2); 1 3C NMR 6^ (D 20): 41.8 (N(CH 2) 2N); 
45.1, 46.3 (NCH2); 64.6, 65.5 (0CH2); MS m/z (Intensity7.) CI: 219 (2, 
M ++2), 218 (13,M++1). 
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The trihydrobromide salt of the title compound (0.20g, 0.43 mmol) was 
dissolved in water (1 ml) and basified (pH 14) by the addition of 
tetramethylammonium hydroxide. The aqueous layer was extracted with 
chloroform (10 x 1 ml) and the combined chloroform extracts dried and 
evaporated to give the title compound as a colourless o i l (0.09g, 96%). 
l\\ NMR <5H (CDC13): 2.40 (3H,br,s,NH), 2.76-2.85 (12H,m,NCH"2), 3.56-3.64 
(8H,m,0CH2). 
4,10,13-Tris(benzoxycarbonylmethyl)-l,l-dioxa-4,10,13-triazecyclopeuta-
decane (33). Caesium carbonate (68mg, 0.21 mmol) was added to the 
triamine (32) (13mg, 0.06 mmol) and 2-bromobenzylacetate (48mg, 0.21 
mmol) dissolved i n DMF (3 ml). The suspension was s t i r r e d (60°C, 36h), 
monitoring the reaction by analytical HPLC (cation exchange). Solvent 
was evaporated, the residue taken into dichloromethane (2 ml), f i l t e r e d 
and the f i l t r a t e evaporated to give an orange-brown residue. Preparative 
HPLC (cation exchange) gave the title compound as a colourless o i l (7mg, 
18%). Rt 8.8 min; h NMR <5H (CDClg): 2.84 (411,s,N(CH2)2N), 2.87 (4H,t,J 
5.0 Hz,NCH2), 2.94 (411,t,J 5.0 Hz,NCH2), 3.47 (6H,s,NCH2C0), 3.50-3.56 
(8H,m,0CH2), 5.12 (6H,s,C02CH2), 7.34 (15H,s,ArH); MS m/z (Intensity?.): 
662 (3,M++1), 661 (6,M +), 571(3,M+-C7H6), 514 (4,M++2-CH2C0.2Bz). 
Also isolated was the mixed dibenzyl methyl ester derivative of (33), 
(3£) as a colourless o i l (6mg, 177.). R_t 6.9 min; H NMR 8^ (CDClg): 
2.83-2.93 (12H,m,NCH2), 3.47-3.58 (14H,m,0CH2,CH>2C0), 3.67 (3H,s,CHg), 
5.13 (4H,s,CH2Ph), 7.35 (10fl,s,ArH); MS m/z (Intensity?.): 586 (13,M++1), 
438 (4,M++2-CH2C02Bz). 
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1,7-DiozG-4,10,13-triezacyelopeQtadecaae-4,lO,13-triacetie e,cid 
irikydrockloride (DTCTA) (12)- ^11 glassware fo r t h i s step was steeped 
in hydrochloric acid (6 M) fo r 18h p r i o r to use. The dibenzyl methyl 
ester (34) (6mg, 0.01 mmol) was dissolved in hydrochloric acid (1 ml, 
6 M) and heated (110°C, 18h). The aqueous layer was washed with d i e t h y l 
ether ( 3 x 1 ml) and deuterated chloroform (1 ml) and subsequently 
evaporated to give the title compound as a glassy white s o l i d (5mg, 
977.). h NMR <5H (D 20, pD 4.5, t-BuOD): 3.33 (4H,t,J 4.5 Hz,NCH2CH2Q), 
3.44 (4H,s,N(CH2)2N or CH2C0), 3.57-3.60 (4H,m,NCH_2CH20), 3.63 (4H,s, 
N(CH2)2N or CH2C0), 3.80 (8H,t,J 4.7 Hz,NCB2CH_20), 3.83 (2H,s,CB2C0); 
MS m/z (Intensity?.) FAB: 392 (13,M++2). 
5.1.8 Synthesis of (+)-(2S)- (4-AminobutylJMTA 
(2S)-Hethyl-2,6-diamiBohexanoate dihydrockloride (57). (+)-(2S)-Lysine 
hydrochloride (49) (16.Og, 87.6 mmol) was dissolved i n methanol (150 ml) 
and acetyl chloride (15 ml) added cautiously. The reaction mixture was 
refluxed (18h) and p a r t i a l l y evaporated. A white c r y s t a l l i n e s o l i d 
precipitated which was collected and dried to give the title compound 
(15.4g, 757.). MPt. 214-216°C (dec); Analysis Found: C, 35.8; H, 7.7; N, 
14.0. Required for C7H16N202.2HC1: C, 36.1; H, 8.1; N, 14.37.; IR v 
(Nujol): 3000br (NH+), 2000br (NH+), 1745 (CO) and 1605 (NHj) cm"1; h 
NMR <5H (D 20): 1.44- 1.62 (2H,m,CH2), 1.74 (2H,quin,J 7.5 Hz,CH_2CH2NH2), 
1.89-2.11 (2H,m,CH2), 3.03 (2B,t,J 7.7 Hz,CH2NB2), 3.85 (3B,s,CH3), 4.19 
(lH,t,J 6.4 Hz,CH); l 3C NMR 6Q (D 20): 45.6, 50.3, 53.3 (CH 2); 63.1 
(NCB2); 76.7, 77.7 (CH3,CH); 194.7 (CO); MS m/z (Intensity?.) CI: 161 
(23,M++1), 144 (9,M+-NH2). 
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(2S)-N-(2-Amimeihyl)-2,6-iimiv,(}he%&mmi4e (58). The methyl ester (57) 
(7.09g, 30.4 mmol) was added i n small batches over l k to etkylenediamine 
(100 ml) at 90°C, s t i r r i n g continuously. The reaction mixture was 
refluxed (6h) and the ethylenediamine removed by d i s t i l l a t i o n . The 
residue was taken into sodium hydroxide solution (25 ml, 4 M), 
evaporated, dissolved i n methanol (30 ml), f i l t e r e d , the f i l t r a t e 
evaporated to leave a residue and the process repeated from the methanol 
stage. The subsequent residue was dissolved in dicklorometkane (100 ml), 
f i l t e r e d , and the f i l t r a t e evaporated to give a clear brown o i l (5.32g, 
937.) of the title compound. Found M+: 188.1640. Required f o r CgH^O: 
188.1637; IR ( f i l m ) : 3340 (NH), 1650 (CO) and 1570 (NH) cm"1; *H 
NMR £ H (CDClg): 1.37-1.60 (13H,m,NH2,CH2), 1.82-1.91 (lH,m,CH2), 2.71 
(2H,t,J 6.5 Hz,NCH2), 2.83 (2H,t,J 6.0 Hz,NCH2), 3.38 (lH,t,J 3.8 Hz, 
CH), 7.56 (lH,br,s,CONH); 1 3C NMR 6 £ (D 20): 22.2, 31.4, 34.0 (CH 2); 
39.6, 40.2, 41.4, 42.7 (NCH2); 54.6 (CH); 178.0 (CO); MS m/z 
(Intensity?.): 189 (9,M++1), 171 (4,M+-NHg). 
(5S)-5-Amino-3-aza-l,9-s,ona%ediamine (59). The amide (58) (3.75g, 20.0 
nunol) was refluxed in borane-THF (130 ml, 130 mmol) f o r 20h. Excess 
borane was quenched with metkanol (100 ml) and solvents were evaporated 
to leave a residue which was refluxed in hydrochloric acid (160 ml, 6 M) 
for 3h. Evaporation of solvent, entraining in methanol (2 x 20 ml) and 
further evaporation gave the title compound as a hygroscopic white s o l i d 
(6.28g, 987.). Found M+: 174.1850. Required f o r C g H ^ : 174.1844; IR 
"max ( f i l r a ) : 3 3 0 0 b r ( N H> NH 2) cm"1; h NMR <$H (D 20): 1.46- 1.58 (2H,m, 
CH2CH.2CH2), 1.66-1.92 (4H,m,CH2CH2CH2), 3.01 (2H,t,J 7.5 Hz,NCH2), 2.70-
2.79 (lH,m,NCHH), 3.38-3.53 (5H,m,NCHH,NCH2), 3.71 (lH,quin,J 6.4 Hz, 
CH); 1 3C NMR S Q (D 20): 21.1, 26.1, 29.5 (CH 2); 35.2, 38.7, 44.8, 48.4, 
48.9 (CH,NCH2); MS m/z (Intensity?.): 175 (2l , M + + l ) , 157 (12,M+-NHg). 
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(5S)-5-AiaiBO-9-beazamdo-3-azaoooylamiBe (60). The tetraamine tetra-
hydrochloride (59) (13.8g, 43.0 mmol) was dissolved in water (100 ml) 
and converted to the free tetraamine by adding potassium hydroxide 
(9.65g, 172 mmol). Addition of copper carbonate (5.71g, 25.8 mmol) to 
the s t i r r e d solution at 50°C gave an intense blue colour. After 
continued s t i r r i n g (30 min, 50°C), benzoyl chloride (6.5 ml, 55.9 mmol) 
was added over lh to the cooled solution (0°C), maintaining the pH above 
9 with periodic addition of potassium hydroxide p e l l e t s . The solution 
was allowed to achieve room temperature and s t i r r i n g was continued f o r 
l h . The brown-black solution was f i l t e r e d and the f i l t r a t e treated with 
hydrogen sulphide over 30 min. F i l t r a t i o n followed by p a r t i a l 
evaporation and exhaustive extraction with chloroform, with subsequent 
drying and evaporation of the combined extracts, gave the title compound 
as a pale yellow o i l (6.40g, 547.). Found M ++l: 279.2010. Required for 
C 1 5H 2 ?N 40: 279.2027; IR i / ^ ( f i l m ) : 3300br (NH,NH2,C0NH), 3060, 1640 
(CO) and 1600 cm"1; XH NMR ^ (CDClg): 1.35 (7H,br,s,NH,NH2,CH2), 1.58 
(4H,br,s,CH2), 2.25-2.33 (lH,dd,J 12 Hz,8.7 Hz,CH), 2.51-2.74 (6H,m, 
NCH2), 3.37 (2H,dt,J 2x6.5 Hz,C0NHCII2), 6.38 (lH,br,t,CONH), 7.39-7.50 
(3H,m,ArII), 7.75-7.78 (2H,AB system,J A g 6.6 Hz,ArH); 13C NMR 8^ (CDClg): 
23.4, 29.5, 35.6 (CH 2); 39.7, 41.6, 50.8, 52.4, 56.4 (CH,NCH2); 126.8, 
128.3, 131.1; 134.7; 167.5 (CO); MS m/z (Intensity?,): 280 (23,M++2), 
279 (100,M++1). 
(5S)-9-BeQzamido-l,5-bis(4-tolBeQesnlphonamido)-3-(4~tolueBesulphouyl)-
3-azanoBa®e (61). 4-Toluenesulphonyl chloride (2.70g, 14.2 mmol) was 
added in small batches over 30 min to a s t i r r e d solution of the 
benzamide (60) (1.05g, 3.78 mmol) and potassium carbonate (1.96g, 14.2 
mmol) in water (40 ml) at 50°C. The temperature was raised to 80°C and 
s t i r r i n g continued (18h). The water was decanted leaving a white so l i d 
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which was dried in vacuo, crushed to a powder and suspended in hot 
dichloromethane. F i l t r a t i o n gave the title compound as a white powder 
(1.29g, 467.). MPt. 144-146°C; Analysis Found: C, 58.0; H, 6.1; N, 7.4. 
Required for C g g H ^ O ^ : C, 58.4; H, 6.0; N, 7.67.; IR (KBr): 3290 
(NH), 3060, 3030, 1640 (CO), 1600, 1580, 1530 (NH), 1320 (S0 2) and 1160 
(S0 2) cm"1; h NMR 8R (CDClg): 0.84-0.88 (lH,m,CH2), 1.03-1.12 (2H,m, 
CH2), 1.43- 1.50 (2H,m,CH2), 1.69- 1.75 (lH,m,CH2), 2.31 (3H,s,ArCH"3), 
2.43 (6H,s,ArCH3), 3.14-3.19 (5H,m,NCH2,CH), 3.25-3.32 (2H,m,NCH2), 
3.35-3.41 (2H,m,NCH2), 5.30 (lH,d,J 6.3 Hz,CHNHTs), 5.35 (lH,br,t,NHTs), 
6.49 (lH,br,t,NHCO), 7.18 and 7.60 (4H,AB system,J A f l 8.1 Hz,Ar(Ts)H), 
7.32 and 7.72 (8H,AB system,J A f l 8.7 Hz,Ar(Ts)H), 7.37-7.49 (3H,m, 
Ar(Ph)H), 7.81-7.84 (2H,AB system,J A g 8.8 Hz,Ar(Ph)H); MS m/z 
(Intensity^) FAB: 743 (2,M++3), 430 (1,M+-310). 
(+)-(2S)-2-(4-Benzataidobutyl)-l ,4,7,10-teirakis(4-toluenesulphonyl)-
1,4,7,10-tetraazacyclododecane (62). 1,5- Bis(4- toluenesulphonato)-3-
(4-toluenesulphonyl)-3-azapentane (2.79g, 4.93 mmol) i n DMF (50 ml) was 
added dropwise over 3h to the t r i t o s y l a t e d compound (61) (3.65g, 4.93 
mmol) and caesium carbonate (4.01g, 12.3 mmol) in DMF (200 ml) at room 
temperature. After s t i r r i n g at room temperature f o r 18h, the reaction 
mixture was heated at 60°C (72h). A further batch (0.42g, 7.39 mmol) of 
1,5-bis(4-toluenesulphonato)-3-(4-toluenesulphonyl)- 3- azapentane was 
added in one l o t , and s t i r r i n g continued (12h, 60°C). Solvent was 
removed under reduced pressure and the residue dissolved in dichloro-
methane (100 ml). After washing with water (2 x 30 ml) and drying, the 
organic layer was evaporated. Column chromatography (gradient eluent 
0.5-1.57. methanol in dichloromethane) of the residue afforded the title 
compound as a glassy s o l i d (3.41g, 727.). MPt. 108-110°C; [a]^2 +14.0° 
(c 1.00 in CH9C1.?); R. 2.9 min (reverse phase); Analysis Found: C, 58.2; 
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H, 5.6; N, 7.0. Required f o r C ^ H ^ O ^ : C, 58.6; H, 5.9; N, 7.37.; IR 
v ( f i l m ) : 3400 and 3290 (NH), 3040, 1650 (CO). 1600, 1580, 1530 (NH), 
1340 and 1160 cm"1; h NMR <$H (CDgCN,333K): 0.67 (2H,br,s,CH2), 1.09-
I . 14 (2H,m,CH2), 1.27-1.45 (2H,m,CH2), 2.35, 2.41, 2.46 and 2.53 (12H, 
4xs,ArCH3), 2.57-4.22 (17H,7xm,NCH2,NCH,NHCH2), 6.86 (lH,br,s,NH), 7.16-
7.27 (4H,AB system,ArH), 7.37-7.51 (9H,AB system,ArH), 7.63-7.83 (8B,AB 
system,ArH); 1 3C NMR 6^ (CDClg): 21.4 (CHg); 28.7, 39.4, 49.4, 51.9, 
55.4, 65.9 (NCH2,NCH,CH2,all br ) ; 126.8, 127.1, 128.2, 129.8; 131.0, 
134.5, 135.6, 143.4, 143.9, 144.5, 167.3 (CO); MS m/z (Intensity?.): 968 
(5,M++5), 967 (14,M++4), 966 (36,M++3), 965 (56,M++2), 964(100,M ++l), 
809 (21,M+-154). 
(+)-(2S)-2-(4~Be'&zamidob%iyl)-l,4,7,10-tetraazacyclododeca®e (63)-
Ammonia (100 ml) was condensed into a mixture of the tetratosylated 
macrocycle (62) (0.50g, 0.52 mmol) in THF (20 ml) and ethanol (2 ml) at 
-78°C. Lithium (0.18g, 25.9 mmol) was added in small portions to t h i s 
mixture and an intense blue colour developed which discharged over 1-10 
min. The reaction mixture was allowed to warm to room temperature, 
water (20 ml) was added and solvents evaporated. The residue was 
dissolved in hydrochloric acid (20 ml, 6 M), washed with d i e t h y l ether 
(3 x 10 ml), evaporated, redissolved in potassium hydroxide solution (10 
ml, 6 M) and extracted with dichloromethane ( 4 x 5 ml). The combined 
extracts were evaporated to give a colourless o i l . Preparative HPLC 
(cation exchange) afforded the title compound as a colourless o i l 
(0.10g, 577.). +2.5° (c 0.80 in CH2C12); E t 7.3 min; Found M ++l: 
348.2616. Required f o r C 1 9B 3 4N 50: 348.2763; 1H NMR <$H (CDClg): 1.41-
1.48 (4H,m,CH2), 1.58-1.66 (2H,m,CH2), 2.38 (4H,br,s,NH), 2.46 (lH,dd,J 
12 Hz,7.7Hz,NHCHH), 2.67 (14H,s,NCH2), 3.46 (2H,dt,J 2x6.4 Hz,C0NHCH_2), 
6.58 (lH,br,t,C0NH), 7.39-7.49 (3H,m,ArH), 7.76-7.80 (2H,AB system,J A R 
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9.3 Hz,ArH); MS m/z ( I n t e n s i t y ! ) : 348 (10(),M++1). 
(+)-(2S)-2-(4-AaiQobtttyl)-l,4,7,10-tetraazacyelododecaiie-l,4,7,10-
teiraacetic acid trihydrochloride (65). Ethyl bromoacetate (190mg, 1.24 
mmol) was added to the macrocyclic amine (63) (75mg, 0.22 mmol) and 
potassium carbonate (I76mg, 1.28 mmol) i n DMF (3 ml) and the mixture 
heated (90°C, 18h). Evaporation of solvent and preparative HPLC (cation 
exchange) gave the tetraester (64) as a colourless o i l , R^  10.7 min. 
The tetraester (64) was hydrolysed according to the method f o r (L2) to 
22 o 
give the title compound as a white gum (97mg, 777.). +2.7" (c 0.75 
in H 20); Analysis Found C, 41.3; H, 5.9; N, 11.75. Required f o r 
C 2 OH 3 7N 50 g.3HCl: C, 41.1; H, 6.3; N, 12.07.; H NMR ^ (D 20): 1.47 (2H, 
br,s,CH 2), 1.74 (2H,br,s,CH2), 1.95 (2H,br,s,CH2), 3.05, 3.47 and 4.00 
(25H,3x vbrs,CH,NCH2,CH2NH2); MS m/z (Intensity?.) FAB: 476 (0.6,M++1). 
5.1.9 Attempted Synthesis of (2S)-(4-Nitrophenyl)D0TA 
(2S)-netkyl-2-amino-3-(4-Bitrophenyl)prop(moete hydrochloride (41). 
(2S)-(4-Nitrophenyl)alanine (41) (7.51g, 36.8 mmol) was dissolved i n 
methanol (25 ml) and acetyl chloride (2.5 ml) added cautiously. The 
reaction mixture was refluxed (18h) and p a r t i a l l y evaporated. A white 
c r y s t a l l i n e s o l i d precipitated which was collected and dried to give the 
title compound (6.11g, 667.; l i t . 6 887.). h NMR <$H (D 20): 3.41 (lH,dd,J 
15 Hz,7.4Hz,CH2), 3.51 (lH,dd,J 15 Hz,6.4Hz,CH2), 3.86 (3H,s,CH3), 4.56 
(lH , t , J 6.9 Hz,GH), 7.55 and 8.27 (4H,AB system,J A B 6.8 Hz,ArH); 1 3C NMR 
<5C (D 20): 36.2 (CH 2); 54.4 (CH,CH3); 125.0, 131.3; 142.7, 148.0; 170.4 
(CO); MS m/z (Intensity?.) CI: 225 (46,M++1), 165 (10,M+-C0.?Me). 
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(2S)-2-Jlmino-3-(4-nitrophenyl)propeni!iiiLiide (13). Triethylamine (3.6 ml, 
25.9 mmol) in die t h y l ether (100 ml) was added to the ester (42) (6.11g, 
23.5 mmol) in methanol (3 ml). The solution was f i l t e r e d and the 
f i l t r a t e concentrated to a limpid yellow o i l . Ammonia was bubbled 
through a solution of the o i l in methanol (100 ml) f o r l h . The reaction 
vessel was t i g h t l y stoppered and allowed to stand (24h). Evaporation of 
6 
solvent gave the title compound as a red-brown o i l (3.61g, 74%; l i t . 
927.). IR f f f l a x ( f i l m ) : 3400 (NH), 1680 (CO) and 1610 (NH) cm"1; 1H NMR <5H 
[(CD 3) 2S0]: 2.04 (2H,br,s,NB2), 3.03 (lH,dd,J 12 Hz,8.4Hz,CH2), 3.31 
(lH,dd,J 12 Hz,4.8Hz,CH2), 3.66-3.71 (lH,m,CH), 7.31 (lH,s,NH 2), 7.66 
(lH,s,NH 2), 7.79 and 8.41 (4H,AB system,J A f i 8.5 Hz,ArH); 1 3C NMR <$c 
[(CDg) 2S0]: 41.6 (CH 2); 56.8 (CH); 123.9, 131.4; 146.8, 148.5; 177.1 
(CO); MS m/z (Intensity?.): 210 (30,M++1). 
(2S)-2-Amino-(4-nitrophenyl)propyl<wiae dihydrochloride (H). The amide 
(43) (3.61g, 17.3 mraol) was refluxed in borane-THF (80 ml, 80 mmol) f o r 
20h. Excess borane was quenched with methanol (25 ml) and solvents were 
evaporated to leave a residue which was refluxed i n hydrochloric acid 
(100 ml, 6M) f o r 3h. Evaporation of solvent, entraining in methanol 
(2 x 20 ml) and further evaporation gave the title compound as a yellow 
s o l i d (1.95g, 427.; l i t . 6 857.). Analysis Found: C, 39.8; H, 5.2; N, 
15.7. Required f o r C gH 1 3N 30 2.2HCl: C, 40.3; H, 4.85; N, 15.77.; IR v 
(Nujol): 3360 (NH) and 1590 cm"1; h NMR <$H (D 20): 3.36 (lH,dd,J 12 Hz, 
8.6Hz,CH2), 3.49-3.67 (3H,m,CH2), 4.16-4.27 (lH,m,CH), 7.77 and 8.47 
(4H,AB system,J A B 8.7 Hz,ArH); 1 3C NMR ^ (D 20): 36.0 (NCH2); 40.7 
(CH 2); 50.2 (CH); 124.3, 130.6; 141.9, 147.3; MS m/z (Intensity?.) CI: 
272 (3,M ++1+2[H 3 7C1]), 267 (2,M ++2[H 3 5C1]). 
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( 2 S ) - 3 - ( 4 - N i t r o p h e a y l ) - l , 2 - b i s ( 4 - t o l a e n e s u l p h o a a i B i d o ) p r o p e Q e (45). 
4-Toluenesulphonyl chloride (3.56g, 18.7 ramol) was added i n small 
batches over l h t o the diamine dihydrochloride (44) (2.00g, 7.46 mmol) 
in pyridine (100 ml) at 0°C. The vessel was t i g h t l y stoppered and l e f t 
(0°C, 24h). The solution was poured onto crushed ice and the o i l which 
separated taken into dichloromethane (100 ml), washed with hydrochloric 
acid (2 x 50 ml, 0.1 M), dried and evaporated. Recrystallisation from 
ethanol gave the title compound as a pale yellow s o l i d (0.89g, 24%). 
Mpt. 135-137°C; Analysis Found: C, 54.7; H, 5.0; N, 8.4. Required f o r 
C23 H25 N3°6 S2 : C' 5 4 ' 9 ; H' 5 * 0 ; N' 8 - 3 7 , ; I R "max ( f i l m ) : 3 2 8 0 (NH)» 3 0 2 0 ' 
1600, 1520 (N0 2), 1350 (N02,S02) and 1160 (S0>2) cm"1; !H NMR <$H (CDClg): 
2.33 (3H,s,ArCH3), 2.39 (3H,s,ArCHg), 2.70 (lH,dd,J 15 Hz,9.4Hz, 
ArCH2CH), 2.91 (lH,dd,J 12 Hz,5.1Hz,ArCH2CH), 3.07 (2H,br,s,CHCH_2NH), 
3.47 (lH,br,s,CH), 5.24 (lH,br,s,NH), 5.40 (lH,br,s,NH), 6.99-7.05 
(4H,AB system,Aril), 7.25-7.28 (2H,AB system,J A B 8.1 Hz,ArH), 7.36-7.39 
(211,AB system,J A B 8.2 Hz,ArH), 7.68-7.71 (2H,AB system,J A B 8.2 Hz,ArH), 
7.80-7.84 (2H,AB system,J A Q 8.4 Hz, ArH); MS m/z ( I n t e n s i t y ! ) : 504 
(100,M++1). 
(2S)-2-(4-Mitrobeazyl)-l,4,7,10-tetrakis(4-tolaeaesulphoByl)-l,4,7,10-
tetraazacyclododecane (4Q)- The ditosylated compound (45) (0.89g, 1.77 
mmol) was added to a solution of sodium (0.08g, 3.54 mmol) i n ethanol 
(50 ml) and refluxed (2h). Solvent was evaporated and the residue taken 
into DMF (200 ml). l,8-Bis(4-toluenesulphonato)-3,6-bis(4-toluene-
sulphonyl)-3,6-diazaoctane (1.35g, 1.77 mmol) in DMF (100 ml) was added 
dropwise over 3h to t h i s solution at 60°C. S t i r r i n g was continued 
(90°C, 24h). Water (100 ml) was added and the solution extracted with 
dichloromethane (4 x 50 ml), washed with hydrochloric acid (2 x 50 ml, 
1 M), dried and solvent evaporated to give a dark red-brown o i l . 
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5.1.10 Attempted Synthesis of (2S)-(4-AniEobityl)WDTA 
( 2 S ) - 2 - A m m - 6 - h e n z a m d o h e x Q B o i e acid (50). The title compound was 
synthesized according to the method f o r (60). After treatment with 
hydrogen sulphide and f i l t r a t i o n , the f i l t r a t e was adjusted to pH 4 by 
adding concentrated hydrochloric acid. A white so l i d precipitated which 
was collected and suspended i n methanol. F i l t r a t i o n gave the title 
compound as a white powder (917.). MPt. 264-266°C ( l i t . 7 267-269°C); 
Analysis Found: C, 62.2; H, 6.8; N, 10.75. Required f o r C13H18N2Q3: C, 
62.4; H, 7.2; N, 11.27.; IR i< (KBr): 3320 (NH), 3040 (OH), 1640 (PhCO, 
NH3), 1580 (C0 2) and 1540 (C0 2) cm"1; :H NMR <$H (D 20, pD 11.0): 1.25-
1.37 (2H,m,CH2), 1.48-1.59 (4H,m,CH2), 3.15 (lH,t,J 6.4Hz,CH), 3.29 
(2H,t,J 6.9Hz,NCH2), 7.39-7.55 (3H,m,ArH), 7.62-7.66 (2H,AB system,J A B 
8.7 Hz,ArH); MS m/z (Intensity?.) FAB: 250 (83,M +). 
(2S)-[lethyl-2-amiv>o-6-be%zamidohexav>oate (51). The title compound was 
synthesized according to the method f o r (57). Work-up involved evapor-
ation of the reaction mixture; the residue was taken into dichloro-
methane, washed with aqueous sodium carbonate solution, dried and 
evaporated to give the title compound as a colourless o i l (427.). IR u m _ 
max 
(f i l m ) 3300 (NH), 3060, 1740 (ester CO), 1640 (amide CO), 1600 and 1540 
(amide NH) cm"1; h NMR ^  (D 20): 1.61-1.72 (2H,m,CH2), 1.77-1.85 (2H,m, 
CH2), 2.08-2.17 (2H,m,CH2), 3.55 (2H,t, J 6.3Hz,NCH.2), 3.91 (3H,s,CH3), 
4.32 (lH,t,J 6.4Hz,CH), 7.64-7.79 (3H,m,ArH), 7.88-7.91 (2H,AB system, 
J A B 6.8 Hz,ArH); MS m/z (Intensity?.): 265 (100,M++1), 188 (10, M++1-Ph). 
(2S)-2-Amino-N-(2-aminoeihyl)-6-benzamidohexanamide (52). The title 
compound was synthesized according to the method f o r (58). After 
re f l u x i n g (3h), the ethylenediamine was removed by d i s t i l l a t i o n to give 
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t h e title compound a s a brown o i l (887.). I R ^ m a x ( f i l m ) : 3280 (NH), 
3 0 6 0 , 1640 ( C O ) , 1605 and 1540 ( a m i d e NH) cm" 1; *H NMR ^ ( C D C l g ) : 1.43-
1.52 (2H,m,CH 2), 1.62 ( 6 H , b r , s , N H 2 , C H > 2 ) , 1.80- 1.86 (2H,m,CH 2), 2.80 (2H, 
t , J 6.0Hz,CH 2CH. 2NH 2), 3.28 ( 2 H , d t , J 2x6.01lz,NHCH_ 2CH 2NH. 2), 3.36-3.41 (1H, 
m,CH), 3.46 ( 2 H , d t , J 6.6 Hz,6.3 Hz,PhC0NHCH 2), 6.54 ( l H , b r , t , C H C 0 N H ) , 
7.39-7.49 (3H,m,ArH), 7.62 ( l H , b r , t , P h C O N H ) , 7.77-7.80 (2H,AB s y s t e m , J A B 
7.3 H z , A r H ) ; 1 3 C M R S Q ( C D C l g ) : 2 2 . 8 , 2 9 . 2 , 34.5 ( C H 2 ) ; 3 9 . 5 , 41.6, 
4 1 . 8 , 55.1 (NHCH 2, CH 2NH 2,CH); 126.9, 128.5, 131.4; 134.7; 167.6 ( P h C O ) , 
175.4 (CHCONH); MS m/z ( I n t e n s i t y ? . ) : 293 ( 1 0 0 , M + + 1 ) , 275 (95,M +-NH 3). 
(5S)-5-Amino-ll-pheuyl-3,10-diaza%ndecylaiaim (53). T h e title compound 
was s y n t h e s i z e d a c c o r d i n g t o t h e method f o r ( 5 9 ) . A f t e r r e f l u x i n g ( 3 h ) 
i n h y d r o c h l o r i c a c i d ( 6 M) and e v a p o r a t i o n o f s o l v e n t , t h e r e s i d u e was 
t a k e n i n t o a s m a l l volume o f p o t a s s i u m h y d r o x i d e s o l u t i o n ( 6 W) and 
e x t r a c t e d w i t h d i c h l o r o m e t h a n e ( x 4 ) . D r y i n g a n d e v a p o r a t i o n o f t h e 
o r g a n i c l a y e r g a v e t h e title compound a s a c o l o u r l e s s o i l (667*). I R v 
( f i l m ) : 3 2 6 0 b r (NH), 3020 and 1570 (NH) cm" 1; h NMR <$H ( C D C l g ) : 1.44 
(12H,br,s,NH. 2,NH,CH 2), 2.36 ( l H , d d , J 12Hz,8.8Hz,NCH 2), 2.61-2.69 (7H,m, 
N C H 2 ) , 2.78-2.82 (lH,m,NCH. 2), 3.78 ( 2 H , s , P h C H 2 ) , 7.24-7.33 (5H,m,ArH); 
MS m/z (Intensity7«): 265 ( 1 0 0 , M + + 1 ) , 174 ( 4 3 , M + + l - C H 2 P h ) . 
(5S)-1,5-Bis(4-tolueaesulphoaaisido)-11-pheay 1-3,10-bis(4~toluene-
snlphouyl)-3,10-diazaundeca%t (54). The title compound was s y n t h e s i z e d 
a c c o r d i n g t o t h e method f o r ( 6 1 ) . A f t e r s t i r r i n g (80°C,18h) and 
d e c a n t i n g t h e w a t e r l a y e r , t h e o i l y r e s i d u e was t a k e n i n t o d i c h l o r o -
methane. The w a t e r l a y e r was e x t r a c t e d w i t h d i c h l o r o m e t h a n e ( x 4 ) . The 
d i c h l o r o m e t h a n e s o l u t i o n s w e r e c o m b i n e d , d r i e d a n d e v a p o r a t e d . Column 
c h r o m a t o g r a p h y (1.57. m e t h a n o l i n d i c h l o r o m e t h a n e ) a f f o r d e d t h e title 
compound a s a c o l o u r l e s s o i l (777.). I R v ( f i l m ) : 3 2 8 0 b r (NH), 3020, 
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1600, 1330 and 1160 c m ; 2H N&1R <$H ( C D C l g ) : 0.85-0.90 (2H,m,CH. 2), 1.06-
1.20 ( 2 H , m , C f l 2 ) , 1.37-1 .49 (2H,m,CH 2), 2.41, 2.42, 2.43 and 2.44 (12H, 
4 x s , A r C H 3 ) , 2 .84-2.90 (lH,m,CHCH 2NTs), 3.00-3.26 (6H,m,NTsCH 2), 3.71 
( 2 H , s , C H 2 P h ) , 4.20 ( 2 H , d t , J 2 x l 5 H z , N H T s C H 2 ) , 5.16 ( l H , d , J 5.9Hz,CHNHTs), 
5.27 ( 2 H , t , J 5.6Hz,NHTsCU 2), 7.17-7.34 ( 1 3 H , m , A r ( T s ) H , A r ( P h ) H ) , 7.58-
7.61 (2H,AB s y s t e m , J A B 8 . 2 H z , A r ( T s ) H ) , 7.68-7.83 ( 6 H , m , A r ( T s ) H , A r ( P h ) H ) ; 
1 3 C NMR 6 C ( C D C l g ) : 21.4 ( C H 2 ) ; 21.5 ( C H g ) ; 2 7 . 3 , 31.3 ( C H 2 ) ; 4 2 . 5 , 
4 7 . 8 , 5 0 . 8 , 5 2 . 5 , 53.1, 55.2 ( N C H 2 ) ; 1 2 7 . 2 , 127.4, 127.8, 128.3, 128.6, 
129.8, 130.0; 1 3 4 . 6 , 136.6, 136.9, 1 3 7 . 2 , 143.4, 144.1; MS m/z 
( I n t e n s i t y ? . ) : 880 ( 0 . 4 , M + ) , 727 ( 0 . 9 , M + + 2 - T s ) . 
(2S)-2-(M-Benzyl-4-amiaob^lyl)-l,4,7,10-teirakis(4-tolue&est&lpho%yl)-
1,4,7,10- tetraazacyclododecaae (55). The title compound was s y n t h e s i z e d 
a c c o r d i n g t o t h e method f o r ( 6 2 ) . A f t e r work-up, r e c r y s t a l l i s a t i o n f rom 
m e t h a n o l g a v e t h e title compound a s a w h i t e s o l i d (347c). MPt. 218-219°C; 
A n a l y s i s Found: C, 59.0; H, 6.0; N, 6.3. R e q u i r e d f o r C 5 4 H 6 5 N 5 0 1 Q S 5 : C, 
58.7; H, 5.9; N, 6.37.; I R v ( f i l m ) : 3020, 1600, 1340 and 1160 cm" 1; 
h\ NMR <5H ( C D C l g ) : 0.94 ( 2 H , b r , s , C H 2 ) , 1.09 ( 2 H , b r , s , C H 2 ) , 1.18-1.25 
(2H,m,CH. 2), 2.39 (3H,s,ArCHg), 2.44 ( 1 2 H , s , A r C H 3 ) , 2.86, 3.32, 3.59, 
3.94, 4.23 (19H,5xvbrm,NTsCH 2,NTsCH,NTsCH 2Ph), 7.21-7.35 (15H,m, 
A r ( T s ) H , A r ( P h ) H ) , 7.60-7.74 ( 1 0 H , m , A r ( T s ) H ) ; 1 3 C NMR S Q ( C D C l g ) : 14.2 
( C H 2 ) ; 21.5 ( C H g ) ; 22.7, 27.4, 29.7, 3 1 . 9 , 4 5 . 1 , 4 7 . 8 , 50.5, 52.0, 63.2 
(NCH. 2,NCH,CH 2, a l l b r ) ; 127.1, 127.3, 127.6, 127.8, 128.3, 128.6, 129.9; 
136.2, 143.4, 143.9, 144.6; MS m/z ( I n t e n s i t y ? . ) : 1104 ( 2 , M + + 1 ) , 949 ( 1 2 , 
M + + 1 - T s ) . 
(2S)-2-(N-Be®zyl-4-aminobuiyl)-l,4,7,10-ieiraazacyclododecane (56). The 
title compound was s y n t h e s i z e d a c c o r d i n g t o t h e method f o r ( 6 3 ) t o g i v e 
a p a l e y e l l o w o i l (787.). h NMR 6^ ( C D C l g ) : 1.25- 1.38 (4H,m,CH 2), 1.46-
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1.54 (2H,ra,CH 2), 2.11 ( 5 H , b r , s , N H ) , 2.38-2.47 (lH,m,NCH 2CH), 2.56-2.71 
(16H,m,NCH 2,NCH), 3.77 (2H,s,NHCH 2Ph), 7.20-7.30 (5H,m,ArH); MS m/z 
( I n t e n s i t y / . ) : 334 ( 4 , M + + 1 ) , 174 (3,M ++3-(CH. 2) 4NHBz). 
5.2 K I N E T I C EXPERIHERITS 
5.2.1 h W M . E x p e r i m e n t s 
S p e c t r a were r e c o r d e d on a B r u k e r AC 250 s p e c t r o m e t e r ( 2 5 0 . 1 3 MHz) 
a t 293K. The pD was k e p t c o n s t a n t a t 5.0 by a dg-sodium a c e t a t e 
( 0 . 1 4 M J - d ^ - a c e t i c a c i d ( 0 . 0 6 M) b u f f e r i n D 2 0 . L i g a n d and m e t a l i o n 
c o n c e n t r a t i o n s were b o t h 0.028 M. t - B u t a n o l was t h e i n t e r n a l s t a n d a r d . 
Y t t r i u m ( I I I ) was added t o t h e l i g a n d i n s o l u t i o n a s Y ^ O ^ ^ ^ D ^ , 
t h e D 2 0 s a l t o b t a i n e d by a d d i n g D 20 t o Y ( N 0 g ) 3 . 6 H 2 0 , e v a p o r a t i n g and 
r e p e a t i n g t h i s p r o c e s s t w i c e . 
Where i r r a d i a t i o n o f an AB " d o u b l e t " was r e q u i r e d d u r i n g t h e c o u r s e 
o f s p i n - s p i n d e c o u p l i n g e x p e r i m e n t s , t h e d e c o u p l i n g power was a p p l i e d t o 
t h e more i n t e n s e o f t h e two p e a k s . 
5.2.2 1 3 C NMR E x p e r i m e n t s 
T h e 1:1 Y(DOTA) c o m p l e x ( 0 . 0 1 2 M) was p r e p a r e d by m i x i n g a s o l u t i o n 
o f Y ( N 0 3 ) 3 . 6 H 2 0 i n D 2 0 ( 0 . 5 ml, 4.8 x 1 0 " 2 M) w i t h a s o l u t i o n o f t h e 1 3 C 
t e t r a c a r b o n y l - l a b e l l e d a n a l o g u e o f D0TA ( 3 7 ) i n D 2 0 ( 0 . 5 m l , 4.8 x 1 0 " 2 
M). The combined s o l u t i o n was a d j u s t e d t o pH 4.5 w i t h sodium h y d r o x i d e 
s o l u t i o n ( 2 . 5 M). A f t e r l e a v i n g t o s t a n d a t room t e m p e r a t u r e f o r 10 min 
1 ^ 
and c h e c k i n g t h e C NMR s p e c t r u m ( B r u k e r AC 250, 62.9 MHz, 200 s c a n s , 
0 .27s a c q u i s i t i o n t i m e , 2 . 0 0 s r e l a x a t i o n d e l a y , 8K d a t a s t o r a g e , 293K) 
t h e s o l u t i o n was a d j u s t e d t o t h e r e q u i r e d pH by a d d i n g c o n c e n t r a t e d 
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n i t r i c a c i d and made up t o 2 ml w i t h d e i o n i s e d w a t e r . pH m e a s u r e m e n t s 
above 0 were made w i t h a Jenway 3020 pll m e t e r . 
5.2.3 K i n e t i c E x p e r i m e n t s I n v o l v i n g N i ( I I ) 
S p e c t r a were r e c o r d e d on a U v i k o n 930 s p e c t r o p h o t o m e t e r ; k i n e t i c 
m e a s u r e m e n t s were made on t h e same m a c h i n e and on a P e r k i n - E l m e r 
Lambda 3 s p e c t r o p h o t o m e t e r . Y t t r i u m ( I I I ) - l i g a n d s o l u t i o n s ( e x c e p t t h a t 
o f Y(DOTA), s e e S e c t i o n 3.3) were a l l o w e d t o s t a n d a t 298K i n b u f f e r a t 
t h e r e l e v a n t pH f o r 20 min b e f o r e a d d i n g a s o l u t i o n o f N i ( N O ^ ) 2 • T h e pH 
of t h e s o l u t i o n was m e a s u r e d b o t h b e f o r e and a f t e r N i ^ + a d d i t i o n w i t h a 
Jenway 3020 pH m e t e r . A l l m e a s u r e m e n t s were made a t 298K. 
5.2.4 R e a g e n t s 
YtNOg^.eh^O was o b t a i n e d from A l f a ; N i t N O g ^ - o l ^ O , c a l c i u m 
c h l o r i d e ( a s a 1M s o l u t i o n ) and sodium h y d r o x i d e ( a s p e l l e t s ) f r om BDH; 
c o n c e n t r a t e d n i t r i c a c i d and h y d r o c h l o r i c a c i d , 15M and 12M 
r e s p e c t i v e l y , f rom May and B a k e r t o g e t h e r w i t h g l a c i a l a c e t i c a c i d ; 
g l y c i n e was o b t a i n e d f r o m S i g m a , DTPA from W.R. G r a c e and s o d i u m a c e t a t e 
and sodium p e r c h l o r a t e from A l d r i c h . 
5.3 S T A B I L I T Y CONSTANT MEASUREMENTS^ 
P o t e n t i o m e t r i c t i t r a t i o n s were c a r r i e d o u t a t 298 ± 0.1K. T he 
m o l a r i t i e s o f t e t r a m e t h y l a m m o n i u m h y d r o x i d e ( S i g m a ) t i t r a n t s o l u t i o n s 
were c o r r e c t e d f o r c a r b o n a t e c o n t a m i n a t i o n by p r e v i o u s t i t r a t i o n a g a i n s t 
d i l u t e h y d r o c h l o r i c a c i d (0.1 M, BDH). I o n i c s t r e n g t h was k e p t c o n s t a n t 
w i t h t e t r a m e t h y l a m m o n i u m n i t r a t e (0.1 M, S i g m a ) . 
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T h e t i t r a t i o n s y s t e m c o n s i s t e d o f a d o u b l e - w a l l e d g l a s s c e l l 
t h e r m o s t a t t e d a t 298 ± 0.1 K c o n t a i n i n g t h e l i g a n d s o l u t i o n c o u p l e d t o a 
M e t t l e r DV401 a u t o m a t i c b u r e t t e c o n t a i n i n g t h e t i t r a n t . T h e pH was 
m o n i t o r e d w i t h a C o r n i n g 001854 c o m b i n a t i o n m i c r o e l e c t r o d e . T i t r a t i o n s 
were c o n t r o l l e d by a BBC m i c r o c o m p u t e r w h i c h a l s o h a n d l e d d a t a s t o r a g e . 
D a t a w e r e t r a n s f e r r e d t o an MTS m a i n f r a m e c o m p u t e r by t h e program KERMIT 
and a n a l y s e d u s i n g t h e program SUPERQUAD. 
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